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Abstract 
Invasive fungal infections are a major threat to immune-compromised patients. There is a 
critical need to develop new antifungal agents because of increasing resistance to the common 
antifungal drugs. 
In the first part of this dissertation, methods for preparation of novel barbiturate saponin 
as antifungals and their biological activities would be described. Barbiturates and steroidal 
saponins have shown remarkable antifungal activity in the biological assays. Therefore, attempts 
were directed to combine the barbiturate with the steroid to give novel antifungal agents. The 
need for extensive SAR studies and to better understand these compounds efforts were directed 
to synthesize novel saponin barbiturates.   
Glycosylation of barbiturates was achieved under basic conditions to synthesize mono 
and disaccharide barbiturates. Saccharide molecules were directly introduced into the barbiturate 
without requiring protection and deprotection of saccharides. Efficient methods were developed 
for synthesis of 3β derivatized steroid derivatives containing ether, carbonate, ester and 
carbamate linker.  Synthesized mono and disaccharide barbiturates were incorporated into the 
steroidal skeleton to give the novel antifungal agents. Several reaction conditions were explored 
to give the best yield under the most efficient reaction conditions. However, a better 
understanding and extensive SAR study needs to be done in order to develop more promising 
and potent antifungal compounds.  
The second part of this dissertation describes the progress towards monocysteine metal 
complex synthesis and their biological activities. In this attempt, several protection deprotection 
strategies were explored and some novel protective groups were designed for peptide synthesis. 
xvii 
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CHAPTER-1: INTRODUCTION 
 
The increasing burden of fungal infections, particularly in immune-compromised 
patients, has become a serious threat to human life.  Fungal infections are generally categorized 
as superficial and systemic mycoses. Past two decades have witnessed a continuous increase in 
the incidence of fungal infections. Invasive fungal infections remain a leading cause of morbidity 
and mortality in patients suffering from haematological malignancies and that undergoing 
haematopoietic stem cell transplantation (HSCT)
1
.
 
This significant increase, ironically, is 
believed to be due the advances in medical treatment, specifically the use of antibiotics, 
immunosuppressant drugs and steroids that suppress a patient’s immune system thus making 
them more prone to fungal infections. As a result, invasive candidiasis has risen to become the 
fourth most common cause of hospital-acquired bloodstream infections in the U.S
2
.  
Several other factors that predispose a patient to invasive fungal infections include 
neutropenia caused due to chemotherapy, defective functioning T-lymohocytes caused as a result 
of organ transplant and HIV infection
2
.
 
Prolonged usage and high doses of corticosteroids lead to 
impaired macrophage function. Various invasive and noninvasive medical procedures like 
vascular catheters, parentreal nutrition, hemodialysis and peritoneal dialysis cause barrier defect 
in compromised patients
3,4
. Medical procedures are both invasive and aggressive. This in turn 
disrupts the protective anatomical barriers and thus allows fungi to reach the normal sterile body 
site
12
. Major increase in invasive fungal infections have been observed not only in ever 
increasing community of organ transplant or AIDS patients, but also in patients who are 
hospitalized with severe illnesses and have to receive induction or consolidation chemotherapy 
and have to undergo bone marrow transplantation
5,6
.  
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The search for new antifungal drugs is spurred by a dramatic increase in the incidence of 
fungal infections, growing primary and secondary resistance to popular drugs and the emergence 
of resistant strains to currently available antifungal therapy
7
. The past few years have seen the 
introduction of several new agents but the search for a new and better antifungal is ongoing. 
Antifungal research and development is challenging. Not only the fungal cell wall share 
similarity with the mammalian cells, but also a metabolic pathway similarity between the fungal 
and mammalian cells makes the target specific drug design a daunting task. This limits the 
availability of pathogen-specific targets
8
. Clinical development is hampered by challenges in 
timely and definitive diagnosis of the less common or more resistant fungi. Despite these issues, 
some novel products are progressing in development
9
.  
The systemic antifungals have been available since 1950s
10
. The development of the 
polyene antifungals represented a major advancement in medical mycology. The early 
development of antifungal agents such as nystatin and amphotericin B
11
 was characterized by 
compounds with only limited efficacy because of their inherent toxicity and by the lack of 
substantial developments for decades. The 1980s saw the development of the triazoles
11
, which 
revolutionized medical mycology, as these compounds were available both as intravenous and 
oral formulations, and were effective against fungal pathogens that were refractory to the 
polyenes (Fig. 1.1)
9
.  
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Figure 1.1 Timeline for systemic antifungal agent development 
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The incidence and prevalence of invasive fungal infections saw a dramatic increase from 
1980s. It was during this period that attention was diverted to develop new antifungals after a 
long period of slow development in antifungal discovery. During 1990s, triazoles were further 
modified and amphotericin B was reformulated with lipid compounds. Efforts were made to 
lessen the toxicity of these drugs and make them useful as systemic antifungals. The less toxic 
lipid based formulation of amphotericin B led to exploration of true efficacy of this drug
11
.  
The most common fungal pathogens continue to be the species of Candida and 
Aspergillus
13-15
. Parallel to the increase in fungal infections, the new millennium also saw the 
introduction of two new triazoles (voriconazole and posaconazole) and three echinocandins 
4 
 
(anidulafungin, caspofungin and micafungin) that have been licensed for the treatment and 
prevention of these infections
16
. The new class of antifungals ‘echinocandins’ are characterized 
by their inhibition of the synthesis of (1,3)-β-d-glucan (a key component of many fungal cell 
walls). These are the first class of antifungal agents that act against a specific component of the 
fungal organisms and not the mammalian cells 
17,18
. Their safety profile is remarkable and has set 
the bar for new antifungals that are under development. The mechanism of action of antifungal 
agents for currently used drugs and those currently in development stage is illustrated in Fig.1.2. 
 
Protein
DNA 
Synthesis
a
b
c
d
Echinocandin
Cell membrane
Cell wall
Sordarins
Azoles, Polyenes
and Terbinafine
Flucytosine
 
Figure 1.2 Mechanism of action of antifungal agents
9
. 
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The antifungals acting on the cell wall are echinocandin that inhibit the cell wall 
formation. Sordarins act by interfering the assembling of proteins. Azoles, polyenes and 
terbinafine disrupt the fungal cell wall (Fig.1.2). Flucytosine interferes with the synthesis of 
DNA and antibodies and vaccines prevent the fungal infection by blocking them or destroying 
the fungal cells
9
. 
 
1.1 Systemic antifungal development 
The discovery of the antifungal activities of griseofulvin, in 1940s was the first landmark 
in the development of active and safe antifungal agents. This was followed by azole, 
benzimidazole, by Wooley in 1944
19,20. Elson’s report on the fungistatic properties of 
propamidine followed in 1945
21
. This was followed by discovery of the first polyene macrolide 
antifungal, nystatin, by Hazen & Brown’s in 195022. Amphotericin B (AmB) was discovered in 
1955 and introduced to treat several human cases of blastomycosis in 1957
23
. Later the 
introduction of oral griseofulvin and topical chlormidazole in 1958 and the subsequent 
introduction of IV AmB in 1960 ushered in the beginning of a new era of antifungal 
therapy
18b
.After this initial introduction of AmB the advances in the search for new antifungal 
agents slowed down for almost three decades. The oral agent 5-fluorocytosine (flucytosine-5FC), 
developed in 1964 was initially effective in the treatment of infections caused by Candida 
albicans and Cryptococcus neoformans but soon developed resistance and limited its use as 
monotherapy. Nonetheless, 5FC is still used in combination with Amphotericin B
24
. 
Azole antifungals miconazole and clotrimazole were introduced as topical agents in 1969, and 
represented the only two additions to the antifungal agents in the 1960s. The 1980s saw the 
development of the triazoles, which revolutionized the antifungal agent discovery since these 
6 
 
compounds were available both as intravenous and oral formulations. In addition, these agents 
were effective against fungal pathogens that were refractory to the polyenes. The 1990s were 
perhaps the most prolific period in antifungal development. It is during this time that triazoles 
were further developed and amphotericin B was reformulated with lipid compounds. These lipid-
based preparations were considerably less toxic and allowed the true efficacy of Amphotericin B 
to be explored
11
. 
The expansion in antifungal development continued into the new millennium with the 
advent of new class of antifungal called echinocandins. Since 2001, the echinocandin class has 
continued to expand with the introduction of micafungin and anidulafungin. The triazole class 
has also expanded with the addition of voriconazole and posaconazole, both of these have 
increased activity against fluconazole-resistant Candida spp. and filamentous moulds
15
. 
 
1.2. Pharmacological Targets for antifungal agents 
Fungi are eukaryotes and relatively closely related to humans. Fungal DNA is organized 
into chromosomes within the cell nucleus and they have distinct cytoplasmic organelles. Fungi 
also have similar DNA replication and protein synthesis mechanism. This close resemblance of 
biosynthetic pathways to mammalian cells makes it extremely hard to have pathogen-specific 
targets. Cell membrane that serves important role in cell structure, division, and metabolism is 
made up of sterols. The only difference between the mammalian and the fungal cell is the sterol. 
This makes identification of new targets difficult. In the pathogenic fungi, the main sterol is 
ergosterol and this has been exploited as the target of antifungal drug action by several classes of 
antifungal agents including the polyenes, azoles, and allylamines. Mainly three targets i.e. 
plasma membrane sterols, nucleic acid synthesis and cell wall constituents (chitin, 1,3-β-glucan, 
7 
 
and mannoproteins) have been exploited extensively so far with varying degrees of success. 
Various fungal targets and mode of action is depicted in Fig.1.2. 
 
1.3. Antifungal Agents Chemical Classification  
Fungal infections can be either systemic or superficial. They are usually difficult to 
diagnose and treat. Since fungi are eukaryotic, antibacterial are ineffective in treating them. 
Fungi closely resemble the human cells therefore, the currently available antifungals are toxic 
and non-selective in their action. The currently available antifungals can be chemically divided 
into following classes namely polyene, azoles, pyrimidines, echinocandins, sordarins and 
saponins. These classes are discussed in detail below. 
 
1.3.1. Polyenes Antifungals 
These are also known as ergosterol disruptors.  The polyene antifungals (Fig.1.3) act by 
complexing with ergosterol present in the fungal plasma membrane as shown in Fig.1.4. This 
binding leads to depolarization in the membrane, pore formation and increased membrane 
permeability. This results in the leakage of the cytoplasmic contents and ultimately death of the 
fungal cell. Thus, the polyenes are fungicidal
25
. The polyenes (AmB, nystatin) are large (26-28 
carbon molecules) macrolide structures, with many hydroxyl groups, which confers the 
amphipathic nature to the compounds (Fig.1.3).  
8 
 
Figure 1.3 Polyene antifungals 
 
Polyene Amphotericin B (Fig.1.3) was isolated from S. nodosum in 1956.  It has broad spectrum 
of antifungal activity against Blastomycesdermatitidis, Coccidioides immitis, Cryptococcus 
neoformans, Histoplasma capsulatum, Paracoccidiodes brasiliensis, Sporotrichiumspecies and 
Torulopsis glabrata
25,26
.  
Since, Amphotericin B is amphiphilic it can bind through both hydrophilic hydrogen 
bonds and hydrophobic, non-specific Van der Waals forces to ergosterol in fungal cell 
membrances
27
. Amphotericin B has a greater affinity to bind ergosterol and ergosterol-containing 
membranes than cholesterol or cholesterol-containing membranes
27a,28,29
.  
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Figure 1.4 Disruption of fungal cell membrane by Amphotericin
30
. 
 
Amphotericin B binds with up to 10 times more avidity to ergosterol than to cholesterol in the 
mammalian cells
26
. This provides high specificity to amphotericin for fungal cells. Amphotericin 
shows a rapid lethal action against the fungal pathogens in vitro, but these antifungals agents are 
not lethal in vivo
31
. A direct antifungal effect of AmB stimulates release of cytokines and 
interleukin-1 from mammalian phagocytic cells and macrophage superoxide ion, all of which 
augments the antifungal activity
32-34
. 
However, amphotericin B has been shown to affect mammalian cells, and nephrotoxicity 
is a common side effect reported with the clinical usage
35
.  Almost every patient develops some 
form of renal malfunction
2b
. Besides nephrotoxicity and infusion toxicity, amphotericin B also 
produces local thrombophlebitis, nausea and vomitting
36,37
. These toxicities can easily be 
minimized to varying degrees by pretreatment regimens. Second important polyene antifungal is 
Nystatin that was discovered in 1950 from the fermentation broth of Streptomyces noursei. 
10 
 
Because of unfavorable adverse effect profile of Nystatin, it is only used as a topical antifungal 
agent
38
. It is mostly non-absorbable after oral administration. It is effective in the treatment of 
oropharyngeal candidiasis
39
. 
 
1.3.2. Azoles 
Azoles are fungistatic antifungal agents with a broad-spectrum activity. These synthetic 
compounds can be classified as either imidazoles or triazoles according to the number of 
nitrogen atoms in the five-membered azole ring, as indicated below (Fig.1.5).  
 
Figure 1.5 Azole nucleus 
The imidazoles consist of ketoconazole, miconazole, and clotrimazole (Fig.1.6). The triazoles 
include itraconazole, fluconazole, voriconazole, posaconazole and ravuconazole. A triazole 
based pharmacophore has replaced the earlier imidazole pharmacophore in systemically active 
azoles because the triazole group enhances the specificity for fungal cytochrome p450 (erg11) 
targets and slows metabolism of the agents in vivo
40
. 
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Figure 1.6 Chemical structure of imidazole and triazole class of azoles
5
 
 
This class of antifungal agents has been most successful so far in terms of the number of 
different agents that have entered clinical use. However, because of toxicity and bioavailability 
problems associated with them, most of these antifungal imidazoles are formulated only for 
topical use and thus limited in their potential as systemic agents
41
. Agents licensed for clinical 
use in invasive fungal disease are fluconazole, itraconazole, posaconazole and voriconazole
9
. 
The antifungal activity of azole drugs results from the reduction of ergosterol synthesis by 
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inhibition of fungal cytochrome P450 3A-dependent C14-α-demethylase (Fig.1.7)42,5. Thus, 
azoles inhibit the conversion of lanosterol to ergosterol. This leads to depletion of ergosterol in 
fungal cell membrane
42-44
. 
 
 
Figure 1.7 Pathway of sterol synthesis of ergosterol and blocks by azoles
60
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The selective action of azole drugs on fungal cells results from their greater affinity for fungal 
than for human cytochrome P450 enzymes. Imidazoles exhibit a lesser degree of selectivity than 
the triazoles, accounting for their higher incidence of drug interactions and side effects.  The in 
vitro antifungal activity differs with each compound and the clinical efficacy may not coincide 
exactly with in vitro activity. The azoles are broad spectrum with primarily being active against 
C. albicans, C. neoformans, C. immitis, H. capsulatum, B. dermatitidis, P. brasiliensis, C. 
glabrata, Aspergillus spp. And Fusarium spp
2b,45a
. The azoles are relatively nontoxic with a 
relatively minor adverse reaction as gastrointestinal upset. Though all azoles have been reported 
to cause abnormalities in liver enzymes and, very rarely, clinical hepatitis
45
.  
Ketoconazole was introduced in 1981 as an oral azole antifungal for treatment of 
systemic fungal infection. It is a broad spectrum antifungal but causes hepatotoxicity and 
produce endocrine abnormalities by suppression of testosterone and ACTH-stimulated cortisol 
synthesis
2b,46a
.  Ketoconazole has greater ability to inhibit mammalian cytochrome P450 
enzymes. Therefore, it is less selective for fungal P450. As a result, systemic ketoconazole has 
fallen out of clinical use in the USA but is still used as a dermatologic cure. 
Itraconazole is another triazole antifungal agent with broad spectrum of activity. It also 
has activity against Aspergillus spp. Itraconazole is available for oral and intravenous usage. 
Because of inconsistent bioavailability after oral administration, itraconazole is given with food. 
Also, low pH enhances drug absorption after oral administration
2b,41,46a
.  Itraconazole interacts 
with hepatic microsomal enzymes just like other lipid-soluble azoles. When taken with 
rifamycins (rifampin, rifabutin, and rifapentine) bioavailability of itraconazole is reduced. 
However, it does not affect mammalian steroid synthesis, but its effect on the metabolism of 
other hepatically cleared medications is much less than those of ketoconazole. Although 
14 
 
itraconazole displays potent antifungal activity, its effectiveness can be limited by reduced 
bioavailability. Newer oral liquid and intravenous preparation utilizes cyclodextran as a carrier 
molecule to enhance solubility and bioavailability.  Absorption of Itraconazole in cerebrospinal 
fluid, eye and saliva are minimal
2b,41
. Itraconazole has been replaced by voriconazole as the azole 
of choice for aspergillosis. It is used extensively in the treatment of dermatophytoses and 
onychomycosis
2
. 
A highly water-soluble azole is Fluconazole and display good cerebrospinal fluid penetration. Its 
oral bioavailability is high compared to ketoconazole and itraconazole. Since fluconazole has the 
least effect of all the azoles on hepatic microsomal enzymes, the drug interactions are also less 
common. Fluconazole has the widest therapeutic index of the azoles, allowing aggressive dosing 
for a variety of fungal infections. The drug is available in oral as well as intravenous 
formulations. It is the treatment of choice for secondary prophylaxis of cryptococcal meningitis. 
Intravenous fluconazole has been shown to be equivalent to amphotericin B in treatment of 
candidemia in ICU patients with normal white blood cell counts. Fluconazole is the agent most 
commonly used for the treatment of mucocutaneous candidiasis. Activity against the dimorphic 
fungi is limited to coccidioidal disease, and in particular for meningitis, where high doses of 
fluconazole often obviate the need for intrathecal amphotericin B. Fluconazole displays no 
activity against aspergillus or other filamentous fungi
2
.  
Voriconazole is water-soluble second generation triazole and is available in intravenous 
and oral formulations. Voriconazole is approved for first-line treatment of invasive aspergillosis,                    
Oesophageal candidiasis
45b
. It is active against Aspergillus spp, Fusarium spp. and Candida spp. 
(including the fluconazole resistant or less susceptible spp. of C. glabrata and C. krusei)
26
. It also 
shows activity against the Fusarium and Scedosporium infections, which are hard to treat
46b
. 
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Observed toxicities of Voriconazole therapy include skin rash and hepatic enzymes transaminase 
elevation
47
, encephalopathy or hallucinations
48
. 
Posaconazole is the broadest spectrum member of the azole antifungal family, it is 
lipophilic second generation triazole antifungal with activity against most species of candida and 
aspergillus
50
. It was approved in 2006 by the FDA for prophylactic treatment of these
49
. It is the 
only azole with significant activity against the agents of zygomycosis and mucormycosis
51,52
. 
Posaconazole is rapidly distributed to the tissues, resulting in high tissue levels but relatively low 
blood levels. The toxicity associated with posaconazole therapy is gastrointestinal (14%), with 
hepatic transaminase elevation and hyperbilirubinemia occurring in 3%,
53
 and headache
54,55
, 
elevation of liver enzymes and skin rash
54
. 
 
1.3.3. Pyrimidines 
Another important antifungal agent is flucytosine. It is a nucleoside analogue that was 
synthesized in 1957 as a cytosine analogue. It interferes with both DNA and RNA synthesis and 
function
5
. It was designed for treatment of leukemia, but did not display any cytotoxic activity 
and was ineffective
2b
. Later in 1963 its antifungal properties were discovered. It acts as an 
antifungal agent through conversion into 5-fluorouracil within the fungal cells and gains entry in 
the cell via cytosine permease. Fluorouracil becomes incorporated into RNA, causing premature 
chain termination, and it inhibits DNA synthesis through effects on thymidylate 
synthase
41,45,46,56
.  This drug is selectively toxic to fungi because mammalian cells lack cytosine 
permease and do not convert large amounts of flucytosine to 5-fluorouracil. Flucytosine is 
primarily used in adjunct therapy with amphotericin B for Cryptococcus neoform
57-59
, if used 
alone it develops resistance quickly. This is used for treatment of candida endophthamitis and 
16 
 
meningitis, cryptococcal meningitis and in trichosporonosis
41,46
. Most filamentous fungi lack 
these enzymes and hence useful spectrum of flucytosine is restricted to pathogenic yeasts
58
. 
 
1.3.4. Echinocandins   
New millennium saw the introduction of a new class of antifungal agents called 
‘Echinocandins’. Presently there are three echinocandins that have been approved by the Food 
and Drug Administration (FDA). Caspofungin was approved first, in 2001, followed by 
micafungin in 2005 and anidulafungin in 2006
16
.  
 
 
Figure 1.8 Structures of Echinocandins Caspofungin, micafungin and anidulafungin
60 
 
The echinocandins are large natural cyclic lipopeptide molecules that represent the fourth 
class of antifungal agents available for the treatment of systemic fungal infections after polyenes, 
azoles and pyrimidines. Echinocandins (Fig.1.8) are products of cyclopentamine, which is 
formed during the fermentation of some fungi such as Zalerion arboricola or Aspergillus 
nidulans
61,62
. Since the incidence caused by fluconazole-resistant non-albicans fungal species is 
on rise it is predicted that echinocandins are going to play a major role in the treatment of these 
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types of infections
63,64
. These agents are active against candida and aspergillus, but not 
against C. neoformans or the agents of zygomycosis and mucormycosis
64
. 
The fungal target of the echinocandins is the synthetic cell-wall enzyme complex β-(1,3)-
D-glucan synthase
65
. Echinocandins inhibit the synthesis of β-(1,3)-D glucan, which is an 
essential component of the cell wall of several fungi, by noncompetitive inhibition of  an enzyme 
UDP-glucose β-(1,3)-D-glucan- β (3)-D-glucosyltransferase (commonly referred to as 1,3-β -D 
glucan synthase)
66-67
. Fungi are eukaryotes like human beings but the cell-wall is different from 
the mammalian cells, and therefore represents a good target for antifungal drugs
72
. Fig.1.9 is a 
diagrammatic representation of the glucan synthase protein complex, and its regulatory 
network
17
. Mechanistic details of glucan synthesis and its inhibition by echinocnadins is still 
unclear, largely because a membrane-associated protein complex is involved. There is no doubt 
that the component to which echinocandins bind is Fks1p, but their non-competitive inhibitory 
effects on glucan synthesis do not necessarily imply that Fks1p itself is the catalytic subunit, nor 
is it clear whether the echinocandin-binding site is external or internal to the cell membrane.  
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Figure 1.9 Transmembrane Fks1p and Fks2p protein complex involved in 1,3-β -D glucan synthesis fungal 
cell membrane
17
 
 
Echinocandins specifically target the cell-cycle regulated FKS1 gene transcription which is, 
linked to the cell-wall (Fig.1.9) remodeling and encodes for components of glucan synthase
70,71
. 
The inhibition of glucan synthase destabilizes the integrity of the fungal cell wall species of 
Candida, thus making the cell wall less rigid and unable to resist osmotic pressure, which 
ultimately leads to cell lysis
73-74
.  
All three echinocandins display good in vitro and in vivo fungicidal activity against most 
Candida spp., including strains of C. albicans, C. glabrata, C. tropicalis, C. dubliniensis, and C. 
krusei that are amphotericin- or fluconazole-resistant
17
. Echinocandins are usually extremely 
well tolerated, with only minor gastrointestinal side effects and flushing. Because of the large 
molecular weight of the all three echinocandin, a poor oral absorption is observed. Therefore, all 
three compounds are available as intravenous formulations only. Although, the metabolism of 
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these compounds is not fully understood and is still under investigation, but almost the entire 
drug is degraded by non-oxidative pathways in the liver
75
.   
Caspofungin has potent in vitro inhibitory activity against Aspergillus spp. and moderate 
activity against some other moulds such as H. capsulatum, C. immitis and B. dermatitidis. 
Although it is also active against P. carinii and moderately against dematiaceous fungi
78
, but it 
does not show any activity against C. neoformans, Trichosporon spp., Fusarium spp., S. 
schenckii, zygomycetes and hyalohyphomycetes
76,77
. Because of limited interactions of 
Caspofungin with cytochrome P-450 system as it is neither a substrate nor an inhibitor, it has 
only few side effects like headache, fever, nausea, rash, phlebitis at the site of infusion and 
reversible elevation of hepatic enzyme levels
78
.  
Micafungin was approved for the treatment and prophylaxis of O. candidiasis in patients 
undergoing stem cell transplantation
78
. Micafungin has less drug interaction compared to 
capsofungin
79,80
. Micafungin has been found to display superior activity than fluconazole when 
used as a prophylactic for stem cell transplant patients
80
.  
Anidulafungin was approved for use in the treatment of O. candidiasis, candidaemia, 
peritonitis and intra-abdominal abscesses due to Candida spp
78
. It is highly active in vitro against 
a wide range of Candida spp., including species that are resistant to azoles (C. krusei), 
amphotericin B (C. lusitaniae) or other echinocandins (C. parapsilosis)
82,84
 and also against 
Aspergillus spp
85
. It is unique in echinocardin class of antifungals because of its ability to slowly 
undergo a process of biotransformation rather than metabolism in humans
78
. The most common 
adverse effects associated with it were found to be hypotension, vomiting, constipation, nausea, 
fever, hypokalaemia and elevated hepatic enzymes
78,83
. 
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All echinocandins are fungicidal against most Candida species and retain activity against 
azole-resistant strains
67
. However, there are notable gaps in their fungal spectrum of activity. The 
toxic-effects profile of the three echinocandins is favourable, and certainly less of a problem 
compared to amphotericin B, whether in complex with lipid or not
75
. Caspofungin might have a 
narrower therapeutic window with respect to liver-function tests and concurrent use with 
cyclosporin than micafungin and possibly anidulafungin
75
. 
 
1.3.5. Sordarins 
 Sordarin (Fig.1.10), isolated from Sordaria araneosa in 1971
86
, has been identified as 
selective inhibitors of fungal protein synthesis. These are semi-synthetic natural products that
87
 
have generated considerable interest as new antifungal agents. Several types of novel sordarin 
derivatives were developed preclinically in the 1990s by Glaxo–wellcome and merck88. These 
compounds primarily exert their antifungal effect by specifically inhibiting the protein synthesis 
elongation cycle without affecting protein synthesis machinery in mammalian systems
89
. 
 
Figure 1.10 Chemical structure of Sordarin 
 
The proposed mechanism of action of these compounds is the inhibition of a novel target for 
antifungal agents: elongation factor 2 in protein biosynthesis
90
. They exert their effect by 
blocking the function of fungal translation. Since these specific targets are, absent in mammalian 
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cells or electron transport chain their action is selective for the fungal cells
91
. Some sordarin 
derivatives have shown excellent in vitro activities against a wide range of pathogenic fungi, 
including Candida spp., C. neoformans, P. carinii and certain filamentous fungi and some 
emerging invasive fungal pathogens
92
. 
 
1.3.6. Saponins 
Saponins have attracted a lot of attention in past few years. They are the emerging class 
of new antifungal agents as seen by scientist. Saponins are the secondary metabolites in the 
biosynthetic pathway of plant metabolism. Saponins have also been identified in some marine 
organisms and insects
95
. Their usefulness as antifungal agents recently has attracted a lot of 
attention from the researchers. Chemically, they generally occur as glycosides of steroids or 
polycyclic triterpenes
93
. These chemical compounds are amphiphilic in nature and are made up 
of two parts. The aglycone part is glycoside free termed as sapogenin. Because of their 
amphiphilic character, they are able to interact with cell membranes and are also able to decrease 
the surface tension of an aqueous solution. Because of this activity, they are named “saponin”, 
which in turn is derived from the Latin word “sapo”, meaning formation of a stable soap-like 
foam in aqueous solution
94
. Saponins consist of a sugar moiety usually containing glucose, 
galactose, glucuronic acid, xylose, rhamnose or ethylpentose, glycosidically linked to a 
hydrophobic aglycone (sapogenin) which may be triterpenoid or steroid (Fig.1.11) in nature
96
. 
Based on the chemical nature of the aglycone (also known as sapogenin), saponins can be 
divided into steroidal, steroidal alkaloidal and triterpenoid saponins (Fig.1.11). The aglycone part 
of the saponins may contain one or more unsaturated C–C bonds. The oligosaccharide chain is 
normally attached at the C3 position (monodesmosidic), but many saponins have an additional 
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sugar moiety at the C26 or C28 position (bidesmosidic)
97
. The great complexity of saponin 
structure arises from the variability of the aglycone structure, the nature of the side chains and 
the position of attachment of these moieties on the aglycone. Experiments demonstrating the 
physiological, immunological and pharmacological properties of saponins have provoked 
considerable clinical interest in these substances
97
. 
 
Figure 1.11 Classes of saponin. 
 
Steroidal saponins derived from plant source are mainly the compounds containing 27 carbon 
atoms forming the core structures, i.e., spirostan (Fig.1.12) and furostan
98
. 
 
 
 
 
 
Figure 1.12 Core structure of spirostane 
 
 
Saponins have been reported to have a numerous pharmacological activities
99
. Few of the 
important ones are permeabilizing of the cell membrane
99a
, stimulation of luteinizing hormone 
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release leading to abortifacient properties
99c
, immunomodulatory potential via cytokine 
interplay
99b
, lowering of serum cholesterol levels
99c
,  cytostatic and cytotoxic effects on 
malignant tumor cells
99a
, adjuvant properties for vaccines as immunostimulatory complexes
99a
, 
and synergistic enhancement of the toxicity of immunotoxins
99b,c
.  
Both the aglycone and oligosaccharide moieties of saponins have been shown to be 
important for their biological activity
110-112
. The effectiveness of saponins has long been 
recognized in herbal medicine but they were not typically viewed as potential drug targets in the 
past due to their structural complexity. One exception to this rule is digoxin (Fig.1.13) which is a 
cardiac glycoside isolated from the leaves of the foxglove plant Digitalis lanata and has been 
marketed for over 200 years to treat congestive heart failure. Digoxin binds to Na
+
/K
+
 ATPase 
pumps in cardiac cell membranes and alters the membrane potential by changing the 
concentration of ions, which in turn increases the contraction strength of the cardiac muscles
111
.
 
Digoxin is an unusual saponin and is available only by isolation from natural sources. The 
advances in the synthesis of glycoconjugates have not yet been successful in synthesis of this 
alkaloidal saponin.  
24 
 
 
Figure 1.13 Antifungal saponins 
 
A steroidal saponin isolated from bulbs of the lily plant Ornithogalum saudersiae OSW-1 
(Fig. 1.13) has shown in vitro anti-tumor activity levels that are 10-100 times more effective than 
many well-known anticancer compounds including taxol and cisplatin
113
. Because of its unusual 
mechanism of action, it has the potential to be effective against cancers that are resistant to 
currently available chemotherapy. OSW-1 causes damage to the mitochondrial membranes, 
which in turn disrupts the calcium levels in the cytoplasm of the cell and ultimately leads to cell 
death by apoptosis. At the same time, OSW-1 has been documented to possess potent in vitro 
antifungal properties. For example, a derivative of the triterpene medicagenic acid (Figure 1.13), 
isolated from alfalfa root extracts was revealed to be effective against fungal skin infections in 
guinea pigs and did not show dermal toxicity in rhesus monkeys. It also showed promise toward 
the treatment of invasive fungal infections by successfully treating Cryptococcus neoformans 
infections in mice with a minimal inhibitory concentration of 4 μg/mL. This saponin was also 
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effective against amphotericin B-resistant strains of Candida tropicalis
113
. It was synthesized in 
three steps from medicagenic acid and acetobromomaltose in 49% overall yield.
112 
Another 
important saponin CAY-1 has been identified to be effective in the treatment of invasive fungal 
infections (Fig.1.14). CAY-1 was isolated in 0.1 % yield from the fruit of the cayenne pepper 
plant, Capsicum frutescens to provide sufficient quantity for preliminary testing for antifungal 
activity and cytotoxicity toward mammalian cells
113
. The preliminary studies indicated CAY-1 to 
be an effective antifungal agent against sixteen fungal strains of Candida species, Aspergillus 
fumigatus, Cryptococcus neoformans, and Neurospora crassa. The most promising result was 
the activity of CAY-1 against C. neoformans (IC90 < 1μg/mL), a fungal species responsible for 
cryptococcal meningitis in HIV/AIDS patients, a fatal disease if left untreated.
113 
 
 
Figure 1.14 Structure of antifungal saponin CAY-1. 
 
The predominant mechanism of antifungal activity of saponins is due to their ability to complex 
with sterols in fungal membranes which results in loss of membrane integrity (Fig.1.15). The 
precise mechanism is not fully understood and is still under investigation. Experimental analysis 
suggests the formation of transmembrane pores. Aggregation of the saponin-sterol complexes in 
the membrane may be mediated by interactions between the sugar residues of the saponin 
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molecules.  The sugar chain attached to C-3 is usually critical for both the membrane-
permeabilizing and antifungal properties of saponins, and removal of these sugar residues 
often results in loss of biological activity
102
. 
 
 
 
Figure.1.15 Proposed mechanism for membrane disruption by saponins
103
. 
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1.4. Resistance to antifungal agents 
Resistance to antifungals can be divided into two categories namely clinical resistance 
and in vitro resistance. A lack of clinical response to the antifungal agents used to treat the 
fungal infections is termed as clinical resistance. Low levels of the drug in the serum and/or 
tissue due to various reasons like immune-compromised state in AIDS patients and 
noncompliance with medication regimen can lead to clinical resistance. Even high doses of 
fungicidal agents are not able to eradicate the fungal infection from the host. The in vitro 
resistance has been divided into primary (innate or intrinsic resistance) and secondary (acquired) 
resistance. This form of resistance was rare in the past but is now most frequently reported in 
AIDS patients who suffer from recurrent azole-resistant oropharyngeal or esophageal 
candidiasis
114
. 
 
Azoles resistance 
Resistance may be defined as a treatment failure in association with high or rising 
minimum inhibitory concentrations (MICs) for the same fungal strain while receiving a therapy. 
Many factors such as pharmacodynamic parameters, fungal virulence, host and differences in 
susceptibility testing methods further impair the analysis of a possible link between MIC and 
outcome
101
.  Several mechanisms of azole-resistance have been identified, including enhanced 
efflux of the azole by up-regulation of multidrug efflux pumps, alterations in the cellular target 
of azoles (Erg11p), and modification of the ERG11 gene at the molecular level
101
. Resistant 
strains either exhibit a modification in the quality or quantity of target enzyme, reduced access to 
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the target, or some combination of these mechanisms. These changes bring about the increased 
efflux or alteration in drug metabolism or both. These mechanisms are summarized in Fig.1.16. 
  
Figure 1.16 Mechanisms by which microbial cell might develop resistance. 1, The target enzyme is overproduced, 
so that the drug does not inhibit the biochemical reaction completely. 2, The drug target is altered so that the drug 
cannot bind to the target. 3, The drug is pumped out by an efflux pump. 4, The entry of the drug is prevented at the 
cell membrane/cell wall level. 5, The cell has a bypass pathway that compensates for the loss-of-function inhibition 
due to the drug activity. 6, Some fungal “enzymes” that convert an inactive drug to its active form are inhibited. 7, 
The cell secretes some enzymes to the extracellular medium, which degrade the drug
102
. 
 
Resistance to the echinocandins has been attributed to mutations in the genes that code 
for 1,3-β-D-glucan synthase, specifically Fks1 and, to a lesser extent, Fks2. Mutations in these 
genes result in alterations in the formation of the Fks1 catalytic subunit of the glucan synthase 
complex which is the primary target of the echinocandins
73
. Another proposed mechanisms of 
resistance to the echinocandins include the presence of a drug efflux pump in the fungal cell wall 
12
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and overexpression of cell wall transport proteins. The incidence of resistance to echinocandins 
is rare
73
. 
 
1.5. Prevention and Control of Antifungal Resistance 
There are definite guidelines and strategies for appropriate use of antimicrobials but none 
of them provide a strategic plan for combating antifungal resistance. Therefore, analogous 
comprehensive strategy to address the threat of antimicrobial resistance could be suggested for 
antifungals
106-108
. The strategy must aim to decrease the transmission of resistant organisms. This 
could be achieved by measures that include:  
(i) Rational use of available antifungal agents. 
(ii) Rapid and accurate diagnosis of fungal infections.  
(iii) Appropriate dosing with special emphasis on avoiding treatment with low antifungal dosage. 
(iv) Treatment with the appropriate antifungal. 
(v) Therapy with combinations of existing agents.  
(vi) Use of surveillance studies to determine the true frequency of antifungal resistance. 
(vii) Treatment must aim to decrease the transmission of resistant organisms.  
Advancement in rapid diagnosis of fungal infection is an urgent need. Diagnosis plays an 
important role in timely treatment and prevention of spread of infection. Unfortunately, progress 
in developing diagnostic methods specific to fungi has been slow.  
 
1.6. Clinical need for New Antifungal Agents 
Eight hundred million years of evolution have generated approximately 1.5 million 
fungal species that occupy many distinct ecological niches, yet only about 300 fungi cause 
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diseases in humans
103
. The identification of antifungals that act specifically against these 
pathogens is a particular challenge because of fungal diversity, individualized pathways for 
infection, and fungal use of multiple mechanisms that circumvent exogenous toxins. These 
highly regulated mechanisms include innate resistance to specific antifungal drugs, formation of 
biofilms, natural selection of spontaneous mutations that increase expression or decrease 
susceptibility of the drug target
103
, stress-related tolerance that enhances short-term survival, 
modification of chromosomal ploidy, and overexpression of multidrug efflux pumps. However, 
the economic cost of fungal infection and its associated mortality, especially in debilitated and 
high investment patients, remain unacceptably high. The most prominent fungal pathogens 
affecting humans include Aspergillus fumigatus, Candida albicans, C. glabrata, C. parasilosis, 
C. tropicalis, C. krusei, and Cryptococcus neoformans. Although the skin, mucosal surfaces, and 
immune system usually provide robust defenses, weakened immune system dramatically 
increases susceptibility to debilitating and life-threatening opportunistic fungal infections. Fungal 
infections are normally treated with a modest repertoire of drugs derived from five antifungal 
classes that target DNA and RNA synthesis, ergosterol, the ergosterol biosynthetic pathway, or 
the biosynthesis of the cell-wall component 1,3-β-D-glucan. Unfortunately, the prophylactic use 
of fungistatic azoles such as fluconazole has been associated with an increased frequency of 
innate or acquired drug resistance in clinical isolates and the selection of non-albicans Candida, 
non-fumigatus Aspergillus, opportunistic yeast-like fungi, zygomycetes, and hyaline molds. 
Despite the fact that broader-spectrum third-generation azole drugs and the more expensive 
echinocandin class of antifungals prevent an increased proportion of life-threatening infections, 
Candida species still remains the fourth most common cause of hospital-acquired bloodstream 
infection and kill 40% of the patients, whereas disseminated Aspergillus infections kill up to 
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80% of affected patients
109
. Because of its economic and clinical impact, a focus is on multidrug 
therapy. Therefore, it is also important that physicians have access to a large number of 
antifungal medications to improve their chances of finding one that is both effective for treating 
the infection and will not interact with other medications the patient may be taking. The 
availability of molecular genetic tools has led to a rapid expansion in our understanding of the 
mechanisms by which microbial resistance emerges and spreads and promises to greatly improve 
efforts to develop novel and effective compounds for future use. With increased use and 
availability of different classes of antifungal agents, it is anticipated that we will see an 
increasing number and variety of fungal species resistant to these agents. Unfortunately, due to 
increased resistance and the emergence of new opportunistic infections, there is still a dire need 
for the development of new antifungal compounds. 
 
1.7. Fungal Strains for Antifungal studies  
Fungi are abundant worldwide and most of the fungi are inconspicuous. They are 
noticeable as mushrooms and molds. Although fungi play an essential role in decomposition of 
organic matter and have a fundamental role in nutrient cycling and exchange. They have also 
been used as source of food, fermentation of various food products, and production of 
antibiotics. Many fungal species produce bioactive compounds like alkaloids and polyketides 
that can be dangerous to humans. Fungi are ubiquitous and some species are responsible for 
causing serious diseases in humans, some of them can become fatal if left untreated for a long 
time. Mostly fungal infections are treatable in generally healthy individuals. However, the same 
infections become more difficult to treat in individual with weakened immune systems such as 
patients with HIV/AIDS, diabetes, undergoing organ transplant, chemotherapy or taking 
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antibiotics. In these cases, the fungal infections can get complicated and become life threatening. 
Generally there are three types of fungal infections namely, superficial, subcutaneous and 
systemic fungal infection. A fourth category is the opportunistic fungal infection mainly found in 
immune-compromised patients. 
 
Opportunistic Infections Causative Organism Target Organs 
Candidaisis, Thrush, 
Vulvovaginitis 
Candida albicans GI tract and vagina 
 
Cryptococcal meningitis Cryptococcus neoformans Through inhalation, may cause 
mild lung infection. Mainly 
affects CNS 
Aspergillosis 
 
Aspergillus sp. Lung, brain, sinuses and other 
organs 
Mucormycosis 
 
Murcor sp. Sinuses, eyes, blood and brain 
Pneumocystis carinii pneumonia Pneumocystis carinii 
 
Lungs (especially prevalent in 
HIV patients) 
 
Organisms responsible for the opportunistic fungal infections may not be a threat to healthy 
individuals, but can cause life-threatening infections in the immune-compromised patients 
especially those suffering from HIV and other immune-deficiencies, cancer, diabetes, 
undergoing organ transplant, blood transfusion or receiving corticosteroid treatment. These 
organisms are prevalent throughout the U.S. and worldwide. Based on these the following fungal 
strains were chosen for our studies. 
 
1. Candida albicans 
Candida albicans is found on the skin and mucosal surfaces of all human beings. This 
remarkably successful and versatile human pathogen is harmless but can cause life-threatening 
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infections when the immune system is weakened
115
. This opportunist pathogen usually invades 
host tissues and eliminates the competing bacterial flora (e.g. from broad-spectrum antibiotic 
use). Invasive candidiasis is particularly common in intensive care units where mortality rates 
reach 45–49%115b. Prior colonization of mucosal surfaces with C. albicans can also lead to 
debilitating superficial infections in otherwise normal hosts. Approximately 75% of all women, 
usually have one episode of Candida vaginitis in their lifetime, with half having at least one 
recurrence
116
. 
 
Figure 1.17 Candida albicans- yeast and new hyphae stages
115a 
C. albicans grows vegetatively as yeast or hyphae, and each form contributes to pathogenesis. C. 
albicans yeast cells colonize mucosal surfaces and facilitate dissemination of the organism 
through the blood stream
116
. Hyphae, by contrast, are important for host invasion and tissue 
destruction
115
. Factors affecting these diverse growth patterns during infection are poorly 
understood, but it is clear that innate immune mechanisms in mammalian epithelial cells 
normally prevent C. albicans from becoming a pathogen. Research has suggested the interactions 
between C. albicans and the mammalian innate immune system dictate the virulence potential of 
this specialized pathogen, yet relatively little is known about the molecular mechanisms 
underlying these interactions
116
. 
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2. Cryptococcus neoformans 
Cryptococcus neoformans is composed of two varieties namely C. neoformans variety 
neoformans and variety grubii. Cryptococcus neoformans grows as unicellular yeast and 
replicates by budding
117
.  
 
Figure 1.18 Encapsulated pathogenic yeast fungus Cryptococcus neoformans
117a
  
During mating hyphae are made which eventually creates basidiospores at the end of the hyphae 
before producing spores. The cells are capable of producing a characteristic polysaccharide 
capsule
117b
  under conditions like low glucose, serum, 5% carbon dioxide, and low iron to name 
a few. Also, on exposure to radiation such as gamma-radiation C. neoformans grows rapidly. 
Radiation appears to increase the electron-transfer capability of melanin in the fungus thereby 
increasing the total metabolic activity of fungal cells
118
. A fully grown C. neoformans has a 
prominent capsule which is mostly composed of polysaccharides. For microscopic identification, 
the India ink stain is used for easy visualization of the capsule in cerebral spinal fluid. As the 
particles of ink pigment do not enter the capsule that surrounds the spherical yeast cell, this 
results in a zone of clearance or "halo" around the cells and allows for quick and easy 
identification of C. neoformans. For identification in tissue, Mucicarmine stain provides specific 
staining of polysaccharide cell wall in Cryptococcus neoformans. Infection caused by C. 
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neoformans is termed cryptococcosis. It is responsible for infections predominantly for lungs, 
although fungal meningitis and encephalitis have been reported as a secondary infection 
especially for AIDS patients
118
. Those with a fully functional immune system rarely contract 
infections with this fungus. There C. neoformans is often referred to as an opportunistic 
fungus. It is a facultative intracellular pathogen
117
.
  
 
3. Candida glabrata 
Until recently Candida glabrata was considered a relatively nonpathogenic saprophyte of 
the normal flora of healthy individuals, rarely causing any serious infection in humans
114
.  A 
widespread and increased use of immunosuppressive therapy together with broad-spectrum 
antimycotic drugs has increased the frequency of mucosal and systemic infections to a 
considerable amount
114
. Candida glabrata is haploid yeast of the genus Candida, previously 
known as Torulopsis glabrata. Candida species are most frequently isolated from the oral cavity 
and are detected in approximately 31 to 55% of healthy individuals
114
. C. glabrata has shown to 
be a highly opportunistic pathogen of the urogenital tract, and of the bloodstream (Candidemia). 
It is especially prevalent in HIV positive people, and the elderly. 
 
Figure 1.19 Candida glabrata 
118b
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Depending on the site of infection, C. glabrata is often the second or third most common cause 
of candidiasis after C. albicans. C. glabrata infections can be mucosal or systemic and are 
common in immunocompromised persons. C. glabrata infections are difficult to treat and are 
often resistant to many azole antifungal agents, especially fluconazole. Consequently, C. 
glabrata infections have a high mortality rate in compromised, at-risk hospitalized patients. 
Increased colonizations have been observed with severity of illness and duration of 
hospitalization
114
. 
 
4. Aspergillus fumigatus 
Aspergillus fumigatus is a saprophytic fungus that resides in soil, wherein it survives and 
grows on organic debris. It plays an essential role in recycling environmental carbon. Despite the 
fact that this fungal species is not the most prevalent fungus in the world, it is one of the most 
ubiquitous of those with airborne conidia
119
. Inhalation of conidia by immunocompetent 
individuals rarely has any adverse effect, since the conidia are eliminated relatively efficiently by 
innate immune mechanisms. Thus, until recent years, A. fumigatus was viewed as a weak 
pathogen responsible for allergic forms of the disease, such as aspergilloma, an overgrowth of 
the fungus on the surface of preexisting cavities in the lungs of patients treated successfully for 
tuberculosis, or farmer’s lung, a clinical condition observed among individuals exposed 
repeatedly to conidia. 
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Figure 1.20 Aspergillus fumigatus
 119a
 
 
The increase in the number of immunosuppressed patients and the degree of severity of modern 
immunosuppressive therapies has changed the situation dramatically in recent years. Over the 
past 10 years, A. fumigatus has become the most prevalent airborne fungal pathogen, causing 
severe and usually fatal invasive infections in immune-compromised patients in developed 
countries
119
. A fourfold increase in invasive aspergillosis (IA) has been observed in the last 12 
years. Aspergillus fumigatus is an opportunistic filamentous fungus, which is the most frequent 
cause of invasive fungal infections in severely immune-compromised patients. A fumigatus is 
characterized by its angiotropism and propensity for angioinvasion
120
. Inhalation of asexual 
spores (conidia) by susceptible persons initiates invasive aspergillosis, which then germinates 
within the alveolar spaces, and penetrate the respiratory epithelium and vascular endothelium
120
. 
The release of proinflammatory cytokines and activation of the coagulation cascade is caused by 
the vascular invasion by A fumigates. This results in events like intravascular thrombosis and 
tissue ischemia that may cause sequestration of Aspergillus-infected tissue, limiting the delivery 
of immune effector cells and antifungal drugs to the site of infection
120
. Host with quantitative or 
qualitative defects in their polymorphonuclear leukocytes usually have extensive fungal 
proliferation and coagulative necrosis as prominent features of invasive aspergillosis. Even the 
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treatment with the advanced novel antifungal agents has not been able to reduce the mortality 
rate in immunosuppressed patients with invasive aspergillosis. Modulation of host angiogenesis 
by secreted A fumigatus secondary metabolites is a novel aspect of the pathogenesis of this 
important opportunistic fungus. 
 
 
1.8. Aim of project 
The aim of this dissertation for the research towards development of novel steroidal 
saponins is threefold. Firstly, literature clearly indicates saponins isolated from natural plant 
sources to be potential antifungal agents with minimal to no fungal resistance. Since the isolated 
yields of these saponins are exceptionally low, the final products are limited in their availability 
in sufficient quantity and purity for extensive biological studies. Therefore, development of 
practical synthesis of steroidal saponins would be able to provide sample in sufficient quantity 
and purity to explore the biological activity and understand underlying mechanism of action. 
Secondly, a multi-drug therapy is usually a remedy to overcome drug resistance. 
Therefore, incorporation of barbiturate derivatives into the steroidal saponins would provide a 
new class of novel barbiturate saponins. These would be studied extensively for their biological 
activity, medicinal utility and their mechanism of action.   
Thirdly, develop a practical synthetic strategy that could be employed at a commercial 
scale. One of the classic challenges of carbohydrate chemistry is to efficiently synthesize 
carbohydrate-based compounds and conjugates. In order to achieve the desired synthesis of 
novel barbiturate saponin derivatives develop methodology that is simple, efficient and cost-
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effective by using unprotected saccharide. This would lead to a diverse array of saponin 
derivatives that could be investigated in future for extensive structure-activity relationship 
studies.  
Finally perform antifungal assay for various steroidal saponin derivatives and sketch the 
SAR studies in order to identify the most potent antifungal agents of this class of compounds. 
For in vitro toxicity studies cell line assay would be performed followed by studies on animal 
models depending on toxicity profile.  
Synthetic challenge  
The structural complexity that makes carbohydrates important in so many biological 
processes sometimes renders their chemical synthesis difficult. Though it is possible to 
synthesize pure oligosaccharides in the laboratory, the regioselective protection of hydroxyl 
groups and the stereoselective assembly of glycosidic bonds present a number of challenges for 
synthetic chemists. The same regioselectivity challenges are also encountered when working 
with monosaccharides. The preparation of complex carbohydrates requires the strategic 
placement of protective groups that mask hydroxyl groups. Whilst the ability to remove one 
protecting group in the presence of another is a key feature, the steric and electronic nature of the 
protecting groups are also important as they greatly influence both the reactivity of the building 
blocks and the outcome of any glycosylation reactions. The properties of the protecting group 
next to the anomeric centre are very important. For example, a participating or non-participating 
functional group plays a significant role in the control of glycoside stereochemistry. Therefore, 
protecting groups on sites near the anomeric centre must be chosen carefully. The biggest 
challenges in carbohydrate synthesis are not only concerned with the stereoselective 
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glycosylation of two or more sugars but also the preparation of monosaccharide derivatives. In 
this case protecting group manipulation is also essential to afford a regioselectively protected 
saccharide so that other functional groups can be introduced at the desired position. Some 
protection strategies are the same for a number of monosaccharides for example glucose, 
mannose and galactose. This is generally the case for pathways to free primary hydroxyl groups. 
Standard methods for the selective protection of this position include tritylation or silylation 
followed by acetylation or benzylation of the remaining secondary hydroxyls. The primary 
protecting group can then be selectively removed. Since the reactivity differences between 
secondary hydroxyls are not that large, one step selective protection is challenging. Some 
methods developed for this purpose include Stannyl activation. By reacting carbohydrate 
hydroxyl groups with tin oxide reagents, stannylene ethers and acetals are formed. These 
stannylenes increase the nucleophilicity of the oxygens so that successive acylation or alkylation 
can be performed regioselectively. Therefore, we would like to develop synthetic strategy to use 
unprotected saccharides in our pursuit of developing novel barbiturate steroidal saponins. 
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CHAPTER-2: SYNTHESIS OF NOVEL STEROIDAL BARBITURATE SAPONINS 
 
The increasing burden of the opportunistic fungal infections and developing resistance to 
the currently available antifungals has created a need for new and more potent antifungal 
compounds. Advances in medical treatment, specifically the use of antibiotics, 
immunosupressant drugs and steroids suppress patient’s immune system and make them more 
susceptible to fungal infections. At the same, the time invasive procedures also contribute to the 
rise in oppportunisitic fungal infections. Ironically even with this fungi seems to be the most 
neglected pathogens, as evident by the fact that amphotericin B, a polyene antibiotic discovered 
in 1956, is still used as a “gold standard” for antifungal therapy. The challenge is to develop 
effective strategies for the treatment of fungal infections considering the increase in opportunistic 
fungal infections in immunocompromised patients. A vast majority of clinically used antifungals 
suffer from various drawbacks in terms of toxicity, efficacy and cost, and developing resistance. 
With this there is a great need to develop novel antifungals belonging to a wide range of 
structural classes that have high selectivity and fewer side effects.  
Recently synthetic derivatives of natural steroids have become a promising approach for 
discovery of new antifungal compounds. M. R. Banday et al.
9b
 synthesized and investigated the 
antifungal activities of fatty acid analogues of cholesterol based on the fact that fatty acids and 
derivatives are reported as antimicrobial compounds. Of the 8 synthesized compounds only 
compounds 1 and 2 (Fig.2.1) showed good antifungal activity against all strains of fungi. 
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Figure 2.1 Active fatty acid analogues of cholesterol reported by M. R. Banday et al.
9b 
 
Additionally series of cholesterol-hydrazone derivatives were synthesized and evaluated for 
antifungal activity by C. Loncle et al. The studies indicated that the tosylhydrazone cholesterol 
derivatives 3 and 4 exhibited activities against Candida albicans at a concentration of 1.5g/ml 
and against Amphotericin B and miconazole resistant strain C. albicans at a concentration of 25 
and 12.5 μg/ml (Scheme 2.1)6b.  
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Scheme 2.1 Synthesis of hydrazone derivatives of cholesterol by C. Loncle et al.
6b
 
 
Several barbituric acid derivatives were synthesized and tested against Candida albicans 
and Candida glabrata. The nitrophenylhydrazone derivatives of barbituric acids were 
synthesized by refluxing the 5-acylbarbituric acid and the corresponding hydrazine in methanol, 
followed by the isolation and purification of the product
56
.  A series of hydrazone and long chain 
barbituric acid derivatives were evaluated. It was observed that hydrazone derivatives of 
barbituric acid had a better antifungal activity compared to the long chain barbiturates. 
Compound BA 22 was the most active of all the evaluated compounds with activity against 
Candida albicans and Candida glabrata at a concentration of 4 µg/mL and 2 µg/mL 
respectively. The antifungal activity of all the synthesized barbituric acid derivatives is 
summarized in table 2.1.   
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Compound Structure C. albicans C. glabrata C. neoformans
 
 A. fumigatus
 
 
BA22 
NO2
N
H
H
N
H
N
HN
O
O O
 
4 µg/mL 2 µg/mL NA NA 
BA23 
NO2
N
H
H
N
N
N
O
O O
CH3
H3C
 
4 µg/mL 4 µg/mL NA NA 
BA24 
NO2
N
H
H
N
H
N
HN
O
O O
NO2
 
NC
* 125 µg/mL NA NA 
BA25 
NO2
N
H
H
N
CH3
H
N
HN
O
O O
 
4 µg/mL 2 µg/mL NA NA 
BA28 
NO2
N
H
H
N
CH3
N
HN
O
O
C6H5
O
 
NC
* 8 µg/mL NA NA 
BA40 
H
N
HN
O
O O
 
NC
* NC* NA NA 
BA41 
H
N
HN
O
O O
 
125 µg/mL NC* NA NA 
BA42 
H
N
HN
O
O O
 
16 µg/mL NC* NA NA 
BA43 
N
N
O
O O
CH3
H3C
 
62 µg/mL 125 µg/mL NA NA 
Table 2.1 Barbituric acid derivatives and their antifungal activities.  
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a. MIC values are reported only for compounds displaying (1) a prominent decrease in turbidity by visual comparison to the control wells 
containing no antifungal and (2) a >25% reduction in fungal growth compared to controls containing no antifungal, as measured spectroscopically 
by absorption at 530 nm.  b. All values were determined after incubation at 30–35 °C for 48 h. c. Compounds that had (1) a slight reduction in 
turbidity to no change and (2) had less than a 10% reduction in growth compared to   controls, as measured spectroscopically by absorption at 530 
nm. NA (Not available) 
The studies clearly indicated that the N,N-dimethyl barbituric acid and barbituric acid 
derivatives had the same range of activity against the fungal strains. Therefore, it was concluded 
that the presence or absence of methyl groups on the nitrogen of the barbituric acid derivatives 
has minimal to no effect on the antifungal activity. After having successfully tested barbiturate 
derivatives for antifungal activity, they were evaluated for toxicity profile. The in vitro toxicity 
studies were conducted on the liver cells, skin cells and the vero cells of animal models. It was 
observed that barbituric acid derivatives (table 2.1) were well tolerated even at concentrations as 
high as 200 µg/mL. With the promising antifungal activity of barbiturates, it was decided to 
develop a new class of novel barbiturate steroidal saponins and explore their antifungal SAR 
studies. 
The need to synthesize novel antifungal compounds is necessary because of the 
increasing burden of the opportunistic fungal infections and developing resistance to the 
currently available antifungals. It is a well-known fact that multi-drug therapy could help 
overcome drug resistance. With this rationale, incorporation of barbituric acid derivatives 
coupled to saccharides into the steroidal skeleton would provide novel agents that would be 
active at two or more drug targets. This in turn could minimize the extent of drug resistance. To 
achieve the set target the synthesis would be carried out in three major steps. 
Step 1: C-glycosylation of barbituric acid and its derivatives with unprotected monosaccharides 
and dissacharides under mild basic conditions in aqueous medium. 
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Step 2: Synthesis of a library of steroidal derivatives with various aliphatic and aromatic linker 
connected through carbamate, carbonate and ether linkage. 
Step 3: Chemical ligation of C-glycosylated barbiturates from step 1 to steroid linker derivative 
(from step 2) into one molecule as shown (Fig. 2.2). 
 
Figure 2.2 Steroidal barbiturate saponin proposed synthesis  
In order to prepare the new class of novel barbiturate steroidal saponins N, N-dimethyl barbituric 
acid or barbituric acids could be coupled to various monosaccharides and dissacharides (Fig. 2.2) 
under glycosylation procedure without employing protection and deprotection techniques. This 
could be further coupled to the steroidal skeleton through various linkers like carbonate, 
cabamate, ether, or ester (both aliphatic and aromatic). A detailed reaction strategy with the 
problems encountered at various stages of synthetic procedure and solutions thereof are 
described in the subsequent sections. 
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2.1. Glycosylation methods 
The usual chemical glycosylation process involves the coupling of glycosyl donor to a 
glycosyl acceptor to give a new covalent bond called glycosidic bond
1
. A glycosidic bond is a 
type of covalent bond that joins a carbohydrate molecule to another group, which may or may 
not be another carbohydrate. The saccharide moiety involved in the glycosylation has to be 
protected to carry out the synthesis of glycosidic bond.  The resulting glycosidic bond can be a 
O-glycosidic bond (containing oxygen), S-glycosidic bond (thioglycosides, oxygen is replaced 
with a sulfur atom), glycosylamine (oxygen is replaced with a nitorgen atom) and C-glycosidic 
bond (oxygen replaced with carbon)
2
. For synthesizing the glycosides, the sugar is usually 
transformed into a fully protected glycosyl donor with an appropriate leaving group at its 
anomeric center. A suitable protected glycosyl acceptor containing one free hydroxyl group is 
then glycosylated with the former
3,4
. The Fischer–Helferich method (Fig. 2.3A) involving the 
direct replacement of the anomeric oxygen atom under acid-catalyzed reaction has been applied 
successfully for glycosylation of many substrates. However, the reversibility of the reaction 
limits its usefulness in the synthesis of complex oligosaccharides and glycoconjugates. In order 
to eliminate the reversible nature of this reaction, preactivation of the anomeric center through 
the introduction of a good leaving group is necessary. 
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Figure 2.3 Generation of glycosidic and saccharide bonds
1 
Koenigs–Knorr method (Fig. 2.3B), introduced in 1901, is the best known for being 
irreversible. The method requires an exchange of the anomeric hydroxyl group with bromine or 
chlorine as the first step to generate a glycosyl-group donor. Followed by the second step in 
which the glycosyl group is transferred to the glycosyl acceptor in the presence of a heavy metal 
ion promoter. Because of some inherent disadvantages associated with this method, it becomes 
experimentally demanding and unsuitable for large-scale synthesis. For instance the reaction  
requires at least equimolar amounts of the heavy metal salt promoter, that is often incorrectly 
termed as “catalyst,” is a limiting factor5-7. Therefore, alternative methods to overcome these 
shortcomings are of interest. 
Other approaches involving the exchange of the anomeric oxygen atom for a fluorine, 
alkylthio, or arylthio as leaving group have been explored since these groups are not affected by 
manipulations of any involved protecting groups. In these methods, the anomeric carbon atom of 
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the sugar residue to be coupled serves as the electrophile and the alcohol as the nucleophile. An 
alternative method to the ones described above is a base-mediated deprotonation of the anomeric 
hydroxy group of a pyranose or furanose moiety to generate an anomeric oxide, which would 
undergo direct and irreversible anomeric O-alkylation to give the corresponding glycoside (Fig. 
2.3C). Surprisingly, this simple “anomeric O-alkylation” method, as termed by Schmidt2a,8, 9 had 
not been used for the synthesis of complex glycosides and glycoconjugates. The direct anomeric 
O-alkylation of various protected and even completely unprotected sugars in the presence of a 
base with triflates or Michael acceptors as alkylating agents has become a very convenient 
method for glycoside-bond formation
10-13
.  
The mechanism, of any well-developed glycosylation method for oligosaccharide 
synthesis follows the same general mechanism (Scheme 2.2). The leaving group of the glycosyl 
donor is freed from the molecule in the presence of a promoter
5,7,13,14
.  The nature of the C-2 
substituent of the glycosyl donor determines the structure of the oxocarbenium intermediate 
formed. Participating groups, such as aryl or alkyl esters and amides, can help stabilize the 
intermediate and tend to favor the formation of 1,2-trans-glycosides (Scheme 2.2). An important 
aspect of this reaction is the formation of an orthoester as a side reaction. This orthoester 
formation is reversible and can have a deleterious effect on the glycosylation depending on the 
nature of the glycosyl donor and acceptor and the reaction conditions employed. Glycosyl donors 
with non-participating groups at C-2, such as ethers, called armed donors, react faster than those 
with participating groups at C-2 (disarmed donors). This is because of the fact that the C-2 
substituent of an armed donor is less electron withdrawing than that of a disarmed donor and 
therefore, the oxocarbenium intermediate forms faster (Scheme 2.2). In this case, the 
stereoselective outcome of the glycosylation is largely solvent dependent. 
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Scheme 2.2 Generalized mechanism for glycosylation reactions
4a
 
 
 
A high anomeric stereoselectivity (Fig. 2.4) is often observed with pyranoses which can result 
from the enhanced nucleophilicity of equatorial oxygen atoms (owing to steric effects and the 
stereoelectronic kinetic anomeric effect due to repulsions of lone electron pairs, dipole effects, or 
both)
4a, 7, 8
.  
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Figure 2.4 The anomeric effect
15 
 
The higher stability of products with an axial anomeric oxygen atom is observed. Chelation 
effects can also be used to promote anomeric stereoselectivity. There are three main 
requirements for an efficient glycosylation method in terms of small amounts of reagents must be 
used, the glycosyl donor must be generated in a simple process and the donor activated by a 
catalytic amount of a reagent and the glycosylation step must be stereoselective and high 
yielding. These demands are not met by any of the methods described above. However, the 
general strategy for glycoside bond formation is reasonable which involves the first step as the 
generation of the glycosyl donor involving the preactivation of the anomeric center (Fig. 2.4) via 
formation of a stable glycosyl donor, ideally through a catalytic reaction to attach a leaving 
group to the anomeric hydroxy group. The second step (activation of the glycosyl donor) consist 
of a sterically uniform high yielding glycosyl transfer to the glycosyl acceptor on the basis of 
activation of the glycosyl donor with a catalytic amount of a promoter and covalent binding of 
water released in this condensation reaction to the leaving group. In this way, the required 
amounts of reagents can be minimized (scheme 2.2). 
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C-GLYCOSIDES 
C-glycosides (also known as C-nucleosides) are the compounds that contain a 
heterocyclic aglycone and a carbohydrate moiety that are connected by a C–C bond.  Naturally 
occurring C-nucleoside pseudouridine 1 (first reported nucleoside), 1-Methylpseudouridine 2, 
2’-Omethylpseudouridine 336 are shown in Fig. 2.516.  
O
OHOH
HO
HN NH
O
O
O
OHOH
HO
MeN NH
O
O
O
OMeOH
HO
HN NH
O
O
1 2 3  
Figure 2.5 Naturally occurring C-nucleosides. 
 
The naturally occurring C-nucleosides usually act as antibiotics, also exhibit anticancer and/or 
antiviral activity
17-19
. C-nucleosides have also been found to be the suitable candidates for use as 
building blocks of oligonucleotides for the construction of triplex DNA in gene therapy
20,21
. C–C 
bond of the C-nucleosides is resistant to hydrolytic and enzymatic cleavage
20
. Daves et al.
22-24 
employed Heck-type coupling reactions to form C–C bonds between the anomeric carbon atom 
of sugar derivatives and heterocycles. Heck reaction conditions can be regioselective and 
stereoselective in the formation of a C–C bond25,26. The anomeric configuration of the C–
nucleoside in the Heck reaction is controlled by presence of a suitable protecting group at the 3’-
hydroxy function of the sugar moiety. This results in formation of glycosidic bond in the least 
sterically hindered face of the glycal ring during the attack by organopalladium reagents and 
results in the formation of the β-anomer23. 
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Of the two major approaches for the synthesis of C-nucleosides in the literature
27,28
, first 
approach uses a preformed aglycone that is coupled to a sugar derivative. In the other approach, 
a functional group is introduced at the anomeric position of the sugar derivative and is followed 
by construction of a heterocyclic base. Hainke et al. reported employing Friedel Crafts reaction, 
for the synthesis of C-glycosides. This involves the attack of nucleophilic species on an 
electrophilic ribose derivative
29
 and lewis acid catalyzed processes
30
. Some synthetic routes 
involve the synthesis of a ring after the formation of a C-glycoside
31,32
. Ramnauth et al. reported 
steroselective C-glycosidation using aryl boronic acids via non-heck reaction conditions (Scheme 
2.3)
33
. 
 
Scheme 2.3. Palladium(II) acetate mediated C-Glycosidation of tri-O-acetyl-D-glucal 1 33 
 
 
Spencer et al. reported radical reactions for C-glycoside synthesis using Titanium (III) 
compounds  and radical generation reaction conditions (Scheme 2.4)
34
. 
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Scheme 2.4 Spencer et al. synthesis of simple C-glycosides using 1
34
. 
 
Heck coupling approach has also been employed for C-glycoside synthesis shown in Scheme 
2.5
35
. 
 
 
Scheme 2.5 The Heck coupling reaction
35
. 
All the above described methods have some disadvantages associated with them either in terms 
of catalyst, percentage yield or non-applicability at commercial scale. There are usually three 
main requirements for an efficient glycosylation method
35
: 
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1. Use of small amounts of the reagents so that the glycosyl donor is generated in a simple 
process and activation of the donor by a catalytic amount of a reagent.  
2. The glycosylation step must be stereoselective and high yielding. 
3. The method must be applicable on a large scale. 
To achieve the above mentioned requirements use of unprotected sugar for glycosylation under 
basic conditions was explored. Use of unprotected saccharides offers various advantages like the 
total number of steps to get the final compound are drastically reduced, improved yields, no need 
for protection and deprotection steps, cost effective and easy applicability at large scale. This 
methodology is described in the following section. 
 
2.1.2. Synthesis of Barbiturate Glycosides 
One of the requirements of synthetic strategy for saponin barbiturates antifungal agents is 
its capability to be used at large commercial scale. To develop such a method it is proposed to 
avoid using the usual protection and deprotection of hydroxyl functionality. The usage of 
protection and deprotection methods where reaction conditions employ inert atmosphere is 
difficult to achieve at commercial scale. In order to develop an industry friendly methodology for 
C-glycosylation that is cost effective, efficient and reproducible at large scale it becomes 
imperative to utilize unprotected saccharide for barbiturate glycosylation. Only one report for 
converting the reducing monosaccharides into C-glucosidic derivatives exploiting the reactivity 
of the aldehydic form of the sugar was reported in 1986 by Gonzalez et al
36
. They developed a 
general methodology for the synthesis of pyrimidine C-nucleosides involving a one-step reaction 
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of aldohexose and aldopentose with barbituric acids in a water solution of sodium carbonate at 
50°C (Scheme 2.6)
36
. 
 
Scheme 2.6 C-glucosylbarbiturates synthesis under basic conditions and proposed reaction mechanism
36 
 
 
The C-glycosylation reaction of barbituric acid proceeds via a proposed mechanism shown in 
Scheme 2.6. It is proposed that the barbituric acid (pKa ~ 4) can act as a nucleophile even in 
absence of a strong base. The initially formed adduct I undergoes elimination to give an 
unsaturated intermediate II, which, can be attacked by another nucleophile. The most probable is 
the intermolecular reaction with the oxygen at carbon 6
36
. 
In our synthetic procedure, we achieved barbiturate glycosylation by employing glucose, 
galactose, lactose and cellobiose (table 2.2 and 2.3). The desired saccharide or disaccharide was 
added to N,N-dimethyl barbituric under mild basic condition in aqueous medium. The reaction 
mixture was carefully heated on a water bath at a temperature not exceeding 80 °C for 5 hours. 
Most of the water was evaporated to give slurry, which was carefully poured in stirring methanol 
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and continued to stir for an hour. During this period product precipitated as white to yellow solid 
material. This gave pure C-glycosylated barbiturate derivatives as a powdered material, which 
were filtered and washed with methanol. The reaction proceeds as per the Scheme 2.7 with a 
proposed mechanism similar to one shown in Scheme 2.6.   
 
Scheme 2.7 C-glycosylation reaction of N,N-dimethylbarbituric acid 4 with (i) galactose, (ii) glucose, (iii) maltose 
and (iv) cellobiose,  in K2CO3 (aq.) to form compounds 5, 6, 7 and 8 respetively.  
A variety of mono and disaccharide substrates could be used for glycosylation of barbituric acid 
and N,N-dimethyl barbituric acid to give a variety of C-glycosylated barbiturate salts as shown in 
table 2.2 and 2.3.  
 
 
O
HO
HO
OH
OH
O
O
HO
OH
OH
N
N
O
O
O
K
N
N
O
O
O
O
H
HO
H
HO
H
H
OHH
OH
K
N
N
O
O
O
O
OH
H
H
HO
H
H
OHH
OH
K
N
N
O
O
O
O
H
HO
H
HO
H
H
OHH
OH
O
H
O
H
HO
H
H
OH
H
OH
N
N
O
O
O
K
i iii
ii iv4
5
7
6 8
 
67 
 
 
Entry Babiturate Monosaccharide C-Glycosylated product 
1. 
N
N
O
O
O
 
O
H
HO
H
HO
HO
H
HH
OH
OH
Mannose 
O
H
HO
H
HO
HO
H
HH
OH
K
N
N
O
O
O  
2. 
N
N
O
O
O
 
O
OH
H
H
HO
H
H
OHH
OH
OH
Galactose 
O
OH
H
H
HO
H
H
OHH
OH
K
N
N
O
O
O  
3. 
N
N
O
O
O
 
O
H
HO
H
HO
H
H
OHH
OH
OH
Glucose 
O
H
HO
H
HO
H
H
OHH
OH
K
N
N
O
O
O  
4. 
N
N
O
H
H
O
O
 
O
H
HO
H
HO
HO
H
HH
OH
OH
 Mannose 
O
H
HO
H
HO
HO
H
HH
OH
K
N
N
O
H
H
O
O  
5. 
N
N
O
H
H
O
O
 
O
OH
H
H
HO
H
H
OHH
OH
OH
Galactose 
O
OH
H
H
HO
HO
H
OHH
OH
K
N
N
O
H
H
O
O 5a 
6. 
N
N
O
H
H
O
O
 
O
H
HO
H
HO
H
H
OHH
OH
OH
Glucose 
O
H
HO
H
HO
H
H
OHH
OH
K
N
N
O
H
H
O
O  
Table 2.2 Glycosylated monosaccharide barbiturate derivates 
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Table 2.3 Glycosylated disaccharide barbiturate derivates 
Entry Barbiturate Disaccharide C-Glycosylated product 
7. 
N
N
O
O
O
 
O
HO
HO
OH
OH
O
O
HO
OH
OH
OH
 
Maltose 
O
HO
HO
OH
OH
O
O
HO
OH
OH
N
N
O
O
O
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8. 
N
N
O
O
O
 
O
OH
H
H
HO
H
H
OHH
OH
O
H
O
H
HO
H
H
OH
H
OH
OH
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O
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OHH
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O
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O
H
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H
H
OH
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OH
N
N
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O
O
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9. 
N
N
O
O
O
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H
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H
H
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O
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O
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H
H
OH
H
OH
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N
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O
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O
HO
OH
OH
OH
 
Maltose  
O
HO
HO
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O
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H
O
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H
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H
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N
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O
H
H
O
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H
H
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H
OH
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H
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H
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8a 
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The monosaccharide and disaccharide glycosylated barbiturate were synthesized in an isolated 
yield of 85-90% with sufficient purity. These were taken to the next step without further 
purification.  
 
2.2. Synthesis of steroid linker derivatives 
In order to synthesize the desired barbiturate saponin derivatives, the C-glycosylated 
barbiturate derivatives from step 1 need to be coupled to a variety of steroids through different 
linkers. The linker could be carbonate, cabamate or ether. It desired that a hydrolysable linker be 
used for the synthesis of antifungal compounds. This linker would be metabolized inside the 
human system to release two separate steroid and barbiturate molecules that can act on same or 
different drug targets to have the antifungal effects. A library of compounds with diverse 
steroidal skeleton would provide in depth understanding of the structure-activity relation of this 
novel class of compounds. Subsequently, help optimize the structure of compounds to provide 
most potent antifungal agent. To achieve this goal different steroid derivates with variable 
linkages were proposed as shown in Table 2.4. 
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Entry Steroid Linker Derivative 
13. 
HO
 
Ether 
OCl
 
14. 
HO
 
Ether O
O
Cl  
15. 
HO
 
Ether O
O
Br  
16. 
HO
 
Ether O
O
I  
17. 
HO
H
H
H
O
O
 
Ether 
O
O
H
HH
O
O
Br  
18. 
HO
H
H
H
O
O
 
Ether 
O
H
H
H
O
O
O
Br  
19. 
HO
 
carbonate OO
OBr  
20. 
HO
H
H
H
O
O
 
carbonate 
O
H
HH
O
O
O
OBr
 
21. 
HO
H
H
H
O
O
 
carbonate 
O
H
H
H
O
O
O
OBr
 
22. 
 
Ester O
O
O
OBr
 
23. 
HO
H
H
H
O
O
 
Ester 
O
H
HH
O
O
O
O
OBr  
HO
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24. 
HO
H
H
H
O
O
 
Ester 
O
H
H
H
O
O
O
O
OBr  
25. HO
 
Carbamate ON
O
HO
 
26.  
HO
H
H
H
O
O
 
Carbamate 
O
H
H
H
O
O
N
O
HO
 
27. 
HO
H
H
H
O
O
 
Carbamate 
O
H
H
H
O
O
N
O
HO
 
Table 2.4 Steroid linker derivatives 
 
2.2.1. Ether linked steroid derivative synthesis 
Literature is replete with the ether synthesis methods that can be applied to a variety of 
substrates. Ethers, in general can be synthesized by reacting an alkoxide nucleophile with a good 
alkyl electrophile. For instance, preparation of allyl ethers has been carried out from the 
corresponding alcohols using several reagents such as allyl bromide
38
, allyl carbonate
39,40
, allyl 
ethyl carbonate
41
.  Similarly, benzyl ethers have been successfully prepared using benzyl 
bromide
42
, benzyl iodide
43
, phenyl diazomethane
44
. In addition, allyl bromide and benzyl 
bromide in presence of a base in a suitable solvent medium are frequently employed for the 
generation of allyl and benzyl ethers respectively.  
Rao et al.
37
 have reported Williamson synthesis in solvent-free environments
45
. The 
alcohol protection was carried out conveniently and efficiently with allyl and benzyl bromides, 
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using solid potassium hydroxide pellets without the use of any solvent (Scheme 2.8). As per 
them the reaction of cholesterol 9 under solvent free conditions with benzyl bromide and 
potassium hydroxide on stirring for more than 15 hours gives compound 10 in 86% yield. 
 
 
Scheme 2.8 Ether synthesis by Rao et al.
37 
 
Bogdal and coworkers have reported
47
 solvent-free allyl and benzyl ether preparation 
using a combination of potassium carbonate and potassium hydroxide bases in the presence of 
tetrabutylammonium bromide under microwave irradiation. However, the reaction requires 
drastic conditions such as high temperature and specialized apparatus. Moreover, their study was 
limited to the preparation of ethers from alcohols. 
Camacho et al.
48
 reported ether synthesis under Pd-catalyzed reaction conditions 
(Scheme 2.9). Addition of alcohols 9 to alkylidenecyclopropanes 12 proceeds presumably via 
activation of the alcohols 9
49
, that serves as a powerful tool in the synthesis of allylic ethers 13. 
They successfully utilized Pd in addition of alcohol pronuclephiles to nonconjugated systems to 
give a regioselective product with wide range of substrates. A reperesentaive example from their 
HO O
O
Br
KOH, 7h
KOH, 16h
9
10
11
86 %
98%
Br
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application to   cholesterol 9 is shown in Scheme 2.9. This method clearly suffers from the 
drawback of long reaction times, high reaction temperatures, expensive catalyst and inefficiency 
at large scale. 
  
Scheme 2.9 Cholesterol ether synthesis by Camacho et al. 
Kashman
50
 et al.  isolated sterol ether while performing phosphorous containing reactions 
with steroids. They reported that in the presence of catalytic amounts of acid, in a solution of a 
steroidal alcohol in dialkyl phosphite, corresponding ether formation was observed. According to 
Kashman
50 
et al. procedure, if cholesterol is heated for several hours in HOP-(OCH3)2 containing 
p-TsOH, 3β-methoxycholest-5-ene is obtained as the product. The overall reaction and its 
mechanism are outlined in Scheme 2.10.  
 
Scheme 2.10 3β-methoxycholest-5-ene synthesis by Kashman50 et al. 
 
Another procedure reported by Wang et al.
51
 (Scheme 2.11) successfully protects the β C-3 
hydroxy by conversion to various alkoxy groups. The reaction involves use of desired 
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bromoalkyl, which forms the corresponding ether 17 under reflux conditions with the steroid 9 in 
presence of potassium iodide in yields of more than 90%. 
O
R
HO
RBr, KI, THF
Reflux, 24-30h, 40-60%9 17
          R= CnH2n+1  n= 1, 2, 4, 6, 8, 10, 12  
Scheme 2.11 Cholesteryl ether synthesis by Wang et al
51
.  
Based on the literature review the steroidal linker derivatives could be synthesized in two ways. 
Either introduce the aliphatic linker into the steroidal skeleton followed by aromatization or vice 
versa. We proposed that the synthesis of compound 18 could be carried out either via pathway 1 
or pathway 2. A reterosynthetic analysis to synthesize compound 18 is outlined in scheme 2.12. 
OO
n
n=1,2
X
X= -CH3, 
-CH2Cl/OH/Br/I
OY
n
n=1,2
Y= OH, Cl
HO
YO
n
X
HO
Y=OH, Cl
HO
Pathway 1
Pathway 1Pathway 2
Pathway 2
n=1,2
X= -CH3, 
-CH2Cl/OH/Br/I
18
9 9
20
19
21  
Scheme 2.12: Retrosynthetic analysis for steroid linker synthesis 
For the methodology development cholesterol was used as a model substrate. Pathway 1 
involves reaction of cholesterol 9 with a suitable alkyl dihalide or dihydroxy substrate to give 
compound 19, which on reaction with aromatic substrate provides compound 18. Pathway 2 
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involves the attaching of aliphatic linker to the 4-hydroxytoluene 21, which can be activated to 
give compound 20 having a leaving group. A further nucleophilic substitution reaction of 
compound 20 with cholesterol 9 would give the desired linker containing cholesterol derivative 
18. A detailed description of reaction conditions and their outcomes are discussed under results 
and discussions. 
 
Results and Discussion 
Cholesterol ether linked carbon spacer synthesis was attempted by introducing simple 
one carbon chain alkyl group by formylation method. A solution of Cholesterol 9 in 
dichloromethane was treated with parafomaldehyde by purging HCl gas through the solution at 0 
°C (Scheme 2.13). The reaction was stirred at this temperature for 3-4 hours under dry conditions 
using calcium chloride pellets in the reaction mixture. It was observed that in the presence of any 
amount of water the reaction was reversible and goes back to the starting material. Calcium 
chloride pellets absorb all water formed in the reaction, thereby allowing reaction to progress in 
the forward direction. The reaction was continuously monitored at this stage. After successful 
completion of reaction product 59 was obtained as white powder in sufficient purity. Same 
procedure was used for cholestanol to give corresponding compound 59a. With the success in 
selective conversion of 3β-hydroxyl group of cholesterol 9 to ether with retention of 
stereochemistry we were encouraged to explore the attachment of other ether linkers. Before 
progressing to the next step we tried coupling reaction of compound 59 with C-glycosylated 
barbiturate 6. Because of limited solubility of sugar in organic solvent, DMSO was the solvent of 
choice for this reaction. Since heating at high temperatures has deleterious effect on sugars, the 
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reaction has to be performed at moderate temperatures. Therefore, coupling of compound 59 to 
compound 6 was attempted with sonication in DMSO. Sonication was chosen as it has two fold 
advantages, firstly sonication enhances molecular interaction in the reaction medium of the 
reactants by providing maximum solubilty and secondly a moderate temperature of nearly 40 °C 
is appropriate for this reaction. Although the reaction did not yield the desired product even after 
several attempts, it helped in exploring reaction conditions for ether synthesis. Therefore, we 
proposed that a longer alkyl chain would be appropriate for reaction at the tertiary carboanion of 
6. 
 
Scheme 2.13 Synthesis of 3β-Cholesteryl ether. 
 
As per the reterosynthetic analysis (Scheme 2.12) first attempt for synthesis of long chain 
steroidal ether was made by following pathway 1 to develop methodology using cholesterol as 
the model substrate. A dry THF solution of the cholesterol 9 was treated with sodium hydride to 
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give the corresponding alkoxide 22, which was reacted with various activated alkyl derivatives 
(Scheme 2.14). 
HO
O
9
19
ONa
i
ii
22
Y
Scheme 2.14 General scheme for synthesis of 3β-Cholesteryl ether,i) NaH, THF, reflux; ii) X
Y
where, X= Cl,                          
Br, OTs; Y= OH, Cl, Br. 
 
 
Entry Reaction Conditions X
Y
 
Boiling Point 
(°C) 
1. Sodium hydride, THF, reflux X=Y= Cl 84 
2. Sodium hydride, THF, reflux X=Y= Br 133 
3. Sodium hydride, THF, reflux X=Cl, Y=OH 131 
4. Sodium hydride, THF, reflux X=OTs, Y= Cl NA 
Table 2.5 Reaction conditions and substrate for cholesteryl ether synthesis 
The ether synthesis was attempted using a strong base like sodium hydride to abstract the 
hydroxyl proton to generate cholesteryl-3β-oxide 22 as intermediate under dry reflux conditions 
in THF (Scheme 2.14). One would assume that the intermediate would react with any suitable 
alkyl chain with an appropriate leaving group. Therfore, alkyl dihalide was chosen as a substrate. 
The rationale behind using dihalide as a substrate was that one halide group on the alkyl chain 
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would react with cholesteryl-3β-oxide 22, and the second halide group would be available for 
reaction at the next step. When the reaction was attempted with dichloroethane (DCE) (Table 
2.5) only the starting material was recovered. A more reactive substrate like dibromoethane 
(DBE) (table 2.5) with better leaving group (bromo) makes it more reative towards the in situ 
generated oxide ion. It also has a higher boiling point that would help the reagent to stay in the 
reaction medium longer under reflux conditions without escaping. Again only, the unreacted 
starting material was recovered. At this point, we decided to use alkyl substrate containing two 
different functional groups such as ethylene chlorohydrin that would make the alkyl substrate 
more stable on one terminal and reactive on the other. The presence of hydroxyl group on one 
terminal makes the substrate more stable at refluxing temperature by retaining it in the reaction 
medium via formation of hydrogen bond. When chlorohydrin was incorporated as the reagent 
once again only the unreacted starting substrate was recovered. It appeared that the chloro group 
either is not reactive enough or is being hydrolysed to hydroxyl group thereby rendering the 
substrate unreactive towards nucleophilic substitution by cholesteryl-3β-oxide 22 (Scheme 2.14). 
Therefore, the free hydroxyl of ethylene chlorohydrin was transformed to tosylate to provide the 
reagent. After attempting, the reaction under dry conditions using THF and sodium hydride as a 
base no desired compound was isolated except for the unreacted starting material. After several 
unsuccessful attempts we chose to follow pathway 2 (Scheme 2.12).  
In our second attempt for synthesis of Cholesteryl-3β-ether derivative 25 (scheme 2.15) 
efforts were directed in synthesizing the activated aromatic linker 24 (Scheme 2.15).  
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Scheme 2.15 Cholesteryl-3β-ether derivative synthesis with p-cresol derivative; i) NaOH, H2O; ii) Cl
OH
, 
MeOH- H2O; iii)  MsCl, py; iv) sodium hydride, THF, reflux. 
Under basic conditions, the hydroxyl proton of p-cresol 21 is abstracted to give the 
corresponding sodium 4-methylphenolate 22.  A reaction with ethylene chlorohydrin gave 
compound 23. The hydroxyl of compound 23 was converted to a mesylate leaving group by 
reaction with mesylate chloride under basic conditions to give compound 24. Reaction of 
cholesterol 9 in presence of sodium hydride in refluxing THF with compound 24 afforded 
desired cholesteyl-3β-(2-(p-tolyloxy)ethoxy ether 25. For reaction with C-glycosylate 
barbiturate, the methyl group in compound 25 has to be functionalized to a group that can act as 
a leaving group. This can be achieved by transformation to the corresponding bromo derivative 
18 (Scheme 2.12). 
According to the literature procedure
52
 bromination at the benzylic position can be 
achieved under microwave reaction conditions using NBS, benzoyl peroxide as shown in 
Scheme 2.16. 
 
N
O
O
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DMF, MW
N
O
O
Br
26 27  
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Scheme 2.16 Microwave bromination of 2-p-tolylisoindoline-1,3-dione
52 
The application of the same procedure to our substrate cholesteyl-3β-(2-(p-tolyloxy)ethoxy ether 
25 resulted in a complex mixture of compounds that were difficult to isolate. Although the 
method is very successful for substrates like 26 but in case of cholesterol substrate 25 the 
mixture was a result of non selective mono and dibromination, under the microwave conditions, 
at several secondary, tertiary and allylic carbon centres in the steroid molecule. At this point, we 
had to reconsider our synthetic approach. 
A third attempt for synthesis of ether linked carbon spacer cholesterol derivative was 
made. After careful analysis of the shortcomings of previous synthetic schemes and problems 
encountered, we decided to go a different route as represented by a reterosynthetic analysis in 
Scheme 2.17. 
HO
TsO
OO
HO
OO
Br
OHO
28
29
30 31
9  
Scheme 2.17 Revised reterosynthesis analysis of cholesteryl-3β-ether linker 
According to the reterosynthetic analysis (Scheme 2.17) cholesteryl-3β-(2-(4-
(bromomethyl)phenoxy)ethoxy) ether 28 can be synthesized from its corresponding hydroxyl 
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derivative 29. This in turn can be derived from cholesterol ether linker 30. A cholesterol tosylate 
31 on reaction with suitable alkyl derivative would afford compound 30 (Scheme 2.17). 
The ether-linked carbon spacer cholesterol compound 29 and 30 (Scheme 2.18) were synthesized 
by modifying the methods of Bajaj
53
 et al. To an ice-cooled solution of cholesterol 9 in pyridine, 
p-toluenesulfonyl chloride was added in fractions and stirred for 12h at room temperature. 
Cholest-5-en-3β-tosylate 31 was isolated in practical yield.  Since the resulting tosylate was 
unstable on silica gel column, purification was carried out by recrystallization from hexane to get 
a free flowing white powder. It was taken to the next step without further purification. Cholest-5-
en-3β-tosylate 31 and 7–10 equiv of appropriate diol in anhydrous dioxane were refluxed for 8 h 
under nitrogen atmosphere to afford Cholest-5-en-3β-oxyethan-2-ol 30 in 80–87% yield (Scheme 
2.18). 
 
29
30
HO
TsO
TsCl
Py, rt, 8h
HO
OH
Dry Dioxane
Dry
OHO
(COCl)2
DCM
OCl
OH
HO
OO
HO
9 31
32
 
Scheme 2.18 Synthesis of cholestery-3β-ether linker derivative via tosylate. 
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The compound 30 was converted to its corresponding chloro derivative 32 under dry conditions 
using oxalyl chloride at 0 °C. But a further attempt to attach the aromatic part by reaction with 
hydroxyl benzyl alcohol under reflux conditions resulted in hydrolysis of  32 to give back 
compound 30 instead of desired compound 29 (Scheme 2.18). Therefore, compound 30 was 
converted to a better leaving group like tosylate and bromo. This was subsequently reacted with 
hydroxyl aromatic substrate and the results are summarized in table 2.6. The reaction of 
compound 30 with 4-bromobenzylbromide under basic conditions using bases like sodium 
hydride, sodim hydroxide did not yield the desire compound 33. Conversion of 30 to 
corresponding tosylate, bromo or chloro derivative was also not uselful for synthesizing 
compound 33. 
Entry Steroid (number) Benzyl 
compound 
Reaction 
condition 
Result 
1. 
30  
NaH, THF,  No 
product 
2. 
32 
 
NaOH, 
MeOH-H2O,  
No 
product 
3. 
30A 
 
NaOH, 
MeOH-H2O,  
No 
product 
4. 
30B  
KOH, 
Acetonitrile 
No 
product 
5. 
30  
Cu(acac)2, 
DMF, reflux 
Product 
Table 2.6 Cholesteryl-3β-aryl ether reaction conditions 
OHO
Br
Br
OCl
OH
HO
OBr
OH
HO
OTsO
OH
HO
OHO
Br
Br
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After several attempts to synthesize compound 29, we finally succeeded in our attempt. A 
reaction of compound 30 with 4-bromobenzyl bromide using Cu(acac)2 under reflux conditions 
in DMF (Scheme 2.19) resulted in the formation of desired compound 33.  
 
 
Scheme 2.19 Synthesis of cholesterol-3β-(2-(4-(bromomethyl)phenoxy)ethoxy) ether linker; i) Cu(acac)2, 4-
bromobenzylbromide, DMF, reflux, 8h. 
 
2.2.2. Synthesis of steroid linker containing carbonate, carbamate and ester. 
The synthesis of barbiturate saponin requires bringing together two different substrates 
namely C-glycosylated barbiturate and steroid together in one molecule. The steroid linker plays 
the essential role of transporting the intact molecule to the site of action or inside the body where 
it can undergo hydrolysis to release two independently acting drug molecules. A good linker for 
this approach would be a carbonate, carbamate or ester. Using cholesterol as the model substrate 
the synthetic methodology was developed.  
Cholesteryl chloroformate 34 was reacted with 4-hydroxybenzyl alcohol under basic 
reaction conditions to give Cholest-5-en-3β-yl-4-(hydroxymethyl)phenyl carbonate 35 (Scheme 
2.22). Since hydroxyl by itself is not a good leaving group it has to be transformed to a better 
leaving group for reaction in the next step with C-glycosylated barbiturate 6. We decided to 
transform the hydroxyl group to a chloro group by reacting Cholest-5-en-3β-yl-4-
(hydroxymethyl)phenyl carbonate 35 with oxalyl chloride. This yielded Cholest-5-en-3β-yl-4-
3330
OHO OO
Br
i
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(chloromethyl)phenyl carbonate 36 in good yield (Scheme 2.22). With the chloro derivative in 
hand, we attempted the coupling of steroid fragment 36 to the C-glycosylated barbiturate 6 
(Scheme 2.23). The synthetic challenge was to find a reaction solvent for two different 
compounds 36 and 6 with different solubilities. Cholest-5-en-3β-yl-4-(chloromethyl)phenyl 
carbonate 36 is hydrophobic and does not dissolve in water, whereas C-glycosylated barbiturate 
6 is hydrophilic and dissolves very well in water, DMSO or a mixture of water and DMSO at 
various concentrations. In addition, DMSO seemed to be a solvent of choice for this nucleophilic 
reaction as polar solvents favor these kinds of reactions. However, removal of DMSO and steroid 
solubility remains to be a challenge. After several trials with a variety of solvents like DMSO, 
THF, DCM, DCE, it was observed that a mixture of DMSO, water and DCM provides a suitable 
medium for this reaction. Cholest-5-en-3β-yl-4-(chloromethyl)phenyl carbonate 36 was 
dissolved in minimum amount of DCM and charged to a solution of C-glycosylated barbiturate 6 
and allowed to sonicate (Scheme 2.23). The reaction was monitored continuously by 
1
H NMR. 
After 3 days of continuous sonication, formation of product was evident by 
1
H NMR. The 
observed rate of reaction was very slow which makes is impractical for a large-scale reaction. 
Therefore, it was decided to replace the chloro group with a functional group that can act as a 
better leaving group in the nucleophilic reaction.  
Conversion of Cholest-5-en-3β-yl-4-(hydroxymethyl)phenyl carbonate 35 to 
corresponding tosylate 37 was achieved by reaction with p-toluene sulfonyl chloride under basic 
conditions (Scheme 2.22). Upon reacting compound 37 with C-glycosylated barbiturate 6 in a 
similar way for the chloro compound 36 (Scheme 2.23), it was observed that there was no 
conversion to product even after three days of continuous sonication instead some amount of 
tosylate hydrolysis was observed to give compound 35 (Table 2.7). At the end of fifth day some 
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product formation was observed in the 
1
H NMR. Clearly, tosylate as a leaving group was not a 
solution for our problem. We needed a group more reactive than chloro and stable to hydrolysis. 
At this point it was decided to use the iodo derivative of Cholest-5-en-3β-yl-4-
(hydroxymethyl)phenyl carbonate 35. 
Several literature synthetic procedures indicate the usefulness of Finkelstein reaction for 
conversion of chloro derivatives to the corresponding iodo compounds. A representative 
example demonstrating application of this reaction has been reported by Maloney et al.
54
 in their 
synthesis of δ-trans-Tocotrienoloic Acid (Scheme 2.20). Finkelstein reaction involves the 
treatment of a primary alkyl halide or pseudohalide with an alkali metal halide (e.g. KF, KI) that 
leads to replacement of the halogen via an SN2 Reaction. 
OMe
OMe
Cl
OR OMe
OMe
I
OR
NaI, acetone, reflux
 
Scheme 2.20 An example of finkelstein reaction
54 
 
Encouraged by the reported synthetic application of Finkelstein reaction we tried it on our 
substrate Cholest-5-en-3β-yl-4-(chloromethyl)phenyl carbonate 36. Conversion to Cholest-5-en-
3β-yl-4-(iodomethyl)phenyl carbonate 39 was achieved via SN2 reaction using potassium iodide 
in dark. Although the conversion to iodo derivative was successful but its application on a large 
scale was a challenge due to a very careful handling of iodo compound, reactions can only be 
carried out in dark and susceptible oxidations prompted us to look for better alternatives.  
86 
 
Another useful halide would be bromide. Since we had carbonate in our reaction 
substrate, we had to carefully select the reaction conditions to achieve formation of desired 
molecule. Use of PBr3 alone led to the hydrolysis of Cholest-5-en-3β-yl-4-
(hydroxymethyl)phenyl carbonate 35 and cholesterol 9 was recovered from the reaction (Scheme 
2.21).  
Scheme 2.21 Bromiation of Cholest-5-en-3β-yl-4-(hydroxymethyl)phenyl carbonate 35 using PBr3 
In order to avoid hydrolysis by in situ generation of hydrogen bromide in the phosphorus 
tribromide reaction an obvious choice was to do the reaction under basic conditions. When 
pyridine was employed in the reaction to maintain a favorable pH (above 7) it was observed that 
the bromination proceeded to form a pyridinium salt 44. Any attempt to remove pyridine led to 
the hydrolysis of carbonate to give cholesterol 9. The second attempt was made using carbon 
tetrabromide and triphenyl phosphine
55
 (Scheme 2.22). 
OO
OHO
OO
ON
PBr3
CHCl3 /py
Br
35 44
PBr3, CHCl3
HO
9
Acid Treatment
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(COCl)2
DCM
TsCl
Py, rt, 8h
OO
OTsO
OO
OHO
O
HO
OH
Base
OO
OCl
34
35
36
37
KI
Acetone, dark, 
overnite, rt
OO
OI 39
OO
OBr
1. CBr4, PPh3, DCM
2. MeI, DCM
40
Cl
O
 
Scheme 2.22 Synthesis of Cholest-5-en-3β-yl-4-(hydroxymethyl)phenyl carbonate and its derivatization 
The bromination
55
 was efficiently carried out by using carbon tetrabromide in presence of 
triphenyl phosphine. Excess of triphenyl phosphine was removed by complexation with 
iodomethane and column chromatography. After successfully synthesizing Cholest-5-en-3β-yl-4-
(hydroxymethyl)phenyl carbonate 40 it was employed in synthesis of saponin derivative 43 
(Scheme 2.23). 
 
 
 
Scheme 2.23 Reaction of derivatized cholest-5-en-3β-carbonate derivatives 41 with C-glycosylated barbiturate 42 
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An outcome of various leaving groups in substrate 41 (Scheme 2.23) is summarized in table 2.7. 
Entry Compound 41 
X= 
Reaction 
Condition 
Reaction 
time 
Result 
(% conversion) 
1. -Cl DMSO, 
sonication 
3 days Product 
(30%) 
2. -OTs DMSO, 
sonication 
3 days Product + Hydrolysis 
(20%) 
3. -I DMSO, 
sonication 
NA No Product, oxidation 
4. -Br DMSO, 
sonication 
15 min Product 
(98%) 
Table 2.7 Summary of leaving group reactivity in cholest-5-en-3β-carbonate derivatives 
 
The ester-linked carbon spacer derivatives of cholesterol were synthesized using succinic 
anhydride. A solution of cholesterol 9 in pyridine was reacted with succinic anhydride for 8h at 
room temperature to afford   Cholest-5-en-3β-yloxy-4-oxobutanoic acid 41 in quantitative yield 
(Scheme 2.24). The compound was purified by column chromatography using hexane-
ethylacetate. In the next step, reaction with oxalyl chloride gave the corresponding acid chloride 
42. Since acid is unstable on the silica column it was taken to the next step without further 
purification. To an ice-cold solution of 4-hydroxybenzyl alcohol compound 42 was added. The 
reaction mixture was aalowed to stir at 0 °C for 6h to afford compound 43, which was purified 
by column chromatography. Bromination was done at the next step where compound 43 was 
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treated with carbon tetrabromide and triphenylphosphine to give compound 44. Removal of any 
excess triphenyl phosphine was achieved by complexation with iodomethane. Further 
purification of the compound was done by column chromatography using hexane-DCM to get 
the pure product 44. 
HO
i. CBr4, PPh3, DCM
O
O
O
Pyridine, reflux
(COCl)2
DCM, 0oC
Py, DCM
0oC
9
44
43
42
41
OH
O
O
HO
O
HO
O
O
Cl
O
O
O
O
O
HO
ii. MeI,DCM
O
O
O
O
Br
 
Scheme 2.24. Synthesis of Cholest-5-en-3β-yl-4-(bromomethyl)phenyl succinate 
Similar to the synthesis of Cholest-5-en-3β-yl-4-(hydroxymethyl)phenyl carbonate 35 compound 
45a and 45b can be synthesized. To a solution of cholesteryl chloroformate 34 was added N-
methyl glycine (Sarcosine) and 2-(methylamino)ethanol to afford compound 45a and 45b 
respectively (Scheme 2.24).  
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Scheme 2.25 Synthesis of carbonate and carbamate linked cholesterol derivatives. 
A variety of ether, ester, carbonate and carbamate linker were successfully synthesized as 
summarized in Table 2.8.  
Entry Linker Spacer Steroid derivative 
1. Ether aliphatic O
Cl
 
2. Ether aliphatic OHO
 
3. Ether aliphatic OCl
 
4. Ether aliphatic OBr
 
OO
OHO
HO
OH
Base
34
37
ON
O
HO
O
N
O
HO
O
45a 45b
Cl
O
H
N
O
OH
H
N
OH
Base Base
i. (COCl)2, DCM
ii. 4-hydroxybenzyl 
    alcohol, pyridine,
    0 oC
O
N
O
Cl
O
ON
O
O
O
HO
ON
O
TsO
i. TsCl, pyridine, 0 oC
46
47
48
 
91 
 
5. Ether aliphatic OTsO
 
6. Carbonate aromatic OO
OHO  
7. Carbonate aromatic OO
OTsO  
8. Carbonate aromatic OO
OCl  
9. Carbonate aromatic OO
OBr  
10. Carbonate aromatic OO
OI  
11. Ester aliphatic O
O
HO
O
 
12. Ester aliphatic O
O
Cl
O
 
13. Carbonate aromatic OO
ON
Br
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14. Ester aromatic 
O
O
O
O
HO
 
15. Ester aromatic 
O
O
O
O
Br
 
16. Carbamate aliphatic ON
O
HO
O
 
17. Carbamate aliphatic ON
O
Cl
O
 
18. Carbamate aromatic 
ON
O
O
O
HO
 
19. Carbamate aliphatic ON
O
HO
 
20. Carbamate aliphatic ON
O
TsO
 
21. Carbamate aromatic 
ON
O
O
HO
 
Table 2.8 Synthesized ester, ether, carbonate and carbamate linked carbon spacer cholesterol derivative  
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2.3. Synthesis of Novel Saponin Barbiturates as Antifungal Compounds 
After successfully accomplishing the synthesis of two important fragments of the target 
molecule, the next step is to join them together into one molecule. One of the classic challenges 
in the field of carbohydrate chemistry is that carbohydrate-based compounds and conjugates are 
notoriously hard to synthesize. Not only the chemical synthesis, but the purification and isolation 
of these compounds containing fragments with diverse and completely opposite physical 
properties presents a serious challenge. At the same time, we desire to develop a synthetic 
procedure that can be successfully used at a commercial scale. Another challenge is to simplify 
the reaction strategy for its application at commercial scale. 
Sugars are hydrophilic, so is the C-glycosylated barbiturate fragmement of our molecule. It 
dissolves in polar solvents like water, water-methanol and water-DMSO at various 
concentrations. On the other hand, the steroid linker derivatives are highly lipophilic and 
dissolve in common organic solvents like ethyl acetate, dichloromethane, chloroform, THF and 
to a lesser extent in DMSO. On coming in contact with water, they form micelle and do not 
dissolve in water at any temperature. At the same time heating at high temperatures is deleterious 
to the sugar containing fragment of the molecule i.e. C-glycosylated barbiturate salts. Therefore, 
the reaction has to be carried out at an ambient temperature so as not to decompose saccharide 
either in the substrate or in the formed product. The biggest challenge was to bring the 
hydrophilic C-glycosylated barbiturate derivatives and the hydrophobic steroid derivative in a 
common reaction medium. After several hit and trial runs, it was found that the reaction goes 
well in polar solvent like DMSO. Replacement with any other solvent did not give the desired 
product either because of the solubility issues or insufficient interaction between two substrates. 
Also, carrying out the reaction in DMSO is not a problem but its removal after the completion of 
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the reaction and monitoring reaction progress can become difficult. Because of susceptibility of 
sugar to degrade at high temperature the final compound cannot be heated to reamove the solvent 
at high temperature. High temperature also changes the stereochemistry of the molecule, which 
is not a desired outcome. 
Therefore, to find out the best reaction conditions it was required to run some test 
reactions to optimize the reaction conditions. The model reactions were run using benzyl 
bromide derivatives to explore reaction conditions. After trying solubility in various solvents, it 
was soon found out that DMSO is an excellent solvent for carrying out this type of reaction. In 
this reaction, the C-glycosylated barbiturate derivatives acted as a nucleophile and the benzylic 
carbon with the leaving group undergoes substitution at benzylic position. 
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Scheme 2.26 Benzyl bromide derivative coupling to C-glycosylated-N,N-dimethyl barbiturate. 
 
A variety of benzyl bromide substrates like 4-methylbenzyl bromide  49, 4-chlorobenzyl 
bromide 51, 4-methoxybenzylbromide 53, 4-bromobenzyl bromide 55, 2-(4-
(bromomethyl)phenyl)isoindoline-1,3-dione 57 were reacted with C-glycosylate-N,N-
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dimethylbarbituric acid 6 in DMSO under sonication reaction conditions to give the 
corresponding compounds as shown in Scheme 2.24. The resulting products were isolated using 
cosolvent precipitation. For instance, the isolation of compound 50 was achieved by using water 
and DCM. Water dissolved any unreacted sugar, potassium chloride. Addition of DCM 
precipitated the product and dissolved any unreacted 4-methylbenzylbromide 49. Similar 
procedures were successfully employed for purification of all other compounds. When required  
 a further purification was achieved by silica gel chromatography using DCM:Ethylacetate. In 
the same fashion C-glysolyated barbiturate 6 was used for coupling to steroid linker derivatives 
59. C-glycosylated-N,N-dimethyl barbiturate 6 was dissolved in DMSO and to it was added the 
corresponding solution of steroid linker derivative 59 dissolved in a minimum amount of DCM 
and soniacted for 1-2h to get the desired product 60. It was isolated by cosolvent precipitation 
and a silica gel column chromatography using Hexane-EtOAc. The overall reaction for different 
substrates is outlined in Scheme 2.27. 
Scheme 2.27 Representative example of conjugation of C-glycosylated barbiturate with the steroid linker segment 
 
A series of steroidal saponin derivatives were synthesized using N,N-dimethyl barbituric acid 
and barbituric acid. A representative example is shown in Scheme 2.27 wherein compound 6 is 
reacted with compound 59 under sonication using DMSO as a solvent to give compound 60. 
Several of these derivatives are exemplified in table 2.9 with detailed structure and linkages like, 
ether, carbonate, carbamate and ester. 
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Compound C-glycosylated 
barbiturate 
Steroid derivative  Product 
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Table 2.9 Novel N,N-dimethyl barbiturate steroidal saponins derivatives 
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Compound C-glycosylated 
barbiturate 
Steroid derivative Product 
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Table 2.9 Novel barbiturate steroidal saponins derivatives 
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2.4 Antifungal studies 
The antifungal activity of the synthesized 3β-functionalized cholesterol, barbiturate and 
novel barbiturate saponins were evaluated in vitro using four species of fungi, including Candida 
albicans, Cryptococcus neoformans, Candida glabrata, and the filamentous fungus Aspergillus 
fumigatus. The results of these screenings are summarized in Table 2.10. Of the several 
barbituric acid derivatives tested for their antifungal activity 1,3-dimethyl-5-((2-(4-
nitrophenyl)hydrazinyl)methylene) barbiturate 73 and its demethylated analogue 74 (Table 2.10) 
showed significant antifungal activity (>50% inhibition at the minimal concentration) against 
Candida albicans, and Candida glabrata, with C. glabrata being the most sensitive at the lowest 
concentration ( 2-4g/mL). It was speculated that the presence or absence of methyl group on 
nitrogen of barbiturate has no significant effect on the antifungal activity since both compounds 
73 and 74 showed same range of fungal activity. Barbiturate derivative 72 with basic 
naphthalene showed activity only against Candida albicans.  
The intermediates of the steroidal segment compound 45a tested against Candida albicans 
and Candida glabrata demonstrated comparable fungal activity to compounds 73 and 74. 
Significant antifungal activity (>50% inhibition at the minimal concentration) against two fungal 
strains at concentration of 2-4g/mL was observed. This encouraged synthesizing novel 
barbiturate steroidal saponin derivatives to search for more potent antifugal agents, and study the 
structure activity relationship of this class of compounds. Hydrolysis of the carbonate linker of 
60 (yielding compound 50 and 9) and 63 resulted in the total loss of antifungal activity against 
all tested species. The combination of the hydrolysis and insignificant binding led to the total 
loss of antifungal activity.  Finally, it is speculated that the inversion of stereochemistry in 
compound 50, 56 and 58 must have resulted in the total loss of antifungal activity. 
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  Table 2.10. Antifungal activities of novel barbiturate saponins and analogs (MIC in g/mL). 
 
Compound 
 
Structure 
MIC50 (g/mL)
a,f 
C. albicans
 b
 C. glabrata
 c
 C. neoformans
 d
 A. fumigatus
 e
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73 NN
N
N
O O
O
H
H
H
H
NO2
H  
4 µg/mL 2 µg/mL NC* NC* 
 
74 N
N
N
N
O O
O
H
H
NO2
H  
4 µg/mL 4 µg/mL NC* NC* 
aMIC values are reported only for compounds displaying 1) a prominent decrease in turbidity by visual comparison to the control wells 
containing no antifungal and 2) a >50% reduction in fungal growth compared to controls containing no antifungal, as measured spectroscopically 
by absorption at 530 nm. bATCC no. 10231;cATCC no. 48435;dATCC no. 36556;eATCC no. 16424 fAll values were determined after incubation 
at 35°C for 48 h. *denotes compounds that had 1) a slight reduction in turbidity to no change and 2) had less than a 25% reduction in growth 
compared to controls, as measured spectroscopically by absorption at 530 nm. 
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2.5 Conclusions 
In pursuit to synthesize novel barbiturate steroidal saponins, several new agents were 
synthesized. In absence of any reported literature, procedure for synthesis of this class of 
compounds synthetic methodology was developed using cholesterol as the model substrate. A 
variety of C-glycosylated N,N-dimethyl barbiturate and barbiturate salts were successfully 
synthesized employing mono and disaccharides in one pot synthesis under mildly basic 
conditions. Methodology was established for 3β-steroid linker chain for ether, ester, carbonate 
and carbamate.  
Of the aliphatic and aromatic steroid linker, it was established that an aromatic linker is 
required for coupling to the C-glycosylated barbiturates. The reactivity of the halides towards the 
nucleophilic substitution in the steroidal substrates was studied. Out of the three halogenated 
derivatives, iodo was the most reactive making it nearly impossible to do reaction at the next step 
and mostly progressed with oxidation. Chloro derivatives reacted at a very slow and 
unacceptable rate. Best results were obtained with bromo derivatives as they offered better 
reactivity and yield. A good methodology has been successfully developed to functionalize 3β 
position of cholesterol using various linkers. The synthesized cholesterol derivatives were linked 
to the C-glycosylated barbiturates in an efficient manner with high yileds.  
The antifungal activity of the synthesized 3β-functionalized cholesterol, barbiturate and 
novel barbiturate saponins were evaluated in vitro.  The antifungal activity 1,3-dimethyl-5-((2-
(4-nitrophenyl)hydrazinyl)methylene) barbiturate 73 and its demethylated analogue 74 were in 
the range of  2-4g/mL and indicated that the presence or absence of methyl group on nitrogen 
of barbiturate may not have significant effect on the fungal activity of these agents. Compound 
45a had comparable antifungal activity to compounds 73 and 74. Hydrolysis of the carbonate 
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linker of 60 and 63 rendered these agents with no significant antifungal activity against all tested 
species. It is speculated that stereochemistry and binding affinity of compound 50, 56 and 58 
interfered with their activity and resulted in the total loss of antifungal activity.  
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2. 6. Experimental 
 
General Experimental 
All reagents and solvents were purchased from Sigma-Aldrich and were analytical grade.  Thin-
layer chromatographic analysis (TLC) was performed using silica gel on glass plates and was 
detected under ultraviolet (UV) light and using PMA, Ninhydrin, KMnO4 solution. Column 
chromatography was performed using silica gel porosity 60 Å, partial size 40-75 mm from 
Sorbent Technologies.  The 
1
H and 
13
C NMR spectra were run on Varian 400 MHz Unity in 
CDCl3, D2O, CD3OD or DMSO-d6 as solvents and internal standards.   
 
Synthesis of monosaccharide barbiturate derivatives, General procedure: A solution of 
dimethyl barbituric acid (15g, 0.1 mol) in 70 mL of water, saccharide (18g, 0.1 mol) in 70 mL 
and sodium carbonate were mixed together and heated at 80 °C for 5h. Reaction mixture was 
concentrated to one fifth of its original volume by evaporation, poured over methanol (1L) and 
stirred for 1h. White solid precipitate was isolated by filtration to give the pure product 
 
Synthesis of potassium 1,3-dimethyl-2,4,6-trioxo-5-(β-D-glucopyranose)-
hexahydropyrimidin-5-ide (6): A solution of N,N-dimethyl barbituric acid (15g, 0.1 mol ) in 70 
mL of water, glucose (18g, 0.1 mol) in 70 mL  and sodium carbonate were mixed together and 
heated at 80 °C for 5h. Reaction mixture was concentrated to one fifth of its original volume by 
evaporation, poured over methanol (1L) and stirred for 1h. White solid precipitate was isolated 
by filtration to give the pure product in a yield of 90%. 
1
H NMR (400 MHz, D2O): δ 4.36 (d, J = 
9.9, 1H), 4.21 (t, J = 9.4, 1H), 3.72 – 3.60 (m, 2H), 3.48 – 3.40 (m, 1H), 3.35 (t, J = 9.0, 1H), 
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3.29 (d, J = 9.5, 1H) and 3.03 (s, 6H) ppm. 
13
C NMR (400 MHz, D2O) δ 154.34, 95.58, 86.22, 
79.76, 78.43, 76.21, 69.66, 69.48, 60.87 and 27.85 ppm. 
 
Synthesis of sodium 1,3-dimethyl-2,4,6-trioxo-5-(β-D-galactopyranose)-
hexahydropyrimidin-5-ide (5): Galactose (10 g, 55.5 mmol) and 1,3-dimethylbarbituric acid 5 
(10 g, 64.0 mmol) were dissolved in water (100 mL) and sodium carbonate (5.60 g) was added to 
it. The mixture was then heated at 80 °C for 5h. The solvent was reduced to one fifth of its 
volume by evaporation and the solution was precipitated by pouring into rapidly stirred methanol 
(500 mL). The white solid was collected by filtration. 
1
H NMR (400 MHz, D2O): δ 3.20 (s, 6H), 
3.58 (dd, J 3.5, 9.7, 1H), 3.66 (br s, 3H), 3.93 (d, J= 3.5, 1H), 4.40 (d, J=9.7, 1H) and 4.50 (t, J= 
9.7, 1H)ppm. 
13
C NMR (D2O): δ 28.1, 61.4, 67.8, 70.2, 75.5, 77.0, 79.1, 86.7, 154.7 and 164.7 
ppm. 
 
Synthesis of potassium 2,4,6-trioxo-5-(β-D-glucopyranose)-hexahydropyrimidin-5-ide (5a): 
A solution of barbituric acid (15g, 0.1 mol ) in 70 mL of water, glucose (18g, 0.1 mol) in 70 mL  
and sodium carbonate were mixed together and heated at 80 °C for 5h. Reaction mixture was 
concentrated to one fifth of its original volume by evaporation, poured over methanol (1L) and 
stirred for 1h. White solid precipitate was isolated by filtration to give the pure product in a yield 
of 90%. 
1
H NMR (400 MHz, D2O): δ 4.36 (d, J = 9.9, 1H), 4.21 (t, J = 9.4, 1H), 3.72 – 3.60 (m, 
2H), 3.48 – 3.40 (m, 1H), 3.35 (t, J = 9.0, 1H) and 3.29 (d, J = 9.5, 1H) ppm. 13C NMR (400 
MHz, D2O) δ 154.34, 95.58, 86.22, 79.76, 78.43, 76.21, 69.66, 69.48 and 60.87 ppm. 
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Synthesis of disaccharide barbiturate derivatives, General procedure: A solution of 
dimethyl barbituric acid (15g, 0.1 mol) in 70 mL of water, saccahride (18g, 0.1 mol) in 70 mL  
and sodium carbonate (0.05 mol) were mixed together and heated at 80 °C for 5h. Reaction 
mixture was concentrated to one fifth of its original volume by evaporation, poured over 
methanol (1L) and stirred for 1h. White solid precipitate was isolated by filtration to give the 
pure product 
 
Synthesis of sodium 1,3-dimethyl-2,4,6-trioxo-5-(β-D-maltose)-hexahydropyrimidin-5-ide 
(7): A solution of dimethyl barbituric acid (5g, 0.03 mol ) in 20 mL of water, maltose (11.4g, 
0.03 mol) in 20 mL  and sodium carbonate (0.05 mol) were mixed together and heated at 80 °C 
for 5h. Reaction mixture was concentrated to one fifth of its original volume by evaporation, 
poured over methanol (1L) and stirred for 1h. White solid precipitate was isolated by filtration to 
give the pure product in a yield of 90%. 
1
H NMR (400 MHz, D2O): δ 5.39 (d, J = 1.8Hz, 1H), 
4.5(d, J = 1.8Hz, 1H), 4.38 (t, J =10.8 Hz, 1H), 3.48- 3.85 (m, 9H ), 3.38 (t, J =10.8 Hz, 1H) and 
3.2 (s, 6H) ppm. 
13
C NMR (D2O): δ 154.44, 115.58, 99.92, 94.98, 86.20, 78.78, 78.29, 77.10, 
76.00, 73.08, 72.70, 71.98, 69.46, 69.43, 60.75, 60.54, 48.96 and 27.73 ppm. 
 
Synthesis of sodium 2,4,6-trioxo-5-(β-D-maltose)-hexahydropyrimidin-5-ide (7a): A solution 
of N,N-dimethyl barbituric acid (5g, 0.03 mol ) in 20 mL of water, maltose (11.4g, 0.03 mol) in 
20 mL  and sodium carbonate were mixed together and heated at 80 °C for 5h. Reaction mixture 
was concentrated to one fifth of its original volume by evaporation, poured over methanol (1L) 
and stirred for 1h. White solid precipitate was isolated by filtration to give the pure product in a 
yield of 90%. 
1
H NMR (400 MHz, D2O): δ 5.39 (d, J = 1.8Hz, 1H), 4.5(d, J = 1.8Hz, 1H), 4.38 
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(t, J =10.8 Hz, 1H), 3.48- 3.85 (m, 9H) and 3.38 (t, J =10.8 Hz, 1H) ppm. 
13
C NMR (D2O): δ 
154.44, 115.58, 99.92, 94.98, 86.20, 78.78, 78.29, 77.10, 76.00, 73.08, 72.70, 71.98, 69.46, 
69.43, 60.75, 60.54 and 48.96 ppm. 
 
Pottasium 1,3-dimethyl-5-(β-D-glucopyranosyl-(1→4)-β-D-glucopyranosyl)barbiturate (8) 
Compound 8 (125 mg, 82%) was obtained as a white powdery solid  
1
H NMR (400 MHz, D2O): 
δ 3.16 (s, 6H), 3.28 (dd, J= 8.0, 8.7, 1H), 3.38 (t, J =9.3, 1H,), 3.46 (m, 2H), 3.52 (m, 1H), 3.57 
(t, J= 9.5, 1H), 3.69 (dd, J =5.5, 12.1, 1H), 3.75 (dd, J =9.5, 9.8, 1H), 3.82 (br s, 2H), 3.87 (br d, 
J =12.1, 1H), 4.33 (dd, J= 9.5, 10.1,1H), 4.49 (d, J= 10.1, 1H) and 4.52 (d, J =8.0, 1H) ppm. 
13
C 
NMR  (D2O): δ 165.5, 154.7, 102.9, 86.4, 78.9, 78.8, 77.0, 76.4, 76.2, 75.9, 73.6, 69.9, 69.7, 
61.0, 60.5 and 28.0 ppm. 
 
Pottasium 2,4,6-trioxo-5-(β-D-glucopyranosyl-(1→4)-β-D-glucopyranosyl) 
hexahydropyrimidin-5-ide (8a): Compound 8a (100 mg, 80%) was obtained as a white 
powdery solid  
1
H NMR (400 MHz, D2O): δ 3.26 (dd, J =8.0, 8.7, 1H), 3.36 (t, J= 9.3, 1H,), 
3.47 (m, 2H), 3.55 (m, 1H), 3.52 (t, J= 9.5, 1H), 3.71 (dd, J= 5.5, 12.1, 1H), 3.74 (dd, J= 9.5, 
9.8, 1H), 3.85 (br s, 2H), 3.87 (br d, J= 12.1, 1H), 4.36 (dd, J= 9.5, 10.1,1H), 4.48 (d, J =10.1, 
1H) and 4.55 (d, J= 8.0, 1H) ppm. 
13
C NMR  (D2O): δ 165.3, 155.1, 103.2, 86.4, 78.9, 78.8, 
77.0, 76.4, 76.2, 75.9, 73.6, 69.9, 69.7, 61.0 and 60.5 ppm. 
 
Chloromethylation of steroid, General procedure: HCl gas was purged through a solution of 
desired steroid at 0 °C for 1-3h. The reaction mixture was kept dry by using calcium chloride 
pellets. Reaction was monitored by TLC. After the completion of reaction solvent was 
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evaporated and purified by column chromatography to give the desired steroid in almost 80-90% 
yield. 
 
Synthesis of 1-(chloromethoxy)-3-methylbutane: To a solution of isoamyl alcohol (8.85 gm, 
0.1 mmol) and paraformaldehyde (3 gm, 0.1 mmol) in 1, 2 dichloroethane (20 mL) was added 
Calcium chloride (10 gm). The reaction mixture was cooled to 0 °C and HCl gas  purged through 
it for 2h. Solvent was removed under reduced pressure to give colorless liquid (13.20 mL. yield 
95 %). 
1
H NMR (400 MHz, CDCl3): δ 5.51 (s, 2H), 3.89 – 3.63 (m, 2H), 1.70 (m, J = 15.6, 1H), 
1.52 (m, J = 15.6, 2H), 0.91 (s, 3H) and 0.91 (s, 3H) ppm. 
13
C NMR (CDCl3): δ 66.7, 48.2, 23.2, 
24.6 and 39.8 ppm. 
 
Synthesis of Cholest-5-en-3β-oxymethyl chloride (59): A suspension of cholesterol (1 gm, 
2.58 mmol) and paraformaldehyde (125 mg, 3.87 mmol) in dry DCM (5 mL) with calcium 
chloride (1 gm) was cooled to 0 °C. HCl gas (generated by carefully dropping sulfuric acid over 
sodium chloride) was purged through the solution for about 2h to give a clear solution. Reaction 
was continuously monitored by TLC. Solvent was evaporated under reduced pressure to give a 
white solid. Purified by column chromatography to give 1gm of white solid (88% yield). 
1
H 
NMR (CDCl3, 400 MHz): δ 5.45 (s, 2H), 5.36 (s, 1H), 3.42 (m, 1H) and 1.98-0.84 (m, 43H) 
ppm.
 13
C NMR (400 MHz, CDCl3): δ 141.8, 122.9, 80.3, 58.5, 56.9, 51.2, 46.1, 44.0, 39.7, 38.9, 
37.5, 37.2, 36.3, 35.8, 31.7, 30.3, 29.98, 28.67, 28.12, 27.65, 27.32, 24.61, 23.22, 22.71, 20.71 
and 19.45  ppm. 
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Synthesis of Cholestan-3β-oxymethyl chloride (59a): Synthesis was carried out in the same 
manner as for compound 59 to get 1gm of white solid (89% yield). 
1
H NMR (CDCl3, 400 MHz): 
δ  5.64 (s, 2H), 3.42 (m, 1H), 2.0-0.84 (m, 43H) and 0.63 (s, 3H) ppm. 13C NMR (400 MHz, 
CDCl3): δ  79.3, 56.7, 56.5, 52.2, 46.1, 46.01, 41.0, 40.20, 39.7, 36.9, 36.3, 35.8, 34.5, 32.7, 32.0, 
28.91, 28.38, 28.17, 27.65, 24.63, 24.22, 23.20, 20.71, 19.42, 16.22 and 16.14  ppm. 
 
Synthesis of Cholest-5-en-3β-tosylate (31): A solution of cholesterol (10.0 g, 0.026 mol) in dry 
pyridine (10 mL) was cooled to 0 °C and tosyl chloride (7.4 g, 0.04 mol) was added in portions. 
The reaction mixture was then allowed to stir at 0 °C for 6 h. Diluted mixture with 
dichloromethane (50 mL) and was washed with 5% HCl (2 X 50 mL), water (50 mL), and brine 
(50 mL). Seperated the organic layer and dried over anhydrous Na2SO4. Dichloromethane was 
evaporated to give a white powder (13.2 gm, yield 93.2%). Mp: 132 °C. 
1
H NMR (CDCl3, 400 
MHz): δ 7.80-7.77 (d, J = 7.8, 2H), 7.33-7.25 (d, J = 7.8, 2H), 5.27 (d, J = 4.5, 1H), 4.39 (m, 
1H), 2.44 (s, 3H), 2.39 (m, 2H), 2.12-0.84 (m, 39H) and 0.64 (s, 3H) ppm.
 13
C NMR (400 MHz, 
CDCl3): δ 144.61, 139.03, 134.93, 129.98, 127.82, 123.72, 82.51, 56.83, 56.31, 50.09, 42.47, 
39.85, 39.72, 39.09, 37.08, 36.52, 36.39, 35.97, 32.04, 31.94, 28.82, 28.41, 28.19, 24.45, 24.03, 
23.05, 22.80, 21.82, 21.19, 19.34, 18.93 and 12.04 ppm. 
 
Synthesis of Cholest-5-en-3β-oxyethan-2-ol (30): Dry ethylene glycol (10 g, 0.16 mol) was 
added to a solution of Cholest-5-en-3β-tosylate (3.5 g, 6.5 mmol) in dry dioxane. The resulting 
mixture was refluxed for 4h under N2. The reaction mixture cooled to room temperature and 
solvent removed under reduced pressure. The resulting residue was dissolved in DCM (50 mL) 
and washed with water (2 X50 mL), NaHCO3 (2 X50 mL), brine (50 mL) and dried over sodium 
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sulfate. Solvent removed under reduced pressure. The compound was further purified by column 
chromatography over silica gel using a mixture of petroleum ether and ethyl acetate. Pure 
product was obtained as white solid (6.5 gm, yield 81.6%). 
1
H NMR (CDCl3, 400 MHz): δ 5.35 
(s, 1H), 3.72 (t, J = 11.3, 2H), 3.64 – 3.54 (t, J = 11.3, 2H), 3.19 (m, 1H), 2.37 (d, J = 8.7, 1H), 
2.22 (d, J = 11.1, 1H), 2.08 – 0.79 (m, 39H) and 0.68 (s, 3H) ppm. 13C NMR (CDCl3, 400 MHz): 
δ 140.8, 121.8, 70.5, 61.6, 58.3, 56.5, 50.8, 44.0, 39.6, 39.9, 37.7, 37.2, 36.1, 35.8, 31.9, 30.3, 
29.9, 29.5, 28.1, 27.7, 27.3, 24.6, 23.2, 22.7, 20.7, 19.4 and 11.84 ppm. 
 
Synthesis of Cholest-5-en-3β-oxyethyl-2-tosylate (30B): Solution of cholest-5-en-3β -
oxyethan-2-ol 30  (4.3 g, 0.01 mol) in dry pyridine (15mL) was cooled to 0 °C, followed by 
addition of  p-toluenesulfonyl chloride (3.5 g, 0.018 mol) in portions. The reaction mixture was 
allowed to stir at 0 °C for 6 h. To the reaction mixture dichloromethane (50mL) was added, and 
with 5% HCl (2 X 25 mL), water (2 X 25 mL), and brine (25mL). Dried the DCM layer over 
anhydrous sodium sulfate and evaporated to dryness under reduced pressure. The resulting 
product was purified by recrystallization using acetonitrile to give white powder (5.3 gm, yield= 
91%). 
1
H NMR (CDCl3, 400 MHz): δ 7.80–7.83 (d, J = 8.1 Hz, 2H), 7.33–7.36 (d, J = 8.1 Hz, 
2H), 5.33 (d, J = 4.5 Hz, 1H), 4.16–4.18 (t, J = 4.5Hz, 2H), 3.64–3.67 (t, J = 4.5Hz, 2H), 3.04–
3.10 (m, 1H), 2.48 (s, 3H), 0.85–2.26 (m, 41H) and 0.68(s, 3H) ppm. 13C NMR (CDCl3, 400 
MHz): δ 144.51, 138.87, 134.79, 129.86, 127.71, 123.84, 82.08, 60.78, 56.73, 56.17, 55.74, 
49.94, 42.09, 39.66, 39.28, 38.71, 36.75, 36.41, 36.06, 35.55, 31.94, 31.56, 28.50, 28.06, 27.86, 
24.09, 23.62, 22.93, 22.67, 21.72, 19.02, 18.51 and 11.86 ppm. 
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Synthesis of Cholest-5-en-3β-oxyethyl-2-chloride (32): A solution of Cholest-5-en-3β-
oxyethan-2-ol (2.2gm, 5.1 mmol) in DCM (10 mL) was cooled to 0 °C, followed by addition of 
oxalyl chloride (0.97 gm, 7.65 mmol) and a few drops of DMF. The reaction was stirred at this 
temperature for 6h. Reaction was continuously monitored by TLC. Solvent evaporated under 
reduced pressure to get a white solid in almost quantitative yield.  
1
H NMR (CDCl3, 400 MHz) δ 
5.40 (d, J = 4.5 Hz, 1H), 5.35 (s, 2H), 4.49 (m, 2H), 3.79(m, 2H), 3.2 (m, 1H), 0.83–2.39 (m, 
41H) and 0.65 (s, 3H) ppm. 
13
C NMR (CDCl3, 400 MHz):  δ 140.1, 122.2, 80.6, 67.7, 65.8, 65.4, 
64.7, 58.3, 56.5, 52.5, 50.8, 44.0, 39.9, 39.7, 37.8, 37.2, 36.1, 35.8, 31.9, 30.4, 29.6, 28.2, 27.7, 
27.3, 24.7, 23.2, 22.7, 20.7, 19.1 and 11.6 ppm. 
 
Synthesis of Cholest-5-en-3β-oxyethyl-2-oxy-benzyl alcohol (29): To a DMF (25 mL) solution 
of Cholest-5-en-3β-oxyethan-2-ol 30 (100 mg, 0.232 mmol) and 4-bromobenzyl bromide (57 
mg, 0.232 mmol) was added Cu(acac)2 (60 mg, 0.232 mmol) in portions. The reaction was 
allowed to reflux for 8 h. The crude reaction mixture was diluted with DCM (50 mL) and washed 
with water (2 X25 mL), brine (25 mL). The organic layer was dried over anhydrous sodium 
sulfate. Purification was achieved by silica column using hexane-DCM. A yellowish product 
weighing 41 mg (yield = 30%) was obtained. 
1
H NMR (CDCl3, 400 MHz): δ 7.08 (d, J = 8.2 Hz, 
2H), 6.9 (d, J = 8.2 Hz, 2H), 5.39 (d, J = 4.5 Hz, 1H), 4.80 (s, 2H), 4.29 (t, J = 4.5Hz, 2H), 3.82 
(t, J = 4.5Hz, 2H), 2.89 (m, 1H) and 2.26–0.85 (m, 44H) ppm. 13C NMR (CDCl3, 400 MHz): δ 
155.2, 141.2, 132.9, 128.42, 122.1, 115.65, 84.01, 69.89, 68.02, 58.32, 56.25, 50.80, 44.01, 
40.01, 39.65, 37.76, 36.01, 36.0, 31.91, 30.13, 28.99, 28.12, 26.99, 27.35, 24.6, 23.22, 22.7, 
20.17 and 19.5 ppm. 
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Synthesis of Cholest-5-en-3β-oxyethyl-2-bromide (33): To a solution of Cholest-5-en-3β-
oxyethan-2-ol (2.2gm, 5.1 mmol) in DCM (10 mL) was added carbon tetrabromide (4.2 gm, 2.5 
mmol) and triphenyl phosphine (1.1 gm, 2.5 mmol). The resulting solution was allowed to stir at 
room temperature for 4h. Reaction was monitored by TLC. After completion of reaction, the 
reaction mixture was charged with MeI and allowed to stir for 2h at room temperature. Washed 
reaction mixture with water (2 X 10 mL), Brine (10 mL). Organic layer dried over anhydrous 
sodium sulfate. Compound purified by column to give yellowish solid (2.1 gm, yield= 84%).  
1
H 
NMR (CDCl3, 400 MHz) δ 5.39 (d, 1H, J = 4.5 Hz), 3.8 (t, J = 10.5 Hz, 2H), 3.42 (t, J = 10.5 Hz, 
3H), 3.2 (m, 1H), 0.83–2.38 (m, 41H) and 0.65 (s, 3H) ppm.  13C NMR (CDCl3, 400 MHz): δ 
140.1, 122.2, 80.6, 67.7, 65.8, 65.4, 64.7, 58.3, 56.5, 52.5, 50.8, 44.0, 39.9, 39.7, 37.8, 37.2, 36.1, 
35.8, 31.9, 30.4, 29.6, 28.2, 27.7, 27.3, 24.7, 23.2, 22.7, 20.7, 19.1 and 11.6 ppm. 
 
Synthesis of Cholest-5-en-3β-yloxy-4-oxobutanoic acid (41): To a solution of Cholesterol (5 
gm, 0.013 mol) in dry pyridine (15 mL), succinic anhydride (1.3 gm, 0.013 mol) was added and 
allowed to stir at room temperature for 8h. The reaction mixture was diluted with DCM (50 mL) 
and washed with water. The organic layer was washed with 5% HCl (2 X 50 mL) and brine (50 
mL), dried over sodium sulfate. The solvent was evaporated under reduced pressure to give the 
crude mixture which was purified by column chromatography using hexane- DCM. Pure product 
was obtained as white solid (4.35 gm, yield=90%). 
1
H NMR (CDCl3, 400 MHz)  δ 5.36 (d, J = 
4.5 Hz, 1H),  4.6 (m, 1H), 2.6 (t, J = 10.2 Hz, 2H), 2.7 (t, J = 10.2 Hz, 2H), 2.32 (d, J = 4.5 Hz, 
2H), 0.83–2.05 (m, 39H) and 0.65 (s, 3H) ppm. 13C NMR (CDCl3, 400 MHz):  δ 176.98, 172.4, 
141.02, 121.78, 74.22, 58.23, 56.65, 50.76, 44.09, 43.00, 40.01, 38.51, 37.5, 37.23, 36.22, 35.90, 
32.01, 30.10, 29.88, 29.90, 28.45, 28.10, 27.77, 27.35, 24.69, 23.32, 22.70, 20.71 and 19.4 ppm. 
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Synthesis of Cholest-5-en-3β-yloxy-4-oxobutanoyl chloride (42): To an ice cold solution of 
Cholest-5-en-3β-yloxy-4-oxobutanoic acid 41 (2.5 gm, 4.2 mmol) in DCM (50 mL) was added 
oxalyl chloride (0.63gm, 5.04 mmol) with few drops of DMF and allowed to stir under nitrogen. 
Reaction was stirred at 0 °C for 4 hrs and solvent removed to give the product as white solid (2.6 
gm) in quantitative yields which was taken to the next step without further purification. 
1
H NMR 
(CDCl3, 400 MHz) δ 5.41 (d, J = 4.5 Hz, 1H), 4.04 (m, 1H), 2.6 (t, J = 10.2 Hz, 2H), 2.4 (t, J = 
10.2 Hz, 2H), 2.32 (d, J = 4.5 Hz, 2H) and 0.83–2.15 (m, 40H) ppm. 13C NMR (CDCl3, 400 
MHz):  δ  176.98, 172.4, 141.02, 121.78, 74.22, 58.23, 56.65, 50.76, 44.09, 43.00, 40.01, 38.51, 
37.5, 37.23, 36.22, 35.90, 32.01, 30.10, 29.88, 29.90, 28.45, 28.10, 27.77, 27.35, 24.69, 23.32, 
22.70, 20.71 and 19.4 ppm. 
 
Synthesis of Cholest-5-en-3β-yl-4-(hydroxymethyl)phenyl succinate (43): To an ice cold 
solution of Cholest-5-en-3β-yloxy-4-oxobutanoyl chloride (2.5 gm, 4.2 mmol) in dry pyridine 
(10 mL) was added 4-hydroxybenzyl alcohol (0.52gm, 4.2 mmol) in portions and allowed to stir 
at 0 °C for 2h. Diluted the crude reaction mixture with DCM (50 mL) and washed with water. 
The organic layer was washed with 5% HCl (2 X 50 mL) and brine (50 mL), dried over sodium 
sulfate. The solvent was evaporated under reduced pressure to give the crude mixture which was 
purified by column chromatography using hexane- DCM. Pure product was obtained as white 
solid (4.35 gm, yield=90%). 
1
H NMR (CDCl3, 400 MHz)  δ 7.22 (d, J = 9.1 Hz, 2H), 6.81 (d, J = 
9.1 Hz, 2H), 5.38 (bs, 1H), 5.03(s, 2H), 4.51-4.58 (m, 1H), 2.87 (m, 2H), 2.61 (m, 2H), 2.28 (d, J 
= 9.1 Hz, 2H), 0.85–2.26 (m, 41H) and 0.68(s, 3H) ppm. 13C NMR (CDCl3, 400 MHz): δ 174.2, 
173.1, 150.12, 141.2, 137.89, 127.7, 121.78, 74.2, 67.2, 58.00, 56.05, 50.09, 44.12, 39.89, 38.54, 
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37.42, 37.23, 35.89, 36.10, 31.89, 30.21, 29.89, 29.12, 28.45, 28.12, 27.83, 26.89, 24.6, 23.22, 
22.71, 20.69 and 19.45 ppm. 
 
Synthesis of Cholest-5-en-3β-yl-4-(bromomethyl)phenyl succinate (44): Bromination was 
carried out same way as for compound 33.  100mg of compound was obtained as yellowish 
powder (yield =89%) 
1
H NMR (CDCl3, 400 MHz)  δ 7.39 (d, J = 10.5 Hz, 2H), 7.09 (d, J = 10.5 
Hz, 2H), 5.38 (bs, 1H), 5.18 (s, 2H), 4.63-4.76 (m, 1H), 2.9 (t,  J = 12.8 Hz, 2H), 2.79 (t, J = 12.8 
Hz, 2H), 2.38 (, J = 10.5 Hz, 2H), 0.85–2.26 (m, 41H) and 0.68(s, 3H) ppm. 13C NMR (CDCl3, 
400 MHz): δ 173.2, 172.89, 151.51, 141.2, 134.89, 129.7, 121.78, 121.42, 74.2, 58.03, 56.05, 
50.09, 44.01, 39.89, 38.54, 37.42, 36.23, 35.89, 34.10, 31.89, 30.21, 29.89, 29.42, 29.15, 28.42, 
28.12, 27.77, 27.33, 24.61, 23.22, 22.71, 20.69 and 19.45 ppm. 
 
Synthesis of Cholest-5-en-3β-yl-4-(hydroxymethyl)phenyl carbonate (36): To a solution of 
cholesteryl chloroformate (1.5 gm, 3.33mmol) in THF was added 4-hydroxy-benzyl alcohol (414 
mg, 3.33 mmol) and KOH (467mg, 8.35 mmol) in water (50 mL). The mixture was allowed to 
stir at room temperature for 30 minutes. THF was evaporated under reduced pressure and the pH 
was adjusted to approximately 6. The product was extracted in DCM. The organic layer was 
dried over anhydrous sodium sulfate. Solvent evaporated under reduced pressure to give a white 
solid crude product. Further purification was done by crystallization from methanol to give 1.2 
gm (yield= 66%) of white solid powder. 
1
H NMR (CDCl3, 400 MHz)  δ 7.38-7.36 (d, J = 4.0, 
2H), 7.18-7.15 (d, J = 4.0, 2H), 5.42 (s, 1H), 4.68 (s, 2H), 4.57 (dt, J = 11.0, 5.6, 1H), 2.47 (d, J 
= 8.7, 2H), 2.07 – 0.78 (m, 40H) and 0.68 (d, J = 4.0, 3H) ppm. 13C NMR (CDCl3, 400 MHz): δ 
151.48, 150.45, 139.36, 139.33, 129.89, 128.30, 123.45, 121.44, 79.13, 64.92, 56.88, 56.32, 
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50.18, 42.52, 39.90, 39.72, 38.14, 37.02, 36.75, 36.38, 36, 32.11, 32.03, 28.438, 28.22, 27.84, 
24.48, 24.03, 23.03, 22.77, 21.25, 19.5, 19 and 12.1 ppm.  
 
Synthesis of Cholest-5-en-3β-yl-(4-(chloromethyl) phenyl) carbonate (38): To a solution of 
Cholest-5-en-3β-yl-4-(hydroxymethyl) phenyl carbonate (100mg, 0.19 mmol) in DCM (10mL) 
was added oxalyl chloride (0.02 mL, 0.28 mmol) drop wise at 0 °C in presence of a few drops of 
DMF. Reaction was stirred at 0 °C for 4h. Solvent was removed under reduced pressure to get 
the pure product as a white powder ( 100 mg, yield=100%). 
1
H NMR (CDCl3, 400 MHz) δ 7.45-
7.41 (d, J = 8.3, 2H), 7.25-7.21 (d, J = 8.3, 2H), 5.48 (s, 1H), 5.38 (s, 2H), 4.6 (m, 1H), 2.51 (d, J 
= 8.7, 2H), 2.17 – 0.88 (m, 40H) and 0.68 (d, J = 4.0, 3H) ppm. 13C NMR (CDCl3, 400 MHz): δ 
153.19, 149.89, 133.92, 131.04, 130.16, 122.57, 121.69, 115.61, 109.95, 79.25, 56.89, 56.33, 
50.18, 42.52, 39.91, 39.72, 38.12, 37.02, 36.76, 36.39, 36.00, 32.79, 32.12, 32.04, 28.44, 28.23, 
27.83, 24.49, 24.03, 23.04, 22.78, 21.25, 19.49, 18.92 and 12.09 ppm. 
 
Synthesis of Cholest-5-en-3β-yl-4-(bromomethyl)phenyl carbonate (40): Bromination was 
done in the same way as for compound 33. The product was obtained as yellowish powder (118 
mg, yield=82%). 
1
H NMR (CDCl3, 400 MHz) δ 7.41-7.39 (d, J = 5.3, 2H), 7.17-7.15 (d, J = 5.3, 
2H), 5.43 (s, 1H), 4.68 (m, 1H), 4.48 (s, 2H), 2.51 (d, J = 8.7, 2H), 2.10 – 0.82 (m, 40H) and 
0.68 (d, J = 4.0, 3H) ppm. 
13
C NMR (CDCl3, 400 MHz): δ 153.18, 149.24, 139.32, 130.40, 
130.14, 123.53, 121.69, 115.61, 109.95, 79.25, 56.89, 56.33, 50.18, 42.52, 39.91, 39.72, 38.12, 
37.02, 36.76, 36.39, 36.00, 32.79, 32.12, 32.04, 28.44, 28.23, 27.83, 24.49, 24.03, 23.04, 22.78, 
21.25, 19.49, 18.92 and 12.09 ppm. 
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Cholest-5-en-3β-yl-4-(tosylmethyl)phenyl carbonate (37): Procedure for synthesis is same as 
compound 31. 
1
H NMR (CDCl3, 400 MHz) δ 7.78–7.8 (d, J = 8.1 Hz, 2H), 7.35–7.38 (d, J = 8.1 
Hz, 2H), 7.18-7.15 (d, J = 4.0, 2H), 7.08-7.06 (d, J = 4.0, 2H), 5.39 (s, 1H), 4.49 (m, 1H), 2.50 
(s, 3H), 2.47 (d, J = 8.7, 2H), 2.2.07 – 0.78 (m, 40H) and 0.68 (d, J = 4.0, 3H) ppm. 13C NMR 
(CDCl3, 400 MHz): δ 156.05, 151.48, 143.9, 139.36, 139.33, 138.92, 129.89, 129.65, 128.30, 
122.45, 121.44, 79.13, 69.92, 57.88, 56.42, 50.18, 43.52, 39.90, 38.14, 37.02, 36.75, 36.38, 36, 
32.11, 30.03, 28.23,  27.74, 24.48, 24.3, 23.03, 22.77 and 19.5 ppm.  
 
Synthesis of Cholest-5-en-3β-yl-(4-(iodomethyl)phenyl) carbonate (39): To the acetone (10 
mL) solution of Cholest-5-en-3β-yl-4-(chloromethyl) phenyl carbonate 38 (100mg, 0.154 mmol) 
potassium iodide (0.025 gm, 0.154 mmol) was added. The reaction mixture was allowed to stir in 
dark under nitrogen atmosphere for 5h. Reaction was continuously monitored by TLC and NMR. 
After the completion of reaction solvent was evaporated, diluted with DCM (25 mL), washed 
with water (2 X 10 mL), and dried over sodium sulfate. Solvent was removed to get a dark 
colored product weighing 80 mg. (yield= 69%). 
1
H NMR (CDCl3, 400 MHz) δ 7.41-7.39 (d, J = 
5.3, 2H), 7.17-7.15 (d, J = 5.3, 2H), 5.43 (s, 1H), 4.71 (s, 2H), 4.64 (m, 1H), 2.51 (d, J = 8.7, 
2H), 2.10 – 0.82 (m, 40H) and 0.68 (d, J = 4.0, 3H) ppm. 13C NMR (CDCl3, 400 MHz): δ 
153.18, 149.24, 139.32, 130.40, 130.14, 123.53, 121.69, 115.61, 109.95, 79.25, 56.89, 56.33, 
50.18, 42.52, 39.91, 39.72, 38.12, 37.02, 36.76, 36.39, 36.00, 32.79,  32.04, 28.44, 28.23, 27.83, 
24.49, 24.03, 23.04, 22.78, 21.25, 19.49, 18.92, 12.09 and 7.06 ppm. 
 
Synthesis of Cholest-5-en-3β-yloxycarbonyl(methylamino)acetic acid (44): To a solution of 
cholesteryl chloroformate (1gm, 2.30 mmol) in DCM (200 mL), 2-(methylamino)acetic acid 
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(0.89 gm, 0.01 mol) was added. The resulting reaction mixture was allowed to stir at room 
temperature for 1 h. Washed with 5% HCl (3 X 100 mL), water (3 X 100 mL). Organic layer was 
dried over anhydrous sodium sulfate and solvent removed under reduced pressure. A white solid 
was obtained which was purified by diluting with methanol and sonicating. Filtered and washed 
with methanol to give white solid (1.09 gm, yield= 95%) as pure product. 
1
H NMR (CDCl3, 400 
MHz) δ 5.35 (s, 1H), 4.50-4.48 (m, 1H), 4.03 (s, 1H), 3.97 (s, 1H), 2.96 (s, 3H), 2.36-2.22 (m, 
3H), 1.97- 1.79 (m, 6H), 1.56-0.85 (m, 31H) and 0.66 (s, 3H) ppm. 
13
C NMR (CDCl3, 400 
MHz): δ 174.32, 157.00, 156.17, 121.81, 115.57, 76.01, 75.80, 56.88, 56.35, 55.91, 50.66, 50.47, 
50.19, 42.51, 39,95, 39.73, 38.71, 37.18, 36.76, 36.41, 36.03, 35.53, 32.13, 32.08, 28.46, 28.35, 
28.23, 24.51, 24.08, 23.05, 22.79, 21.26, 19.58, 18.94 and 12.08 ppm.   
 
Synthesis of Cholest-5-en-3β-yloxycarbonyl(methylamino)acetyl chloride (46): Compound 
was synthesized in the same way as compound 42. 
1
H NMR (CDCl3, 400 MHz) δ δ 5.35 (s, 1H), 
4.60 (m, 1H), 4.50 (s, 2H), 3.27 (s, 3H),  2.36-2.22 (m, 3H), 1.97-0.85 (m, 38H) and 0.66 (s, 3H) 
ppm. 
 
Synthesis of 4-(hydroxymethyl)phenyl-2-cholest-5en-3-yloxycarbonyl-N-
methylaminoacetate (47): Compound was synthesized in the manner as compound 43. 
1
H NMR 
(CDCl3, 400 MHz) δ 7.16 (d, J = 10.1 Hz, 2H), 6.98 (d, J = 10.1 Hz, 2H), 5.37 (m, 1H), 4.79 (s, 
2H), 4.03 (s, 2H), 3.97 (s, 1H), 2.96 (s, 3H), 2.36-2.22 (m, 3H), 1.97-0.85 (m, 36H) and 0.66 (s, 
3H) ppm. 
13
C NMR (CDCl3, 400 MHz): δ 169.32, 157.00, 151.17, 140.8, 139.0, 127.81, 121.8,  
72.80, 69.00, 56.88, 58.35, 51.66, 50.66, 44.51, 39,95, 38.71, 37.18, 36.76, 35.41, 32.13, 30.08, 
29.46, 28.35, 27.23, 27.13, 24.51, 23.05, 22.79, 21.26 and 19.58 ppm.   
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Synthesis of Cholest-5-en-3β-yl-2-hydroxyethyl(methyl)carbamate (45): To a solution of 
cholesteryl chloroformate (1.05gm, 2.32 mmol) in DCM (200 mL), 2-methylaminoethanol (1.30 
gm, 0.01 mol) was added. The resulting reaction mixture was allowed to stir at room temperature 
for 1 h. Washed with 5% HCl (3 X 100 mL), water (3 X 100 mL). Organic layer was dried over 
anhydrous sodium sulfate and solvent removed under reduced pressure. A white solid was 
obtained which was purified by diluting with methanol and sonicating. Filtered and washed with 
methanol to give white solid (1.12 gm, yield= 95%) as pure product. 
1
H NMR (CDCl3, 400 
MHz) δ 5.35 (s, 1H), 4.48 (broad s, 1H), 3.73 (s, 1H), 3.41 (s, 1H), 2.94 (s, 3H), 2.34-2.28 (m, 
3H), 1.99- 1.78 (m, 6H), 1.58-0.83 (m, 32H) and 0.66 (s, 3H) ppm; 
13
C NMR (CDCl3, 400 
MHz): δ 139.99, 122.75, 115.57, 56.88, 55.91, 52.10, 50.20, 42.51, 39,94, 39.73, 38.87, 37.22, 
36.78, 36.39, 36.02, 32.12, 32.08, 28.46, 28.22, 24.50, 24.06, 23.05, 22.79, 21.26, 19.58, 18.93 
and 12.07 ppm.   
 
Synthesis of tosylate of Cholest-5-en-3β-yl-2-hydroxyethyl(methyl)carbamate (48): 
Synthesized same as compound 31. 
1
H NMR (CDCl3, 400 MHz) δ 7.78 (d, J = 7.6 Hz, 2H), 7.46 
(d, J = 7.6 Hz, 2H), 5.35 (s, 1H), 4.46 (broad s, 1H), 3.72 (s, 1H), 3.39 (s, 1H), 2.95 (s, 3H), 2.43 
(s, 3H), 2.34-2.28 (m, 3H), 1.98- 1.78 (m, 6H), 1.58-0.83 (m, 32H) and 0.66 (s, 3H) ppm; 
13
C 
NMR (CDCl3, 400 MHz): δ 144.23, 138.69, 139.99, 130.12, 129.11, 122.75, 115.57, 56.88, 
55.91, 52.10, 50.20, 42.51, 39,94, 39.73, 38.87, 37.22, 36.78, 36.39, 36.02, 32.12, 32.08, 29.32, 
28.46, 28.22, 24.50, 24.33, 24.06, 23.05, 22.79, 21.26, 19.58, 18.93 and 12.07 ppm.   
 
General Procedure for coupling of C-glycosylated barbiturates 6 with Benzyl bromide 
derivatives: Benzyl bromide derivative (0.1 mmol) was added to a clear solution of C-
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glycosylated barbiturate 6 (0.1 mmol). The reaction mixture was sonicated to get a clear solution, 
else few drops of DCM were added to get a clear solution. The reaction mixture was allowed to 
sonicate for 15-30 mins depending on the substrate reactivity. After completion of reaction 
dilution with water and DCM precipitated the product. Filtered the mixture to get the pure 
product. 
 
Synthesis of 1,3-dimethyl-5-(4-methylbenzyl)-5-(β-D-glucosyl)pyrimidine-2,4,6-trione (50): 
DMSO (5 mL) is added to compound 6 (100 mg, 0.280 mmol) and sonicated to get a clear 
solution, followed by addition of 1-(bromomethyl)-4-methylbenzene 49 (52 mg, 0.280 mmol). 
Continue to sonicate for another 15 minutes. Dilute with water (1 mL) and DCM (5mL). Collect 
the precipitate by decantation. Dissolve in EtOAc (10 mL) and wash with water (2 X 10 mL). 
Dried organic layer over anhydrous sodium sulfate and removed solvent under reduced pressure 
to get a yellowish solid (32 mg, yield=30%).  
1
H NMR (CDCl3, 400 MHz) δ 7.08 (d, J = 11.2 
Hz, 2H), 6.98 (d, J = 11.2 Hz, 2H), 4.12 (m, 1H), 3.60-3.51 (m, 6H), 3.12 (s, 3H), 3.03 (s, 3H), 
2.45 (s, 2H) and 2.05 (s, 3H) ppm. 
13
C NMR (CDCl3, 400 MHz): δ 179.02, 150.23, 128.96, 
127.99, 135.45, 86.71, 84.01, 77.25, 71.25, 69.01, 62.12, 53.79, 36.78, 29.89 and 21.23 ppm. 
 
1,3-dimethyl-5-(4-chlorobenzyl)-5-(β-D-glucosyl)pyrimidine-2,4,6-trione (52): 1H NMR 
(CDCl3, 400 MHz) δ 7.32 (d, J = 9.6 Hz, 2H), 7.14 (d, J = 9.6 Hz, 2H), 4.12 (m, 1H), 3.55-3.48 
(m, 6H), 3.12 (s, 3H) and 3.04 (s, 3H) ppm. 
13
C NMR (CDCl3, 400 MHz): δ 178.23, 150.67, 
135.98, 129.05, 128.56, 86.07, 84.01, 77.25, 71.25, 69.01, 62.3, 53.79, 36.78 and 29.89 ppm. 
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1,3-dimethyl-5-(4-methoxybenzyl)-5-(β-D-glucosyl)pyrimidine-2,4,6-trione (54): 1H NMR 
(CDCl3, 400 MHz) δ 7.08 (d, J = 11.2 Hz, 2H), 6.98 (d, J = 11.2 Hz, 2H), 4.12 (m, 1H), 3.78 (s, 
3H), 3.60-3.51 (m, 6H), 3.12 (s, 3H), 3.03 (s, 3H) and 2.45 (s, 2H) ppm. 
13
C NMR (CDCl3, 400 
MHz): δ 179.02, 150.23, 128.96, 127.99, 135.45, 86.71, 84.01, 77.25, 71.25, 69.01, 62.12, 53.79, 
36.78, 35.8 and 29.89 ppm. 
 
1,3-dimethyl-5-(4-bromobenzyl)-5-(β-D-glucosyl)pyrimidine-2,4,6-trione (56): 1H NMR 
(CDCl3, 400 MHz) δ 7.62 (d, J = 9.6 Hz, 2H), 7.31 (d, J = 9.6 Hz, 2H), 4.12 (m, 1H), 3.62-3.58 
(m, 6H), 3.10 (s, 3H) and 3.02 (s, 3H) ppm. 
13
C NMR (CDCl3, 400 MHz): δ 178.25, 151.06, 
136.98, 132.0, 131.14, 120.56, 86.07, 84.01, 77.25, 71.25, 69.01, 62.23, 53.07, 36.78 and 29.77 
ppm. 
 
5-(4-(1,3-dioxoisoindolin-2-yl)benzyl)-1,3-dimethyl-5-((2S,3R,4S,5S)-3,4,5-trihydroxy-6-
(hydroxymethyl)-tetrahydro-2H-pyran-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (58):  
1
H NMR (CDCl3, 400 MHz) δ 7.98 (2H, m), 7.80 (2H, m), 7.55 (2H, d, J = 8Hz), 7.45 (2H, d, J 
= 8Hz), 4.12 (m, 1H), 3.62-3.58 (m, 6H), 3.10 (s, 3H) and 3.02 (s, 3H) ppm. 
13
C-NMR (CDCl3): 
δ 167.1, 140.0, 138.2, 135.1, 132.0, 130.2, 127.5, 124.3 86.07, 83.891, 77.51, 71.25, 66.01, 
60.23, 52.07, 36.86 and 29.76 ppm. 
 
General procedure for condensation of glycosylated barbituric acid and steroidal 
derivativies: To a solution of glycosylate barbiturate (0.2 mmol) in DMSO (5 mL) was added a 
solution of corresponding steroidal derivative (0.2 mmol) in DCM (2mL). The mixture was 
allowed to sonicate for 1-2h until precipitate is seen. After the completion of reaction diluted 
120 
 
with ethyl acetate (10 mL) washed with water (3 X10 mL). The organic layer was dried over 
sodium sulfate. Further purification was done by column chromatography using Ethyl 
acetate:Hexane as the eluent. The product was obtained in more than 50% yield and final 
sturcutre was confirmed by NMR. 
 
1,3-dimethyl-2,4,6-trioxo-5-(β-D-glucopyranose)-hexahydropyrimidin-5-(Cholest-5-en-3β-
yl-4-methyl)phenyl carbonate (60): The product was obtained as yellowish powder (102 mg, 
yield=72%). 
1
H NMR (400 MHz, CDCl3) δ 7.03 (dd, J = 22.8, 8.5, 2H), 6.98 (dd, J = 22.8, 8.5, 
1H), 4.55 (m, 1H), 4.08 (m, 2H), 3.84 (s, 1H), 3.53 (d, J = 33.8, 2H), 3.33 (s, 3H), 3.09 (s, 3H), 
2.44 (d, J = 10.9, 2H), 2.05 (s, 2H), 2.01 – 0.80 (m, 40H) and 0.68 (s, 3H) ppm. 13C NMR (400 
MHz, D2O) δ 172.01, 153.34, 150.7, 148.95, 140.82, 135.56, 128.76, 121.87, 121.45, 86.22, 
79.76, 78.43, 76.21, 69.66, 69.48, 60.87, 58.23, 56.54, 52.7, 50.88, 44.09, 38.98, 37.23, 36.12, 
36.78, 36.11, 35.78, 31.09, 30.06, 29.97, 29.79, 28.12, 27.35, 27.85, 24.67, 23.12 and 20.89 ppm. 
 
 
1,3-dimethyl-2,4,6-trioxo-5-(β-D-glucopyranose)-hexahydropyrimidin-5-(Cholest-5-en-3β- 
yl-4-methyl)phenyl succinate (61): The product was obtained as yellowish powder (72 mg, 
yield=67%). 
1
H NMR (400 MHz, CDCl3) δ 7.02 (dd, J = 22.8, 8.5, 2H), 6.89 (dd, J = 22.8, 8.5, 
1H), 4.54 (m, 1H), 4.06 (m, 2H), 3.82 (s, 1H), 3.51 (d, J = 33.8, 2H), 3.31 (s, 3H), 3.06 (s, 3H), 
3.21 (s, 2H), 2.76 (t, J = 12.8 Hz, 2H), 2.44 (d, J = 10.9, 2H), 2.05 (s, 2H), 2.01 – 0.80 (m, 40H) 
and 0.68 (s, 3H) ppm.
 13
C NMR (400 MHz, CDCl3) δ 172.3, 170.89, 151.7, 149.95, 141.82, 
136.56, 128.76, 121.87, 121.45, 86.22, 79.76, 78.43, 76.21, 69.66, 69.48, 60.87, 58.23, 55.98, 
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51.97, 51.08, 44.09, 38.98, 37.23, 36.12, 36.78, 36.11, 35.78, 31.09, 30.06, 29.97, 29.79, 29.1, 
29.6, 27.35, 27.85, 24.67, 23.12 and 20.89 ppm. 
 
1,3-dimethyl-2,4,6-trioxo-5-(β-D-glucopyranose)-hexahydropyrimidin-5-(Cholest-5-en-3β- 
Oxyethyl-2-oxy-)benzaote (62): The product was obtained as yellowish powder (45 mg, 
yield=42%). 
1
H NMR (CDCl3, 400 MHz):  δ 7.08 (d, J = 8.2 Hz, 2H), 6.9 (d, J = 8.2 Hz, 2H), 
4.6 (s, 2H), 4.36 (d, J = 9.9, 1H), 4.22 (t, J = 9.4, 1H),4.15 (t, J = 4.5Hz, 2H), 3.81 (t, J = 4.5Hz, 
2H), 3.68 (m, 2H), 3.31 (t, J = 9.0, 1H), 3.19 (s, 3H), 3.01 (s, 3H), 2.89 (m, 1H) and 2.26–0.85 
(m, 44H) ppm. 
13
C NMR (CDCl3, 400 MHz): δ 151.7, 141.82, 136.56, 128.76, 121.87, 121.45, 
86.22, 79.76, 78.43, 76.21, 69.66, 69.48, 69.91, 67.23, 60.87, 58.23, 55.98, 51.97, 51.08, 44.09, 
38.98, 37.23, 36.12, 36.78, 36.11, 35.78, 31.09, 30.06, 29.97, 29.79, 29.1, 29.6, 27.35, 27.85, 
24.67, 23.12 and 20.89 ppm. 
 
 
1,3-dimethyl-2,4,6-trioxo-5-(β-D-maltose)-hexahydropyrimidin-5-(Cholest-5-en-3β- 
yl-4-methyl)phenyl carbonate (63): Product was obtained as a pale yellow powder (32 mg, 
57%). 
1
H NMR (DMSO-d6, 400 MHz):  δ 7.22 (s, 2H), 7.07 (s, 2H), 5.43 (s, 1H), 5.12 (m, 1H), 
4.5 (d, J = 6.8 Hz, 1H), 4.36 (t, J =12.8 Hz, 1H), 3.46- 3.80 (m, 9H ), 3.36 (t, J =10.8 Hz, 1H), 
3.12 (s, 6H), 3.12 (s, 2H,), 2.49 (d, J = 13.7 Hz, 2H), 2.10 – 0.82 (m, 40H) and 0.68 (d, J = 4.0, 
3H) ppm. 
13
C NMR (CDCl3, 400 MHz): δ 177.89, 154.44, 152.18, 148.89, 139.63, 131.04, 
130.22, 124.30, 121.69, 116.58, 115.64, 108.95, 99.95, 95.98, 87.02, 79.28, 78.24, 78.19, 76.89, 
75.98, 73.18, 72.59, 71.78, 69.41, 69.43, 61.15, 60.54, 56.83, 55.67, 50.18, 47.96, 42.52, 39.87, 
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38.98, 37.69, 37.12, 36.94, 36.56, 35.89, 32.69, 32.52, 32.14, 28.67, 28.23, 27.73, 26.53, 24.51, 
24.03, 23.14, 22.78, 21.21, 19.79, 18.92 and 11.59 ppm. 
 
 
1,3-dimethyl-2,4,6-trioxo-5-(β-D-maltose)-hexahydropyrimidin-5- (Cholest-5-en-3β-yl-4-
(methyl)phenyl succinate (64): The product was obtained as pale yellowish powder (36 mg, 
Yield=45%) 
1
H NMR (DMSO-d6, 400 MHz):  δ 7.08 (d, J = 12.8 Hz, 2H), 6.89 (d, J = 12.8 Hz, 
2H), 5.39 (d, J = 12.8 Hz, 1H), 4.34 (d, J = 12.8Hz, 1H), 5.31 (bs, 1H), 4.61-4.71 (m, 1H), 4.28 
(t, J =10.8 Hz, 1H), 3.58- 3.48 (m, 9H ), 3.38 (t, J =10.8 Hz, 1H), 3.22 (s, 3H), 3.03 (s, 2H), 2.98 
(s, 3H), 2.83 (t,  J = 15.6 Hz, 2H), 2.76 (t, J = 15.6 Hz, 2H), 2.38 (d, J = 10.5 Hz, 2H), 0.85–2.26 
(m, 41H) and 0.68(s, 3H) ppm.
 13
C NMR (CDCl3, 400 MHz): δ 178.2, 173.2, 172.89, δ150.44, 
140.98, 135.02, 130.12, 122.08, 121.42, 115.48, 99.92, 95.01, 87.82, 78.86, 77.89, 77.10, 76.00, 
74.42, 73.18, 72.09, 71.89, 69.45, 69.43, 60.75, 60.54, 58.13, 56.05, 51.09, 49.09, 44.10, 38.54, 
38.25, 37.42, 36.23, 35.79, 34.12, 31.88, 31.01, 29.69, 29.12, 28.95, 28.12, 27.25, 27.77, 27.71, 
27.33, 24.65, 23.12, 22.81, 21.69 and 19.25 ppm. 
 
1,3-dimethyl-2,4,6-trioxo-5-(β-D-maltose)-hexahydropyrimidin-5- (Cholest-5-en-3β-
oxyehtyl-2-oxo-benzyl ether (65): The product was obtained as pale yellowish powder (32 mg, 
Yield=38%) 
1
H NMR (DMSO-d6, 400 MHz):  δ 7.02 (d, J = 18.4 Hz, 2H), 6.75 (d, J = 18.4 Hz, 
2H), 5.31 (d, J = 9.2 Hz, 1H), 5.38 (d, J = 9.2 Hz, 1H), 4.69 (d, J = 9.2 Hz, 1H), 4.42 (t, J = 6.5 
Hz, 2H), 4.36 (t, J =13.0 Hz, 1H), 3.82 (t, J = 6.5 Hz, 2H), 3. 78- 3.36 (m, 9H ), 3.29 (t, J =13.0 
Hz, 1H), 3.2 (s, 6H), 3.05 (s, 2H), 2.89 (m, 1H), 2.26–0.85 (m, 40H) and 0.63 (s, 3H) ppm. 13C 
NMR (CDCl3, 400 MHz): δ 178.2,  155.44, 154.2, 142.2, 131.9, 129.42, 121.90, 115.64, 115.85, 
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100.21, 95.81, 86.21, 84.15, 78.35, 78.25, 76.98, 76.12, 73.18, 72.71, 71.81, 69.89, 68.12, 61.28, 
58.23, 56.39, 52.80, 44.01, 40.01, 38.65, 37.76, 36.84, 36.12, 36.01, 32.19, 28.21, 26.89, 27.25, 
24.36, 23.22, 22.17, 20.17 and 19.6 ppm. 
 
2,4,6-trioxo-5-(β-D-glucopyranose)-hexahydropyrimidin-5-(Cholest-5-en-3β-yl-4-
methyl)phenyl carbonate (66): The product was obtained as yellowish powder (40 mg, 
yield=43%). 
1
H NMR (400 MHz, DMSO-d6) δ 11.2 (s, 2H), 7.00 (dd, J = 20.8, 9.5, 2H), 6.88 
(dd, J = 20.8, 9.5, 1H), 4.56 (m, 1H), 4.08 (m, 2H), 3.86 (s, 1H), 3.63 (d, J = 6.84, 2H), 2.54 (d, J 
= 13.2, 2H), 2.12 (s, 2H), 2.08 – 0.81 (m, 40H) and 0.68 (s, 3H) ppm. 13C NMR (400 MHz, 
DMSO-d6) δ 171.23, 153.87, 151.7, 149.05, 140.84, 135.65, 128.58, 121.96, 121.55, 82.11, 
79.67, 77.83, 76.25, 69.56, 69.28, 61.07, 58.33, 56.52, 52.17, 50.48, 44.19, 38.98, 36.23, 36.11, 
36.74, 36.31, 34.98, 31.13, 30.06, 28.02, 27.35, 27.85, 24.67, 23.12 and 19.86 ppm. 
 
2,4,6-trioxo-5-(β-D-glucopyranose)-hexahydropyrimidin-5-(Cholest-5-en-3β- 
yl-4-methyl)phenyl succinate (67): The product was obtained as yellowish powder (61 mg, 
yield=37%). 
1
H NMR (400 MHz, DMSO-d6) δ 7.02 (dd, J = 12.8, 8.5, 2H), 6.89 (dd, J = 12.8, 
8.5, 1H), 4.57 (m, 1H), 4.04 (m, 2H), 3.80 (s, 1H), 3.49 (d, J = 12.8, 2H), 3.23 (s, 2H), 2.74 (t, J 
= 10.8 Hz, 2H), 2.45 (d, J = 12.8, 2H), 2.07 (s, 2H), 2.05 – 0.83 (m, 40H) and 0.66 (s, 3H) ppm. 
13
C NMR (400 MHz, DMSO-d6) δ 171.89, 170.26, 151.17, 149.75, 142.18, 136.46, 128.76, 
122.08, 121.45, 86.12, 79.71, 78.45, 76.17, 69.56, 69.48, 61.19, 58.31, 56.12, 52.09, 51.08, 
44.09, 38.98, 37.23, 36.12, 36.78, 36.15, 35.78, 31.09, 30.05, 29.97, 29.79, 29.1, 29.6, 27.35, 
27.85, 24.67, 23.12 and 20.69 ppm. 
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2,4,6-trioxo-5-(β-D-glucopyranose)-hexahydropyrimidin-5-(Cholest-5-en-3β- 
Oxyethyl-2-oxy-)benzaote (68): The product was obtained as yellowish powder (25 mg, 
yield=40%). 
1
H NMR (DMSO-d6, 400 MHz):  δ 7.02 (d, J = 12.2 Hz, 2H), 6.82 (d, J = 12.2 Hz, 
2H), 4.56 (s, 2H), δ 4.26 (d, J = 8.9, 1H), 4.12 (t, J = 13.4, 1H), 4.15 (t, J = 14.5Hz, 2H), 3.85 (t, 
J = 14.5 Hz, 2H), 3.66 (m, 2H), 3.32 (t, J = 9.5, 1H), 2.89 (m, 1H) and 2.26–0.85 (m, 44H) ppm. 
13
C NMR (CDCl3, 400 MHz): δ 172.32, 151.7, 142.82, 135.56, 128.76, 122.87, 121.53, 85.22, 
79.76, 78.43, 76.21, 69.66, 69.48, 69.92, 67.23, 60.87, 58.23, 55.98, 52.09, 51.08, 44.09, 38.98, 
37.23, 36.12, 36.78, 36.11, 35.78, 31.09, 30.16, 29.1, 29.6, 27.35, 27.85, 24.65, 23.21 and 20.67 
ppm. 
 
2,4,6-trioxo-5-(β-D-maltose)-hexahydropyrimidin-5-(Cholest-5-en-3β- 
yl-4-methyl)phenyl carbonate (69): Product was obtained as a pale yellow powder (35 mg, 
58%). 
1
H NMR (DMSO-d6, 400 MHz):  δ 7.02 (s, 2H), 6.88 (s, 2H), 5.45 (s, 1H), 5.14 (m, 1H), 
4.6 (d, J = 16.8 Hz, 1H), 4.29 (t, J =12.8 Hz, 1H), 3.45- 3.81 (9H ), 3.36 (t, J =12.8 Hz, 1H), 3.14 
(s, 2H), 2.52 (d, J = 16.7 Hz, 2H), 2.12 – 0.83 (m, 40H) and 0.68 (d, J = 4.0, 3H) ppm. 13C NMR 
(DMSO-d6, 400 MHz): δ 177.91, 154.45, 152.18, 147.89, 140.63, 132.04, 130.22, 125.31, 
121.69, 116.48, 115.42, 108.35, 100.05, 95.48, 87.12, 79.32, 78.24, 78.19, 76.89, 75.98, 73.18, 
72.59, 71.78, 69.41, 69.43, 61.15, 60.54, 56.32, 54.79, 50.18, 48.00, 42.54, 40.87, 38.98, 37.69, 
37.12, 36.94, 36.56, 35.89, 32.69, 32.52, 32.14, 27.73, 26.53, 24.51, 24.03, 23.14, 22.78, 21.21, 
20.79, 18.90 and 12.88 ppm. 
 
2,4,6-trioxo-5-(β-D-maltose)-hexahydropyrimidin-5- (Cholest-5-en-3β-yl-4-(methyl)phenyl 
succinate (70): The product was obtained as pale yellowish powder (40 mg, Yield=56%) 
1
H 
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NMR (DMSO-d6, 400 MHz):  δ 7.02 (d, J = 10.2 Hz, 2H), 6.84 (d, J = 10.2 Hz, 2H), 5.35 (d, J = 
5.4 Hz, 1H), 4.36 (d, J = 10.28 Hz, 1H), 5.30 (bs, 1H), 4.59-4.69 (m, 1H), 4.28 (t, J =13.4 Hz, 
1H), 3.55- 3.42 (m, 9H ), 3.32 (t, J =13.8 Hz, 1H), 3.10 (s, 3H), 3.03 (s, 2H), 2.98 (s, 3H), 2.82 
(t,  J = 15.6 Hz, 2H), 2.76 (t, J = 15.6 Hz, 2H), 2.38 (d, J = 10.5 Hz, 2H), 2.26 –0.85 (m, 40H) 
and 0.65 (s, 3H) ppm.
 13
C NMR (DMSO-d6, 400 MHz): δ 177.2, 173.4, 172.68, 150.44, 141.08, 
136.76, 130.13, 121.84, 121.21, 115.48, 99.82, 95.75, 87.82, 78.84, 77.89, 77.10, 76.00, 74.42, 
73.18, 72.09, 71.89, 69.49, 69.40, 60.75, 60.54, 58.13, 56.05, 51.09, 49.09, 44.10, 38.54, 38.25, 
37.42, 36.23, 35.79, 34.12, 31.88, 31.01, 29.69, 29.12, 28.95, 28.12, 27.25, 27.77, 27.71, 27.33, 
24.65, 23.12, 22.81, 21.79 and 20.52 ppm. 
 
2,4,6-trioxo-5-(β-D-maltose)-hexahydropyrimidin-5- (Cholest-5-en-3β-oxyehtyl-2-oxo-
benzyl ether (71): The product was obtained as pale yellowish powder (22 mg, Yield=35%) 
1
H 
NMR (DMSO-d6, 400 MHz):  δ 7.02 (d, J = 8.4 Hz, 2H), 6.75 (d, J = 8.4 Hz, 2H), 5.25 (d, J = 
9.2 Hz, 1H), 5.36 (d, J = 8.2 Hz, 1H), 4.71 (d, J = 8.2 Hz, 1H), 4.41 (t, J = 13.2 Hz, 2H), 4.36 (t, 
J =13.0 Hz, 1H), 3.80 (t, J = 6.5 Hz, 2H), 3.78- 3.36 ( 9H ), 3.25 (t, J =13.0 Hz, 1H), 3.05 (s, 
2H), 2.89 (m, 1H), 2.26–0.85 (m, 40H) and 0.68 (s, 3H) ppm. 13C NMR (CDCl3, 400 MHz): δ 
177.2, δ156.44, 153.2, 141.2, 132.1, 130.42, 122.50, 115.34, 115.85, 100.21, 95.81, 86.21, 84.15, 
78.50, 77.25, 76.98, 76.02, 73.18, 72.71, 71.82, 68.12, 61.28, 58.25, 56.40, 51.80, 45.01, 41.01, 
38.65, 37.76, 36.84, 36.12, 36.01, 32.19, 30.12, 28.89, 28.21, 26.89, 27.25, 24.36, 23.22, 22.17, 
20.17 and 20.01 ppm. 
 
Synthesis of monobromoarene:  Benzene (10 ml) solution of methyl benzene derivative (5 
mmol), N-bromosuccinamide (0.89 g; 5 mmol), and benzoylperoxide (0.12 g; 0.5 mmol) was 
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refluxed under microwave heating (magnetron power 600 W).  After reaction was completed 
(See Table 1) solvent was evaporated; solid residue was dissolved in dichloromethane (100 ml) 
and washed with saturated water solution of sodium bicarbonate (3x15 ml) and water (3x15 ml).  
Dichloromethane was evaporated and the solid residue was purified by silica gel column 
chromatography with hexane-dichloromethane as an eluent. 
4-(Bromomethyl)phenylphthalimide: Isolated yield (85%). 
1
H-NMR (CDCl3): δ 7.98 (2H, m), 
7.80 (2H, m), 7.55 (2H, d, J = 8Hz), 7.45 (2H, d, J = 8Hz), and 4.55 (2H, s) ppm. 
13
C-NMR  
(CDCl3): δ 167.1, 140.0, 138.2, 135.1, 132.0, 130.2, 127.5, 124.3 and 33.0 ppm.  
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Chapter-3: PROGRESS TOWARDS SYNTHESIS AND EVALUATION OF CYSTEINYL 
METAL PEPTIDES. 
 
3.1 Introduction: Free radicals and oxidative Stress 
Free radicals are defined as any atom/ molecule with an “unpaired electron” in the outer 
shell. These are highly reactive species formed in the body’s cells during normal metabolic 
processes. Free radicals are involved in the body’s host defense mechanism i.e. the immune 
system, cell signaling, inflammation, activation of gene transcription factors. This makes free 
radical an important component of everyday human life. 
Various reactions that take place in the mitochondrial cells (Fig. 3.1.) as shown below
3 
1. 4H
+
 + O2 → 2H2O (~95% of the time) 
2. O2 → *O2
•-
 → H2O2  *Only 1-5% generate free radicals 
 
 
Figure 3.1 Structure of Mitochondrial Cell
3
 
 
These reactions along with others generate Reactive Oxygen Species (ROS) like HO•, RO•, 
HOO•, ROO•, •O2
-
, 
1
O2, H2O2 and Reactive Nitrogen Species (RNS) likeNO•, NO2•, OONO
-
 
1
.                                                               
These free radicals are responsible for the oxidative stress in the body. Oxidative stress is 
typically defined as an imbalance caused by the systemic manifestation of the reactive oxygen 
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species and inability of body’s antioxidant defense systems to detoxify it or repair the damage. 
Various intrinsic and extrinsic factors contribute to the oxidative stress of body. Extrinsic factors 
like environmental pollutants, exposure to irradiation (like space travel) can lead to increases free 
radical production in the human body. Several processes taking place inside the human body 
(intrinsic factors) like regular wear and tear with aging, usual enzymatic and chemical reactions 
and interactions among ROS render the body with increased amount of oxidative stress.
4 
The 
antioxidant defense system for the human body comes from the dietary intake of food rich in 
tocopherol, ascorbic acid or carotene. Several endogenously present antioxidant enzymes like 
superoxide dismutase, catalase, glutathione oxidase and melanin help fight the oxidative stress. 
Following (Fig.3.2) is an illustration to show the processes through which oxidative stress 
damages biological targets.  
 
Figure 3.2 A simplistic representation of how exposure to environmental pollutants may induce an excess of free 
radical (ROS & RNS) and damage biological targets
4
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According to studies carried out by different scientific group it is thought that the oxidative stress 
in humans is involved in the development of many diseases or may exacerbate their symptoms 
by bringing out structural feature changes in DNA and proteins 
5,6,7
. Dimerization or 
polymerization of lipids, cross linkage of proteins, fragmentation of DNA and formation of age 
pigment as some of the structural feature changes brought about by the free radicals. These in 
turn would lead to diseases like cancer
8
, alzheimers
9
, parkinsons, atherosclerosis, schizophrenia, 
bipolar disorder 
10,11
, heart failure, vasospasm,  stroke, arthritis Sickle Cell Disease,
12
 lichen 
planus,
13
 vitiligo,
14
autism,
15
 and chronic fatigue syndrome.
16 
 
3.2 Antioxidant 
In order to protect the healthy cells and organ system of the human body against ROS, the 
humans have evolved a highly sophisticated and complex antioxidant defense system. A variety 
of endogenous and exogenous components, function interactively and synergistically to, 
neutralize the free radicals
17, 18
. These components include
18
 
 Nutrient-derived antioxidants like ascorbic acid (vitamin C), tocopherols and tocotrienols 
(vitamin E), carotenoids, and other low molecular weight compounds such as glutathione 
and lipoicacid. 
 Antioxidant enzymes, e.g., superoxide dismutase, glutathione peroxidase, and glutathione 
reductase, catalyze free radical quenching reactions. 
 Metal binding proteins, such as ferritin, lactoferrin, albumin, and ceruloplasmin that 
sequester free iron and copper ions are capable of catalyzing oxidative reactions. 
 Skin pigment ‘melanin’ plays an important role in protecting against free radicals.  
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Numerous other antioxidant phytonutrients are present in a wide variety of plant foods. Several 
studies conducted have indicated amino acids like cysteine, homocysteine, tyrosine, histidine, 
tryptophan (Fig.3.3) as potential radical scavengers. 
Figure 3.3 Amino acids and peptides as radical scavengers 
 
The oxidative susceptibility of any given amino acid to the free radical attack is dictated in large 
part by its functional R-group on the side chain. The solvent accessibility and the chemical 
properties of vicinal residues are also important
18b
. 
All twenty biologically-derived amino acids are potentially oxidizable, the most reactive 
amino acids tend to be those containing either nucleophilic sulfur-containing side chains like 
cysteine and methionine or aromatic side chains as in tryptophan, tyrosine and phenylalanine 
from which hydrogen can be easily abstracted. Infact aminoacids like tyrosine and cysteine are 
intergarl part of melanin
21,22
 biosynthesis which protects against harmful ultraviolet radiations. 
Melanin decreases effects of ionizing radiation in human and mouse somatic cells and act as 
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radioprotective agent. Therefore, it is thought that it imparts protection against certain types of 
skin cancers. Cysteine is the integral part of glutathione
23
 and imparts radical scavenging 
properties to the molecule. Histidine’s imidazole-contianing side chain is also oxidatively labile. 
The oxidation of these amino acids forms products that quench the free radicals by forming 
different product as shown in Table 3.1. 
 
Amino acid Oxidation product Mechanism of formation 
Cysteine 1. Cystine 
2. Oxyacids 
1. Hydrogen abstraction from SH group and subsequent 
radical dimerization 
2. Hydrogen abstraction from SH group and subsequent 
reaction with oxygen and isomerization 
Methionine  Methionine sulfoxide Routes including both radical and non-radical reactions 
Tryptophan N-formylkynurenine, kynurenine, 5-
hydroxytryptophan, 7-
hydroxytryptophan, 
Hydroxyl attack or one electron oxidation of ring 
Tyrosine 3,4-dihyroxy-phenylalanine, di-tyrosine, 
30chlorotyrosine, 3-nitrotyrosine, 
tyrosine hydroperoxide and subsequent 
cyclized materials  
Hydroxyl attack or one electron oxidation of ring, 
radical-radical dimerization, HOCl, chlorination of 
tyrosine, formation of phenoxyl radical 
Phenylalanine O,m-tyrosine Hydroxyl attack or one electron oxidation of 
ring,Reaction via nitrogen species, dimerization 
Histidine 2-oxo-histidine Hydroxyl attack or one electron oxidation 
Table 3.1 Products generated on exposure of selected amino acids to radical species and postulated mechanism of 
formation
18b 
 
  
The antioxidant properties of peptides are more related to their composition, structure, and 
hydrophobicity
56
. Tyr, Trp, Met, Lys, Cys, and His are examples of amino acids that are 
responsible for antioxidant activity
69
 of several peptides. Usually amino acids with aromatic 
residues can donate protons to electron deficient radicals and exert antioxidant effect. This 
inherent property is responsible for imparting the radical-scavenging properties of the amino acid 
residues
64
. His-containing peptides have antioxidant activity that comes form the hydrogen-
donating, lipid peroxyl radical trapping and/or the metal ion-chelating ability of the imidazole 
group
54,64
. Cysteine has an SH group that is responsible for crucial antioxidant action due to its 
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direct interaction with radicals
63
. Not only presence of a proper amino acid but its positioning as 
well plays an important role in antioxidant activity of peptides
64
. Chen et al.
57
 designed and 
studied antioxidant property of 28 synthetic peptides based on the structure of an antioxidative 
peptide (Leu-Leu-Pro-His-His) from digestion of a soybean protein, conglycinin
55
. Their studies 
revealed that the antioxidant activity of a peptide was more dependent on His-His segment in the 
Leu-Leu- Pro-His-His domain. Removal of His residue from the C-terminus dramatically 
reduced the antioxidant activity. The same study revealed that Pro-His-His sequence displayed 
the greatest antioxidative activity among all tested peptides. Saito et al.
65
 have reported that any 
change in the arrangements of amino acid sequence in tripeptides resulted in different 
antioxidant activities. The specific structural features and peptide linkages have been claimed to 
influence antioxidant ability. For instance, when certain amino acids are incorporated in 
dipeptides they exert higher antioxidative properties
60
. Studies have also indicated that a peptide 
bond or its structural conformation can reduce the antioxidant activity of the constituent amino 
acids. Therefore, it was concluded that the peptide conformation could have both the synergistic 
and antagonistic effects for the antioxidant activity of free amino acids
58
. 
Several other factors can influence antioxidant activity of bioactive peptides like the 
operational conditions applied to isolate proteins, degree of hydrolysis, type of protease
62
, 
peptide structure
65
 and peptide concentration.  Molecular weight (MW) of peptides can also 
influence antioxidant activity. It was found that antioxidant activity of peptides of MW 500–
1500 Da was stronger than that of peptides above 1500 Da and peptides below 500 Da
59
. 
However, it has been postulated that the overall antioxidative activity must be ascribed to the 
integrative effects of these actions rather than to the individual actions of peptides
56
. The peptide 
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linkage between β-alanine, histidine and 1-methylhistidine was also involved in the activities of 
the dipeptides towards radical scavenging activity
70
.  
 
3.3 Aim of the project 
Since reactive oxidative species (ROS) is implicated in the pathogenesis of many chronic 
diseases, such as cancer, cardiovascular and neurodegenerative diseases, finding novel 
antioxidants to combat ROS has attracted much attention
54
. To facilitate the discovery of 
antioxidants, some antioxidant pharmacophores have been identified, among which catechol has 
been given the most attention
54
. The great antioxidant potential of catechol is attributed to the 
fact that the semiquinone radical derived from H-atom donation of catechol can be stabilized by 
an intramolecular hydrogen bond and the electron-donating properties of the ortho-OH. Another 
amino acid with a great potential as a radical capture agent is cysteine. Since cysteine cannot be 
used in its free form because the sufhydryl group is higly susceptible to oxidation. It has to be 
trapped in a fashion where it is stable outside the human body and has a good shelf-life, but 
when it is inside the free sulfhydryl is easily available to capture free radicals in human body. To 
develop novel radical capture compounds based on the above mentioned facts a two-fold aim of 
this project is proposed. Firstly, develop an industrially viable, high yield procedure for Zinc 
monocysteine synthesis. Besides zinc, incorporate other metals like Ca, Mg, Cu and Cd into 
cysteine skeleton (Fig.3.4). Secondly, synthesize ‘Advanced Radical Capture Compounds’ by 
linking cysteine metal complex to other amino acids like tyrosine to get desired peptides. This 
approach will release two amino acids inside the body that have radical capture ability. Cysteine 
would be metabolized to sulfur-containing compound like taurine and glutathione that can fight 
the oxidative stress of body. The metal component would protect the free sulfhydryl and once 
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inside the body it can act as a supplement to induce metallothionein (MT) that has capability to 
scavenge free hydroxyl causing oxidative stress. In addition, studies have indicated an increased 
activity of antioxidant enzymes catalase and glutathione peroxidase by ZMC. 
 
Figure 3.4 L-cysteine metal peptides 
 
3.4. Cysteine metal complexes 
In the pursuit to synthesize, ‘Advanced radical capture compounds’ cysteine was chosen 
as one of the substrates. Cysteine is a non-essential amino acid that can be biosynthesized in the 
human body. The β-sulfhydyl group of cysteine often participates in several enzymatic reactions 
including antioxidant glutathione, where it acts as a precursor. Antioxidant ability of cysteine is 
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typically expressed in the tripeptide glutathione. The oral availability of glutathione is negligible 
and hence it is biosynthesized from L-amino acids cysteine, glycine and glutamic acid.  
Availability of cysteine through diet can sometimes be a limiting factor. Cysteine has also been 
implicated as an important source of sulfide in the human metabolism. In order to make cysteine 
available from outside source i.e diet it has to be masked inside other components. Since the β-
sulfhydryl group is readily oxidized, it has to be protected in a way that is freely available inside 
the human system. To achieve this cysteine β-sulfhydryl group could be complexed with metals 
that do not readily oxidize the free sulfhydryl group. This will impart stability to cysteine and 
extend its shelf-life. One of these metals is zinc that was successfully used to trap free cysteine. 
Its synthesis and properties are discussed in the subsequent sections. At the same time, efforts 
were directed to synthesize other metal complexes of cysteine like calcium, magnesium, copper 
and cadmium besides zinc and are discussed later in this chapter. 
 
3.4.1. Zinc Monocysteine Compound 
Trace elements play a vital role in the human body to maintain a normal growth and 
development through a complex array of physiological functions. They are also responsible to 
balance the toxicity levels inside the human body. One such trace element is zinc, which 
occupies the second spot in being the most abundant trace element in the human body
1
. Zinc 
functions as a cofactor in more than 200 enzyme reactions and is known to be essential for the 
function of numerous transcription factors and nuclear regulatory elements.
2,3
 In humans, severe 
zinc deficiency has been shown to result in stunted growth and impaired development.
4,5
 Zinc 
can also act as an antioxidant by protecting the free sulfhydryl group from oxidation. Because 
some amino acids in various combinations with trace elements have been shown to exhibit 
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increased biologic effect over the individual substances, zinc-monocysteine conjugate was 
developed. Zinthionin (Oral ZMC) for Age Related Macular Degeneration (AMD) was 
developed by Dr. David Newsome
25
.  The reported procedure for preparation of ZMC involves 
reaction of Cysteine HCl with zinc metal
25 
(Scheme 3.1, Table 3.2, entry 1). The reported 
procedure suffers from several drawbacks including poor yields (20-30 %), leaves large solid 
residue as discard and finally use of lyophylization to dry final product
25 
adds to the cost of 
preparation. All this makes the process non-viable at industrial scale. Therefore, we worked on 
improving the synthetic method for the preparation of ZMC. Our synthetic method was 
developed by using L-cysteine HCl and various zinc salts.  
 
Scheme 3.1 Preparation of  Zinc Monocysteine 
The reaction was carried out using zinc salts like zinc acetate, zinc oxide, zinc chloride, zinc 
carbonate. The results are summarized in table 3.2 (entry 2 and 3).  
 
 
 
 
 
Table 3.2 Reaction conditions for ZMC synthesis 
S. No.  Procedure  Yield  
1.  Zn
0
/H2O, Reflux, 2h (reported procedure) 20-30% 
2.  Zn(OAc)2 .2H2O, NaOAc.H2O, Heat 3h  98%  
3. ZnCO3, AcOH, Na2CO3, Heat 3h   97%  
HS OH
NH3
+Cl-
O
S
Zn
O
H2N
O
H2O
H2O
1 2  
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The product was obtained in more than 95% yield and high purity. The isolated product was then 
analysed by NMR, Mass spectroscopy and elemental analysis. It was demonstrated that the zinc 
monocysteine compound was almost 100% pure and is accompanied by two molecules of water. 
A corresponding proton and carbon NMR was recorded in D2O-HCl to confirm the structure (Fig 
3.5). Structure was further confirmed by mass spectroscopy (Fig.3.6). 
 
Figure 3.5 
1
H and 
13
C NMR of ZMC 
 
  
Figure 3.6 Mass Spectrum of ZMC 
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3.4.2 Synthesis of L-cysteine metal complexes 
After successfully establishing the synthetic method for incorporation of zinc in L-
cysteine hydrochloride other metals were incorporated into the Cysteine skeleton (Scheme 3.2).  
 
Scheme 3.2 Cysteine metal complex synthesis 
The reaction of L-cysteine HCl with other metal salts like calcium oxide, calcium hydroxide, 
calcium carbonate, magnesium carbonate, magnesium oxide, cadmium and copper salts were 
carried out in a similar way as for Zinc salts. The results are outlined in Table 3.3 
 
Compound Metal Salt Cys-Metal Complex Water Solubility 
1. CaO/ CaCO3 Cys-Ca (4) Soluble 
2. MgO/ MgCO3 Cys-Mg (5) Soluble 
3. CdCl2 Cys-Cd (6) Insoluble 
4. Cu salts Oxidise cys NA 
Table 3.3 Cysteine metal complexes and their properties. 
 
L-cysteine HCl was reacted with calcium carbonate and calcium oxide to give the corresponding 
L-cysteine monocalcium complex, which was water-soluble. The structure was confirmed by 
proton and carbon NMR and mass analysis (Fig.3.7). Similarly, L-cysteine monomagnesium 
H2N
O
O
S
Metal salt
M
1
Cysteine-metal complex
M= Ca, Mg, Cd, Cu
H2O, Heat
HS OH
NH3
+Cl-
O
3
 
145 
 
complex was synthesized and was also water soluble, whereas, the corresponding L-cysteine 
cadmium complex was water insoluble. All the synthesized L-Cysteine-metal complexes were 
characterized by mass spectroscopy and 
1
H, 
13
C NMR. A representative mass spectrum of L-
cysteine calcium complex and its fragmentation pattern are presented in Fig.3.7. 
 
Figure 3.7 Mass spectrum of Cys-Ca complex 
 
3.5. Cysteinyl Peptide Synthesis 
Common elements in the solution phase peptide synthesis are the assembly of protected 
amino acids, their deprotection and finally purification to obtain the desired peptide molecules. 
This technique has been used successfully for the synthesis of small peptides containing a few 
amino acid residues (Fig.3.8). The main advantage of this technique is that the intermediate 
products can be isolated and purified after each step of synthesis, deprotected and recombined to 
obtain larger peptides of the desired sequence. This technique is highly flexible with respect to 
the chemistry of coupling and the combination of the peptidic blocks
26
.  
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Protected amine 1        Protected amine 2                                                            Amide 
Figure 3.8. Solution phase peptide synthesis 
New strategies for synthesis in solution have been developed, going from the design of 
functional groups for the side chains and condensation of fragments for the synthesis of large 
molecules
27
 to the use of new coupling reagents
28
. The most serious problems for this chemical 
synthesis come from the poor solubility of some protected peptides in organic solvents. 
Researchers commonly experience the problem of limited solubility as to render peptide bond 
formation impossible
29
. This happens because of the fundamental tendency of the protected 
peptide chains to form intermolecular aggregates rather than interact with organic solvents
30
. The 
other serious problems include racemization of the activated C-terminal amino acid in peptides
31
, 
and the lack and cost of high resolving methods for the purification of protected peptide 
fragments. At the same time, solution phase peptide synthesis gives better purity and high yields 
and it is a preferred method of peptide synthesis. In the last few years, more than 250 protecting 
groups have been proposed as suitable for peptide synthesis
32
; however, a relatively small 
number of those is actually used because of the stringent requirements that a protecting group 
should meet, particularly with respect to the requirement of the preservation of other 
functionalities.  
In our case to synthesize cysteinyl peptide metal complex 14 employing L-tyrosine 8 the 
synthetic challenge was to protect and deprotect the side chain reactive groups in a cost effective 
and efficient manner that is industrially viable. Therefore, several methods for the protection and 
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deprotection of β-sulfhydryl group were tried to develop efficient and reproducible synthetic 
methodology. A retrosynthetic analysis of the desired C-T dipeptide 13 is outlined in Scheme 
3.3. The desired metal complexed dipeptide 14 could be synthesized by reaction of the metal 
salts with the unprotected C-T peptide 13. The dipeptide 13 in turn can be prepared from 
commercially available amino acids L-cysteine 7 and L-tyrosine 8. These L-amino acids have 
side chain functional groups that could be suitably protected to give corresponding protected L-
tyrosine 10 and protected L-cysteine 9. Subsequently compound 9 and 10 could be coupled using 
peptide coupling reaction to yield dipeptide 11. The desired coupling is through carboxy terminal 
of L-tyrosine bonding with the N-terminal of L-cysteine. Once the desired peptide bond has been 
synthesized the protective groups can be selectively removed to give compound 12 and the β 
sulfhydrl protection is removed right before capturing the free sulfhydryl group with a metal to 
yield dipeptide metal complex 14 (Scheme 3.3).  
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Scheme 3.3 Retrosynthetic analysis of cysteinyl peptide 
 
3.5.1 Protecting groups for L-cysteine: 
In order to accomplish cysteinyl peptide synthesis using L-Cysteine it is mandatory to 
have appropriate sulfhydryl protective groups. The nucleophilic thiol can otherwise be acylated, 
alkylated, or oxidized to disulfide by air during peptide synthesis. We wanted to develop a 
protective group that is convenient to synthesize from inexpensive starting material. It should 
have inherent properties of being recyclable, stablility to heat, light, and moisture and peptide 
synthesis reaction conditions. At the same time after the completion of peptide synthesis it 
should be easy to remove and purify. The protective group should be usable at large industrial 
scale processes. Due to the sensitivity of the cysteine molecule toward oxidation and elimination, 
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it usually is necessary to protect β-sulfhydryl function in addition to the amino group or the 
carboxyl group during peptide synthesis.  
Even the protected Cysteine is susceptible to several side reactions. The commonly 
encountered side reactions of Cysteine during peptide synthesis are listed below. 
1. Oxidation and alkylation: With thioether protection, cysteine can easily undergo oxidation and 
alkylation. Although this is less critical than in the case of Methionine, but it can occur.
38-40
 The 
Cysteine residues can be protected against oxidation at deprotection stage by using 10% of water 
as scavenger.
41 
2. Elimination: Protected Cysteine on exposure to strong bases, such as sodium in liquid 
ammonia (Benzyl group removal), alkaline conditions, or hydrazynolysis, or exposed to strong 
acids such as HF can easily undergo elimination. The extent of elimination also depends strongly 
on the type of protecting group being used. The StBu is the worst case of elimination followed 
by Acm and Trt.
42, 43
. The Bn group used for protection can also produce elimination. 
3. Reaction of Cysteine with carbocation: Carbocations generated at the deprotection step in 
acidic conditions in peptide synthesis can react with Cysteine. Formation of S-tert-butylated 
Cysteine has been observed after the removal of the Boc group or after deprotection in an 
Fmoc/tBu strategy.
44 
4. Resin reattachment in the acidolytic cleavage resin-bound carbocations are generated that can 
react with both protected and unprotected Cysteine, thus causing reattachment of the peptide to 
the resin.
45
 
5. Transfer of Acm (acetamidomethyl) group to Ser, Thr, Gln, and Tyr during Acm removal.
46-48 
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6. Thiazolidine formation: Thiazolidines of N-terminal Cysteine can result from Histidine- 
protecting groups that generate formaldehyde such as Bom (benzyloxymethyl) or Bum (tert-
butyloxymethyl), when removed. Although this can be minimized using cysteine as scavenger.
49
 
7. Racemization: Cysteine is highly prone to racemize during the anchoring to the solid support 
or during the couplings.
50 
The extent of the racemization also depends on the S-protecting groups 
(StBu > Trt > Acm > MeBn > tBu)
51,52 
and coupling methods used (favored if preactivation in 
the presence of base is performed and in the coupling methods involving the use of base). 
Epimerization of the Cysteine linked to a hydroxyl resin can even take place during the synthesis 
as a result of the repetitive base treatments to remove the Fmoc group, with 2-chlorotrityl resin 
being the least prone to this process.
51-53
The most used protecting groups for the Fmoc/tBu 
strategy are the Acm or Trt groups, when the desired product is the disulfide, and the Trt group, 
when the desired product is the free thiol. For the Boc/Bn strategy, the most used are Bn and 
Meb (p-methylbenzyl) to obtain the free thiol and Acm to obtain disulfides. 
 
3.5.1.1. Thiazolidine protection 
The synthesis of cysteinyl peptide is customarily carried out by blocking amino group 
usually by the N-carbobenzoxy procedure and transforming the β-sulfhydry1 group to a S-benzyl 
thioether
33
 or oxidation to the cysteinyl derivative
34, 35
.  After the condensation is complete, both 
the carbobenzoxy group and the S-benzyl group or the disulfide linkage can be cleaved readily 
by reductive means
36
.  Of these several protective group methods for sulfhydryl protection of L-
cysteine either they utilize harsh deprotection methods or lead to disulfide formation. In order to 
avoid these harsh deprotection conditions the procedure reported by Sheehan
71
 et al. (scheme 
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3.4) was considered to provide an edge over these methods by not using the conventional 
reductive methods for deprotection after completion of peptide synthesis. 
 
Scheme 3.4 Cysteinyl peptide synthesis via thiazolidine
71
. 
 
In our first attempt to prepare cysteinyl peptide we started by employing the procedure reported 
by Sheehan
71
 et al. The procedure involved introduction of isopropylidine group that protects the 
sulfhydryl group from oxidation and tends to stabilize the Cysteine moiety against β-elimination. 
Since, the formation of the thiazolidine from cysteine and acetone involves a reversible 
equilibrium, the isopropylidine group can be removed readily in the presence of water. Using this 
approach, we were able to produce large quantities of L-4-carboxy-2, 2-dimethyl thiazolidine 
HCl 15 in excess of 98% yield, which was then used for further peptide synthesis as shown in 
Scheme 3.5.  
In order to improve handling of compounds a modification in physical properties is very 
helpful which can be achieved by functional group transformation. In case of L-cysteine HCl it 
can be achieved by transforming the free carboxyl group of the thiazolidine 15 to an ester. This 
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would make the handling of compounds better, change their physical properties, and improve 
stability. The peptide synthesis was then explored using the corresponding esters of L-4-carboxy-
2, 2-dimethyl thiazolidine HCl (Table 3.4). Of the several esters synthesized using, methyl, ethyl, 
butyl, octyl alcohol. Only the butyl ester was found to be the best in terms of solubility, and 
purification. 
Table 3.4 L-cysteine ester and their solubility 
 
The free NH group of the thiazolidine moiety 23 is readily available for peptide coupling in both 
the carboxy and the ester derivatives of thiazolidine 15 and 23 respectively (Scheme 3.5). It was 
observed that the thiazolidine protection reaction proceeds fairly easily with quantitive yields 
irrespective of the fact if the protection is done on L-cysteine hydrochloride 1 or its ester 
derivative 22 (Scheme 3.5).   
 
Scheme 3.5 Synthesis of thiazolide ester derivatives 
S.No  Alcohol  Product  Solubility in organic Solvents  
1.  Octanol  Cys octyl ester HCl  (19) Soluble  
2.  Butanol  Cys butyl ester HCl  (20) Soluble in DCM  
3.  Ethanol  Cys ethyl ester HCl (21) Insoluble in DCM, Soluble in Water  
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Even though thiazolidine protection reactions were carried out relatively easily but they suffer 
from several problems. Thiazolidine protection is stable as hydrochloride salt form, in situ 
generation of free NH is better for a reaction. The purification of the obtained peptide is difficult 
and often requires lyophilization. Since the isopropylidine group is not UV active monitoring of 
reaction was a tedious task. The group seems to be highly moisture, pH and heat sensitive 
(decomposition observed at 80 °C).  
Therefore, in our pursuit to find a better sulfhydryl protective group several electron rich 
aromatic aldehydes or ketones were explored for thiazolidine formation using the procedure 
shown in scheme 3.6. As a model reaction benzaldehyde was used to give the corresponding 
thiazolidine derivative 25 (Table 3.5). Further, functionalized aromatic compounds were 
employed to synthesize aromatic thiazolidine derivatives. The thiazolidine synthesis was carried 
out under basic conditions using water and ethanol in a 1:1 mixture as solvent. The reaction was 
performed at room temperature and the product separated as a precipitate at the end of 
completion of reaction. Reaction with benzaldehyde gave the corresponding thiazolidine 25 with 
formation of daistereomers. Thiazolidine formation with 2,3,4-trimethoxy benzaldehyde 
proceeded with an equilibrium and yielded diastereomers. No product formation was observed 
using 2,4,5-trimethoxy benzaldehyde whereas in case of benzophenone pinacol was the only 
isolated product. The results are summarized in Table 3.5.  
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Table 3.5 Thiazolide ester derivatives 
To have better understanding and establish a procedure for thiazolidine synthesis using L-
cysteine hydrochloride another substrate used was p-N,N dimethyl amino benzaldehyde 32. The 
synthesis of compound 32 was done as per standard method
71
. This was used for thiazolidine 
synthesis from L-cysteine HCl
72 
under basic conditions in a mixture of Ethanol:water (1:1) as 
solvent for the reaction. The reaction proceeded well and the compound 33 was obtained as the 
desired product, which separated out a yellow colored precipitate (Scheme 3.6). 
 
 
 
 
 
 
 
Entry  R1 and R2  Reaction Condition Product (yield)  
1.  R1=R2=-CH3 (24) Reflux, 6h Equilibrium (98%) 
2.  R1= Phenyl (25) 
R2=-H  
EtOH-H2O-NaHCO3, 8h Diastereomers (86%)  
3. R1= 2,4,5-trimethoxy phenyl 
R2=-H (26) 
EtOH-H2O-NaHCO3, 8h No product  
4.  R1= 2,3,4-trimethoxy phenyl 
R2=-H (27) 
EtOH-H2O-NaHCO3, 8h Equilibrium, 
Diastereomers (65%)  
5.   R1=R2=Phenyl (28) EtOH-H2O-NaHCO3, 4h Pinacol  
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Scheme 3.6 Synthesis of aryl thiazolidine from p-dimethylaminobenzaldehyde 
 
After successfully establishing procedure for aromatic thiazolidine synthesis several isoindole-
1,3-dione derivatives were synthesized and employed as protection groups. These derivatives are 
discussed in detail in chapter 4. The isoindole-1,3-dione derivatives were synthesized under 
microwave reaction conditions. A representative example of this is outlined in Scheme 3.7. 
Microwave reaction were performed on 4-aminotoluidine 34 to give the corresponding 
compound 35. This was dibrominated to give 36 and subsequently hydrolysed to give the 
corresponding aldehyde 37. Compound 37 on reaction with ethyl 2-amino-3-mercaptopropanoate 
Hydrochloride 16 gave the corresponding thiazolidine derivative 38 (Scheme 3.7). 
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Scheme 3.7 Phthalate protected p-aminotoluidine derivatives as cysteine protection groups 
 
Although various thiazolidine derivatives of L-cysteine hydrochloride were successfully 
synthesized, but a common problem encountered during this synthesis was racemization of the 
final product in most of the cases. Converting L-cysteine to isoproylidine derivative using 
acetone as protection for Cysteine racemization was highly evident and desired peptide synthesis 
could not be achieved as this group was too labile for any further reaction. When using aromatic 
aldehydes and ketones for preparation of thiazolidine derivatives formation of diastereomers was 
observed most of the times. It was not desirable for peptide synthesis as the purification of 
resulting diastereomers was a challenge. Therefore, a selective β-sulfhydryl protection of L-
Cysteine hydrochloride was explored. 
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3.5.1.2. Selective β-Sulphydryl Protection of L-Cysteine hydrochloride  
In order to selectively protect the β-sulphydryl group of L-cysteine HCl 1, carboxy group 
was transformed to the corresponding ester 21 (Scheme 3.8). A model reaction was carried out 
using benzyl chloride under basic conditions to yield product 39 in quantitative yield. The S-
benzylation reaction was successfully carried out with both L-cysteine hydrochloride 1 and its 
ester derivative 21. 
Scheme 3.8 S-benzyl cysteine derivatives synthesis 
A peptide synthesis attempted on compound 41 was successful but the subsequent deprotection 
could not be achieved without oxidizing β-sulfhydryl functionality. Various deprotection 
methods including the hydrogenation were unsuccessful in generating a free sulfur group. An 
oxidized Cysteine (cystine) was recovered in these attempts. In order to synthesize the novel 
cysteinyl metal peptides we required a protective group that is easily removed at the completion 
of peptide synthesis without oxidizing the free sulfhydryl to disulfide derivatives. Therefore, 
analogues of benzylbromide were explored (Fig. 3.9).  
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Figure 3.9 Proposed novel protecting group 
 
The idea was to have a more labile group than benzyl such as phthalate protected amino benzyl 
bromide. After several trials, we successfully introduced compound 44 into 21 as a selective 
protection of β-sulfhydryl group (Scheme 3.9). 
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Scheme 3.9 Synthesis of phthalate based L-cysteine sulfur protection 
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Although we desire to use L-cysteine HCl for our reaction for selective β-sulfhydryl protection 
as a free carboxy group is required for metal complexation. But the free carboxy group changes 
the reaction pH  along with limiting its solubility to polar solvent like water thereby making the 
selective sulfhydryl protection unachievable with 2-(4-(bromomethyl)phenyl)isoindoline-1,3-
dione 44 under basic conditions. Conversion of the L-cysteine hydrochloride 1 to the 
corresponding ethyl ester 21 led to selective β-sulfhydryl protection under basic conditions. The 
problem was the insolubility of L-Cysteine hydrochloride in organic solvents. Therefore, to 
improve Cysteine solubility it was converted to tosylate and long chain esters. One such example 
of L-cystiene tosylate 47 for selective sulfhydryl is outlined in Scheme 3.10. Selective β-
sulfhydryl protection of L-cysteine using trityl chloride (Scheme 3.10) and benzoyl chloride 
were successfully accomplished using the ester 20 and the tosylate 47 of L-cysteine 
hydrochloride 1. These derivatives offered better solubility in organic solvents. The trityl group 
was found to be highly acid labile and unsuitable for peptide synthesis. For the desired peptide, 
synthesis at the N-terminal of compound 48 and 49 it was treated with a base. At this point, it 
was observed that the benzoyl group migrated from sulfur to the nitrogen to give compounds 78a 
and 78b. This is commonly known as Sulfur to Nitrogen migration. As Et3N was added, new 
peaks appeared in NMR.  Sulfur to Nitrogen benzoyl group migration was further explored for 
peptide synthesis and will be discussed later in this chapter. 
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Scheme 3.10 Synthesis of sulfhydryl protection group 
 
In our continued pursuit to find new protective groups pararosaniline was selected as a 
substrate to synthesize new protective groups. The rationale to choose pararosaniline is that it has 
three amino groups that can be protected with a suitable protective group and then introduced on 
L-Cysteine as selective β-sulfhydryl protection group. This would make the resulting L-cysteine 
derivative more stable for peptide synthesis compared to trityl group. For the deprotection the 
amino protection could be removed either under basic condition or by use of hydrazine hydrate. 
The free amine groups would stabilize the carbocation of the pararosaniline derivative thus 
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making it easier at the deprotection step. The amino protective group would provide stability 
under acidic conditions and make it more stable under low pH compared to trityl group. 
Therefore, it was chosen as an alternative to trityl to provide facile protective groups for our 
synthesis of target molecule. 
Pararosaniline 51 has three free amino groups that were protected as phthalate (Scheme 
3.11).  Pararosanilne 51 was reduced using sodium borohydride to the corresponding derivative 
54. It was treated with phthalic anhydride under microwave conditions to yield compound 56 in 
ten minutes at microwave power of 300 watt.  The resulting compound was not reactive enough 
to selectively protect the β-sulfhydryl group of L-cysteine hydrochloride (Scheme 3.11). 
Phthalate was then replaced with succinate and tetrachloro phthalate derivatives to get better 
results. Reaction of 54 with succinic anhydride under microwave power of 500 watt yielded 
compound 55 with better solubility. A further reaction with L-cysteine derivative did not yield 
the desired β-sulfhydryl protection because of lack of functionality at the tertiary carbon of 55. 
Attempts to functionalize the tertiary carbon were unsuccessful. Therefore, pararosaniline 
hydrochloride 51 was directly reacted with succinic anhydride to yield compound 52. A further 
reaction of 52 with 20 gave the desired compound 53.  
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Scheme 3.11 Pararosaniline derivatives as selective β-sulfhydryl protective group 
The obtained compound was further purified and characterized by NMR. A proton NMR 
spectrum of compound 53 is presented in Fig. 3.10. 
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Figure 3.10 Protected cysteine compound 53 
1
H NMR 
 
3.5.2. Protective groups for Tyrosine 
The alkyl ether synthesis for L-tyrosine as reported by Weiss and co-workers
82
 requires 
the protection of the amino group by formylation, and the over-all yield of the three-step method 
is only 30-40%. Earlier, Aberhalden and Guggenheim
83
 reported the synthesis of the glycerine 
monoether, in unspecified yield, through the disodium salt of tyrosine. Solar
81
 et al. reported 
complex method of alkylating L-tyrosine using DMSO under heating conditions with a yield of 
approximately 40%. Yet another method reported by Wunsh E et al.
85
 and used by Capler et al.
84
 
is ether synthesis using copper complex formation. We were successfully able to apply the 
copper complex method to our synthesis that resulted in the overall yield of 70%-80%. Reacting 
L-tyrosine 57 with copper sulfate under basic conditions forms a copper complex 58 as outlined 
in Scheme 3.12. This mixture was then heated to 60 °C then cooled to room temperature, diluted 
with methanol and made more basic using sodium hydroxide. A further reaction with benzyl 
bromide to give 59 and a subsequent copper complex disintegration under acidic condition and 
neutralization with ammonium hydroxide gave the desired compound 60. Free amino group in 
the compound 61 was protected as phthalate using microwave assisted phthalate synthesis. 
Benzyl protected L-tyrosine 61 was reacted with phthalic anhydride in a microwave at power of 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.5
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300-400 watt for 15 mins to give a crude product 62. Recrystallization was done using DCE to 
get a pure compound. A further esterification gave compound 63 (Scheme 3.12).  
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Scheme 3.12 Copper-mediated Tyrosine protection
84 
 
Benzyl ether protection using copper complex method served as a model reaction. We wanted to 
introduce novel protecting groups that are easier to remove at the end of synthesis. Therefore, 
amine group was protected as phthalate in L-tyrosine 57 and carboxy was converted to ester 64 
outlined in Scheme 3.13. Microwave phthaloylation for both compounds 57 and 64 progressed 
well to give compounds 65 and 66 respectively. Compound 65 was further purified by 
recrystallization from dichloroethane and the NMR spectra are presented in Fig. 3.11. 
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Figure 3.11 Protected tyrosine compound 62 1H and 13C NMR 
 
The hydroxyl group of 65 and 66 was selectively protected as acetate to give corresponding 68 
and 69 (Scheme 3.13). Since the peptide bond formation was desired at the carboxy terminal of 
protected tyrosine, attempt to selectively hydrolyse ester led to removal of O-acetate in 
compound 69. Therefore, compound 68 was prepared from 65 and used for peptide synthesis 
Scheme 3.13.  
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Scheme 3.13 α-carboxyl and amine protection in L-tyrosine 
 
The successful results in protection of L-cysteine hydrochloride with our protective group, we 
were encouraged to introduce the same protecting group for L-tyrosine. This would provide the 
advantages at the deprotection step after peptide synthesis as all the protecting groups can be 
removed in one step under same reaction conditions yielding the desired peptide. Synthetic 
challenge for L-tyrosine protection was to specifically introduce the phthalate imide derivative 
44 as a hydroxyl protective group. After several unsuccessful trials the best reaction conditions 
were found to be refluxing acetone using potassium carbonate as base to make the L-tyrosine 
ether compound 67 (Scheme 3.13) The compounds were further purified by crystallization and 
column chromatography as required and taken to peptide synthesis. 
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Selective ester hydrolysis of 67 was subsequently carried out under various basic conditions to 
find the optimum conditions. Under drastic basic conditions, phthalate hydrolysis was observed. 
After several experimental failures, the reaction was finally accomplished by using potassium 
hydroxide-Methanol titration under reflux conditions to give compound 70. The reaction had to 
be performed carefully with titration method to avoid any unnecessary decomposition. The 
hydrolyzed pure compound 70 precipitated out of the reaction medium as the reaction 
progressed.  L-Tyrosine was successful protected using efficient and industrially viable method 
to give the protected L-tyrosine compounds using the novel protective group 44. The reactions 
were reproducible and no racemization was observed under these conditions. 
                                                                                
3.5.3. Peptide Synthesis 
The sensitivity of the cysteine molecule towards oxidation and elimination makes it 
necessary to protect the β-sulfhydryl group during the peptide synthesis. We explored the peptide 
coupling by protecting the reactive β-sulfhydryl group of cysteine as a thiazolidine. This 
eliminated the need to protect the amino group separately and reduced the number of steps in 
peptide synthesis. The thiazolidine 15 was reacted with phthalate protected phenyl glycine 72 
(scheme 3.14). Activation of the carboxy terminal of compound 72 was achieved by conversion 
to the corresponding acid chloride by using oxalyl chloride to yield compound 73 (Scheme 3.14). 
The reaction resulted in formation of the desired peptide 74 but with racemization. The product 
was obtained as mixture of diasteromers. Since an enantiomerically pure product was desired 
further purification remained a challenge and the diastereomer separation could not achieved at 
this stage.  
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Scheme 3.14 Thiazolidine and cysteinyl phenyl glycine peptide synthesis. 
 
Second peptide coupling reaction was attempted using glutamic acid 75 (Scheme 3.15). 
Phthaloyl-L-glutamic anhydride
71
 77 was synthesized from sodium salt of L-glutamic acid 75 
without the intermediate isolation of phthaloyl-L-glutamic acid 76.  Recrystallization from 
xylene provided compound 77 in good yield and sufficient purity that it was taken to next step 
without further purification. Compound 77 on reaction with thiazolidine 15 provides compound 
79. A racemization was observed in this reaction leading to formation of diastereomers and 
making separation of enantiomerically pure compound difficult. When reaction was performed 
using free –NH derivative of 15 no product formation was seen, whereas in situ generation of 
free –NH using sodium acetate and acetic acid to maintain the pH balance favored the formation 
of product 79. 
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Scheme 3.15 Coupling of thiazolidine to L-glutamic acid 
 
A limited success with in peptide coupling of L-glutamic acid with thiazolidine in Scheme 3.15 
prompted to explore alternate methods of peptide synthesis. The challenge was to synthesize 
peptide by coupling the N-terminal of cysteine with the carboxy terminal of tyrosine. To achieve 
the desired peptide bond formation the carboxy group of tyrosine was activated by converting to 
acid chloride by reaction with oxalyl chloride in DCM with few drops of DMF. The resulting 
acid chloride was reacted with thiazolidine ester of L-cysteine (Table 3.5 entry 1) under basic 
conditions (Scheme 3.16). Using DMAP or triethylamine as a base peptide bond was formed but 
with racemization, more so with triethylamine. In addition, with the progress of reaction 
thiazolidine decomposition was observed as a side reaction (Table 3.6). 
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Scheme 3.16 Cysteine-tyrosine peptide synthesis 
 
A series of reaction were attempted for cysteinyl peptide synthesis. The results are summarized 
in Table 3.6. Attempts to react the activated acid chloride of protected L-tyrosine 75 with 
unprotected L-cysteine (Table 3.6 entry 2) under basic conditions did not yield the peptide 
formation. With trityl protected sulfhydryl cysteine (Table 3.6 entry 3) the peptide synthesis 
went well. The deprotection under acidic condition to remove the trityl protection reversed the 
reaction yielding tyrosine, cysteine and other decomposition products including cystine. The 
benzyl protected L-cysteine (Table 3.6 entry 4) was reacted with L-tyrosine to give the desired 
coupled product. Attempts to remove benzyl protection under palladium hydrogenation were 
unsuccessful. A possible explanation for no observed debenzylation would be poisoning of 
palladium catalyst by cysteine sulfur. Any other strong basic conditions employed for 
deprotection were deleterious to the coupled product. Instead, it was observed that the butyl ester 
of L-cysteine HCl when reacted with acid chloride of protected tyrosine compound 68 peptide 
coupling was successful (Scheme 3.16). We also explored the peptide synthesis using our 
protective group 52. L-cysteine hydrochloride was selectively protected to give compound 53 
which was coupled to protected L-tyrosine 68 to successfully give the desired dipeptide (Table 
3.6 entry 5). 
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S.No. Substrate
NH/ NH2 Protected Cysteine=
 
Reaction Conditions Peptide (product number) 
1. Thiazolidine ester 
S NH. HCl
O
O
 
K2CO3, DCM:THF No Conversion  
DMAP, DCM:THF Diastereomers (109) 
Et3N, DCM Product (110) (58%) 
2.  
HS NH2.HCl
COOH
 
NaOH, DCM:THF No Conversion 
NaHCO3, DCM:THF No Conversion 
3.  
S
ClH.H2N
O
O Bu
Tr
 
Et3N, DCM Product (111) (62%) 
4.  
S
NH2
EtOOC
Bz  
Et3N, DCM Product (112) (62%) 
5.  
S
NH2
O
O
N
N
N
O
O
O
O
O
O
.HCl
(53) 
Et3N, DCM Product (113) (71%) 
Table 3.6 Cysteine-tyrosine peptide derivatives 
 
Peptide synthesis involving selective functional group protection of amino acids, 
followed by activating carboxy functional group of one amino acid to add to the other is a 
promising way to synthesize peptide bonds. It suffers from several disadvantages in terms of 
removal of all protective groups at the end of peptide synthesis that lead to racemization and 
other issues. Protection deprotection of functional groups increases the total number of synthetic 
172 
 
steps to arrive at the desired peptide molecule. There are other synthetic techniques mentioned in 
literature like Native Chemical Ligation (NCL)
74
.  This strategy
75
 is mostly used for synthesis of 
proteins, where a chemoselective reaction between two unprotected fragments i.e a C-terminal 
thioester and N-terminal cysteine occurs. As depicted in scheme 3.17 the thioester 81 undergoes 
trans-thioesterification with 82 to give 83. This is a classical example of Sulfur to Nitrogen 
migration resulting in formation of peptide 84 having a free sulfhydryl group. 
 
 
 
Scheme 3.17 S- and N- acylation of L-cysteine
76 
 
Based on the literature procedure of Katritzky et al.
76
 we explored it for our peptide synthesis 
(Scheme 3.17). As a test reaction, S-benzoylation of L-cysteine HCl was performed (Table 6 
entry 1). It was observed that under basic conditions the S-benzoyl group transfers to the amino 
functionality of L-cysteine giving compound 92 (Scheme 3.18). Since, we desired to trap the free 
sulfhydryl group as a metal complex, a further reaction with Zinc acetate under basic conditions 
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led to the formation of desired compound (Scheme 3.18). The overall reaction is summarized in 
Scheme 3.18. 
 
 
Scheme 3.18 Cysteinyl metal peptides 
 
Similarly, various substrates were explored and results are summarized in Table 3.6. The peptide 
synthesis of acid chloride of phthalate protected L-tyrosine (Table 3.6 entry 3) and phenyl 
glycine (Table 3.6 entry 2) with L-cysteine hydrochloride successfully yielded compounds 98 
and 95 respectively with intermediate S-acyl formation. The reaction was carried out in 
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acetonitrile resulted in formation of S-acylated compound, which under basic conditions 
transforms to the desired peptide via S to N migration.   
 
S.No Substrate S-Acylation 
percentage yield 
(product number) 
S to N migration 
percentage yield 
(product number) 
Zinc complex 
percentage yield 
(product number) 
1. 
Cl
O
 
65 
(91) 
65 
(92) 
72 
(93) 
2. 
COCl
N
O
O
 
72 
(94) 
62 
(95) 
75 
(96) 
3. 
OAc
N
Cl
OO
O
 
71 
(97) 
65 
(98) 
70 
(99) 
4. 
O
NPhth
COCl
PhthN  
60 
(100) 
60 
(101) 
72 
(102) 
Table 3.7 Cysteinyl metal peptides derivatives 
For better solubility of L-tyrosine derivatives and L-cysteine hydrochloride derivatives, we 
employed the butyl ester of L-cysteine hydrochloride (Scheme 3.19). Compound 68 was 
transformed to its corresponding acid chloride 75 via reaction with oxalyl chloride. This on 
subsequent reaction with L-cysteine butyl ester hydrochloride led to formation of compound 103. 
Under basic conditions, S to N migration was achieved. Free sulfur was captured by a further 
reaction with acetic anhydride to give compound 104. 
 
 
 
 
 
Scheme 3.19 S to N migration in butyl ester of L-cysteine 
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L-tyrosine derivative 68 was successfully incorporated to give L-cysteine based peptide with a 
free sulfhydryl group. The phthalate protected L-tyrosine was converted to acid chloride 75 and 
reacted with L-cysteine hydrochloride to give the corresponding thioester 103. This under basic 
conditions undergoes S to N migration to give the desired product. At this point we wanted to 
confirm the presence of free thiol group therefore, a reaction with acetic anhydride was 
attempted which successfully gave S-acylated product 104. The free sulfhydryl was then trapped 
as a metal complex by reaction with zinc acetate under basic conditions for peptide metal 
complex formation (Scheme 3.18).  
Further exploration of phenols as radical capture agents was performed on anticancer 
agent A007. Studies indicated that it has potential to act as a radiation protection agent. To futher 
its ability as a radiation protection agent we successfully incorporated thiazolidine ester of 
cysteine in A007 structure (Scheme 3.20) to further explore its biological activities.  
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Scheme 3.20 A007-cysteine coupling reaction 
Acid chloride 106 of compound 105 was obtained by reaction with oxalyl chloride. A further 
reaction with thiazolidine ethyl ester gave compound 107. The ester hydrolysis was achieved by 
careful hydrolysis using sodium hydroxide and methanol under reflux conditions to give 
compound 108. A further purification of compound 108 was achieved by fractional 
crystallization and careful stirring with silica gel.  
 
3.6 Biological studies 
The initial studies to understand the radiation exposure capability of compounds was 
conducted on phenolic compound namely A007.  Mice were exposed to radiation for several 
days. This interferes with the white blood cell (WBC) count, which was monitored. Mice were 
given A007 and then exposed to radiation for several days and now their WBC count was 
monitored. The study revealed that the mice given A007 had their WBC count return close to 
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normal compared to those who were not given A007. The WBC count was monitored for days 
after radiation exposure and a graph representing the outcome is shown in Fig.3.12.  
 
  
Figure 3.12 A-007 as radical scavenger (courtesy Dr. Lee Roy Morgan) 
 
These results clearly indicate that A007 is acting as a radical capture agent. It was postulated that 
the free hydroxyl groups in A007 was able to scavange the free radicals  thus returning the WBC 
count of mice to normal much faster than those not given A007. It is speculated that the inherent 
ability of A007 to capture free radicals is attributed to its aromatic nature and presence of 
hydroxyl functional groups. Once the free radicals are captured, they are stabilized over the 
aromatic system and avoid further reaction inside the animal models.  
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The biological studies of zinc monocysteine have shown to have promising anticancer 
activity. ZMC was used to treat the cancerous kidneys at 30 µM concentration.  The kidneys 
were monitored continuously for cancerous growth. The images of the kidneys taken at day 7 of 
treatment with ZMC reveal the disappearance of cancerous cells (Fig. 3.13).  
  
Figure 3.13 ZMC activity on cancerous kidneys: Kindneys were harvested at E13.5 and cultured for 24 hours in 
EOC media. At day 1 and 3 media was changed. 100µM 8-bromo-cyclic AMP was added to all cultures, and 30 µM 
Zincmonocysteine was added to contralateral (b) kidneys. Kidneys remained in culture until day 7 at which time 
images were taken. (courtsey Dr. David J Tate). 
179 
 
3.7 Conclusions 
Reactive oxidative species (ROS) have been implicated in the pathogenesis of many 
chronic diseases, such as cancer, cardiovascular and neurodegenerative diseases therefore finding 
novel antioxidants to combat ROS has attracted a lot of attention in recent years. Amino acids 
like cysteine and tyrosine are the well-identified antioxidant pharmacophore among other 
hydroxyl rich compounds like catechol and A007. To explore the antioxidant activity A007 was 
studied for its effect in mice and was found to have radical capture ability. To this end A007 was 
successfully coupled to Cysteine derivatives to further study its biological activities.   
Since cysteine cannot be used in its free form because the free β-sufhydryl group, it was 
complexed to several metals like zinc, calcium, cadmium and magnesium. These cysteine metal 
complexes are speculated to have better shelf life and stability. The commercial synthetic 
procedure for ZMC was improved to give better yields and improved methodology. 
‘Advanced Radical Capture Compounds’ were synthesized by linking derivatized L-cysteine to 
L-tyrosine and other substrates and subsequently complexed to metal ions.  In our effort to 
synthesize novel radical capture compounds containing L-cysteine and L-tyrosine we faced 
several problems of selective protection and deprotection of amino acids for peptide synthesis. 
To this end to meet the requirements of a suitable protective group in terms of stability, pH, 
moisture and heat sensitivity we successfully designed several protective groups and utilized 
them in our peptide synthesis. The S to N migration for cysteinyl peptide synthesis was explored 
with great success. Finally, the synthesized ZMC compound was tested for its biological activity. 
It was revealed to have anticancer activity in kidney cancer cells.   
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3.8. Experimental 
 
General Experimental 
All reagents and solvents were purchased from Sigma-Aldrich and were analytical grade.  Thin-
layer chromatographic analysis (TLC) was performed using silica gel on glass plates and was 
detected under ultraviolet (UV) light and using PMA, Ninhydrin, KMnO4 solution. Column 
chromatography was performed using silica gel porosity 60 Å, partial size 40-75 mm from 
Sorbent Technologies.  The 
1
H and 
13
C NMR spectra were run on Varian 400 MHz Unity in 
CDCl3, D2O, CD3OD or DMSO-d6 as solvents and internal standards.   
 
Synthesis L-cysteine Zinc complex (2): Into hot water  (2L) solution of zinc acetate  (65.85g; 
0.3 mol) and sodium acetate (54.4g; 0.4mol) water solution of cysteine hydrochloride 
monohydrate (52.7g; 0.3mol) was added with continuous magnetic stirring. A white precipitate 
formed immediately. White suspension was heated at ~90 °C for 3h with magnetic stirring. After 
cooling to room temperature solid was seperated by filtration, washed with water (3X200mL), 
acetone (3X100mL) and dried at 120 °C for 2h. Isolated yield of white powdery product was 
54.8g (98%). Selected
 1
H NMR (400 MHz, D2O) δ 4.15 (t, J = 2.0, 1H) and 3.18-3.03 (m, 2H) 
ppm; 
13
C NMR (D2O): δ 171.66, 55.52 and 24.52 ppm.  C3H5NO2SZn (MW184.53) m/z: 421.25, 
321.00, 322.17, 221.08, 203.00 and 147. 
 
L-cysteine Calcium complex (4): Preparation was carried out in the same way as L-cysteine 
Zinc compound. Selected
 1
H NMR (400 MHz, D2O) δ 3.52 – 3.41 (m, 1H) and 2.75 (ddd, J = 
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20.6, 13.7, 8.1, 2H) ppm.
 13
C NMR (D2O): δ 177.56, 65.42 and 30.12 ppm.  C3H5CaNO2S 
(MW195.25) m/z: 212.1 and 113.0. 
  
Synthesis of L-cysteine Magnesium complex (5): Preparation was carried out in the same way 
as L-cysteine Zinc compound. Selected
 1
H NMR (400 MHz, D2O) δ 3.52 – 3.41 (m, 1H) and 
2.75 (ddd, J = 20.6, 13.7, 8.1, 2H) ppm.
 13
C NMR (D2O): δ 177.56, 65.42 and 30.12 ppm.   
 
Synthesis of L-cysteine Cadmium complex (6): Preparation was carried out in the same way as 
L-cysteine Zinc compound. Selected
 1
H NMR (400 MHz, D2O) δ 3.52 – 3.41 (m, 1H) and 2.75 
(ddd, J = 20.6, 13.7, 8.1, 2H) ppm.
 13
C NMR (D2O): δ 177.56, 65.42 and 30.12 ppm.   
 
Preparation of L-4-carboxy-2,2-dimethyl thiazolidine hydrochloride (15): A suspension of  
L-cysteine hydrochloride monohydrate (5.0 g; 28.5 mmol )  in 500 ml of anhydrous acetone was 
heated under reflux for six hours. The powdered cysteine hydrochloride dissolved and crystalline 
flakes started to separate slowly. The reaction mixture was concentrated under reduced pressure 
to slurry that was cooled overnight at 0-5 °C. Subsequent filtration gave 5.06 gm (90%) of white 
solid as pure product. Selected
 1
H NMR (400 MHz, D2O) δ 4.72 (t, J = 8.1, 1H), 3.41 (ddd, J = 
52.6, 12.2, 8.1, 2H), 2.00 (s, 1H) and 1.61 (d, J = 5.1, 6H) ppm. 
13
C NMR (D2O): δ 172.1, 68.6, 
66.8, 29.5, 26.8, and 26.8 ppm.   
 
Preparation of (R)-ethyl 2-amino-3-mercaptopropanoate or L-cysteine ethyl ester 
hydrochloride (22): A suspension of L- cysteine hydrochloride monohydrate (1.0 g; 5.7 mmol) 
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in ethanolic HCl was refluxed for 5h to get a clear solution. The reaction was concentrated under 
reduced pressure to give pure product as a white powder in quantitative yield.  Selected 
1
H NMR 
(400 MHz, D2O) δ 4.27 (t, J = 6.9, 1H), 4.19 (q, J = 8.0, 3H), 3.11 – 2.94 (m, 3H), 1.18 (t, J = 
8.0, 4H). 
 
Preparation of ethyl ester of L-4-carboxy-2,2-dimethyl thiazolidine hydrochloride (23): 
This compound was prepared in the same way as thiazolidine using the ethyl ester of L-cysteine 
HCl. 
1
H Selected 
1
H NMR (400 MHz, D2O): δ 4.84 (t, 1H), 4.23-4.17 (q, J = 14.1 2H), 3.38-3.48 
(ddd, J = 54.5, 12.1, 8.2, 2H), 1.68 (d, J = 7.9, 6H) and 1.18-1.15 (t, 3H) ppm. 
13
C NMR (D2O): 
δ 172.6, 66.2, 66.8, 61.3, 29.7, 26.7, 26.7 and 14.1 ppm.  
 
Preparation of 2-Phenylthiazolidine-4-carboxylic Acid: L-cysteine hydrochloride 
monohydrate (3.0 g, 17.08 mmol) was dissolved in water (15 mL) and sodium bicarbonate (1.5 
g, 17.08 mmol) was added followed by addition of benzaldehyde ( 2.17 g, 20.5 mmol) solution 
in ethanol (15 mL). The reaction mixture was stirred at room temperature for 2h, and the solid 
precipitated out was collected, washed with diethyl ether, and dried to afford 2-
phenylthiazolidine-4-carboxylic acid with yields of 70%. Selected 
1
H NMR (DMSO-d6): δ 7.25-
7.55 (m, 5H), 5.67 (s, 0.6H), 5.50 (s, 0.4H), 4.22 (dd, J= 6.9, 4.5 Hz , 0.6H), 4.00 (dd, J =8.7, 7.2 
Hz, 0.4H), 3.27-3.40 (m, 1H) and 3.04-3.16 (m, 1H) ppm. 
 
Preparation of Ethyl 2-Phenylthiazolidine-4-carboxylate (25): L-cysteine ethyl hydrochloride 
(1.0 g, 5.385 mmol) was dissolved in water (15 mL) and sodium bicarbonate (0.45 g, 6.462 
mmol) was added followed by addition of benzaldehyde (0.68 g, 6.462 mmol) solution in ethanol 
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(15 mL). The reaction mixture was stirred at room temperature for 1h. Ethanol was evaporated as 
much as possible, diluted with water and extracted in DCM. Product was obtained as oil in yields 
of 86%. Selected 
1
H NMR (400 MHz, CDCl3): δ 
1
H NMR (400 MHz, CDCl3) δ 7.56 – 7.33 (m, 
5H), 5.83 (s, 0.4H), 5.57 (s, 0.6H), 4.30 – 4.24 (q, J = 8.1, 2H), 4.02 and 3.50 (dd, J = 8.8, 1H), 
3.45-3.50 (m, 1H),  3.10-3.15 (m, 1H) and  1.29 (q, J = 8.0, 3H) ppm. 
 
Preparation of 2-(2,3,4-trimethoxyphenyl)thiazolidine-4-carboxylic Acid (27): 
1
H NMR (400 
MHz, CDCl3) δ 7.11 (d, J = 8.6, 1H), 6.60 (d, J = 8.7, 1H), 5.90 (s, 1H), 4.24 (m, 3H), 3.96 (s, 
3H), 3.83 (s, 3H), 3.83 (s, 3H), 3.43 (dd, J = 10.1, 6.9, 2H) and 1.30 (t, J = 7.1, 1H) ppm. 
 
Preparation of p-dimethylaminobenzaldehyde (32): Dimethylformamide (10g, 148.76 mmol) 
in a RBF was cooled in an ice bath. To it phosphorous oxychloride (6.32g, 41.32 mmol) was 
added carefully dropwise. Mixture was allowed to cool to room temperature after completion of 
addition. This was followed by addition of dimethylaniline (5g, 41.32 mmol), a yellow-green 
precipitate started to form. The reaction mixture was heated for 2hours. The mixture is then 
cooled to room temperature and subsequently poured on ice. Solution was neutralized with 
sodium acetate saturated aqueous solution to pH 6–8. p-dimethylaminobenzaldehyde began to 
precipitate. Stored the crude mixture in refrigerate overnite. Filtered the product, and washed 
several times with water on the filter. A very light-yellow product (12g, 82%) was obtained. 
Selected 
1
H NMR (400 MHz, CDCl3) δ 9.75 (s, 1H), 7.74 (d, 2H), 6.71 (d, J = 9.0, 2H), 3.09 (s, 
3H) and  2.92 (s, 3H) ppm.
 13
C NMR (400 MHz, CDCl3) δ 191.02, 155.42, 130.18, 126.40, 
114.82 and 40.22 ppm. 
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Synthesis of 2-p-dimethylamino benzaldehyde thiazolidine-4-ethyl carboxylate (33):  
Compound was synthesized in the same way as Ethyl-2-Phenylthiazolidine-4-carboxylate 18A. 
Selected 
1
H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.8, 2H), 6.7 (d, J = 8.8, 2H), 5.74 (s, 1H), 
5.52 (s, 1H), 4.25-4.32 (m, 1H), 3.95-4.01 (m, 1H), 3.40-3.49 (m, 1H), 3.15-3.20 (m, 1H) and 
2.97 (s, 6H) ppm.
 13
C NMR (400 MHz, CDCl3) δ 171.5, 148.0, 129.62, 128.7, 114.25, 69.2, 
62.65, 61.32, 40.21, 35.56 and 14.12 ppm. 
 
Synthesis of phthalimides, general procedure: Phthalic anhydride (1.5 g; 0.01 mol), 
corresponding amine (0.01) and N,N-dimethylformamide (20 ml) were mixed together in a round 
bottom flask (100 ml).  The reaction mixture stirred in the microwave reactor equipped with a 
condensor and magnetic stirrer.  The reaction mixture was stirred under microwave irradiation 
with mild solvent refluxing (magnetron power between 300 to 400W).  After completion of the 
reaction the resulting mixture was poured on crushed ice.  This precipitated the compound as a 
white precipitate which was separated by filtration, washed thoroughly with water and dried 
under reduced pressure.  The compounds were obtained in more than 95 percent purity. Further 
1
H-NMR and 
13
C-NMR spectra were recorded to establish structure of molecules. 
 
4-methylphenylphthalimide (35): Isolated in quantitative yield. Selected
 1
H NMR (400 MHz, 
CDCl3):  7.98 (d, 2H), 7.80 (d, 2H), 7.35(s, 4H) and 2.41(s, 3H) ppm. 
13
C NMR(400 MHz, 
CDCl3):   168.0, 138.2, 134.5, 132.0, 130.0, 129.5, 127.1 124.0, and 21.5 ppm.  
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Preparation of dibromoarene, general procedure:  A mixture of methylbenzene derivative 
(3.3 mmol), N-bromsucinimide (10 mmol), and benzoylperoxide (0.31 mmol) in benzene (10 ml) 
was refluxed for three hours under microwave radiation (magnetron power 500W, magnetron 
power 200W with bead).  After completion of the reaction the solvent was evaporated under 
reduced pressure and the solid residue was dissolved in dichloromethane (100 ml).  
Dichloromethane solution was washed with saturated sodium bicarbonate (3X15 ml), water 
(3X20 ml) and subsequently dried over anhydrous sodium sulfate.  The solvent was evaporated 
under reduced pressure and the residue was further purified by filtration through short silica gel 
column with hexane-dichloromethane as solvent. 
 
4,4’-(dibromomethyl)phenylphthalimide (36):  The product was isolated as white powder 
(Yield=90%).  Selected 
1
H-NMR (CDCl3): δ 7.98 (2H, m), 7.82 (2H, m), 7.72 (2H, d, J = 8.0 
Hz), 7.51 (2H, d, J = 8.0 Hz), and 6.68 (1H, s) ppm. 
13
C-NMR (CDCl3): δ 167.1, 141.0, 135.3, 
133.2, 131.0, 128.5, 127.1, 124.0 and 40.2 ppm. C15H9Br2NO2 (MW 395.05). MS (m/z) 396.90 
(50%), 395.90 (10%), 394.90 (100%), 392.90 (50%). 
 
Synthesis of 4-(1,3-dioxoisoindolin-2-yl)benzaldehyde (37): Refluxed 4,4’-
(dibromomethyl)phenylphthalimide (28) in pyridine and water for 30 mins to get the 
corresponding ketone in quantitative yield. Selected 
1
H-NMR (CDCl3): δ 9.87 (1H, s), 7.85 (2H, 
m), 7.79 (2H, m), 7.72 (2H, d, J = 8.0 Hz), and 7.51 (2H, d, J = 8.0 Hz) ppm. 
13
C-NMR (CDCl3): 
δ 191.1, 170.0, 138.3, 133.2, 132.0, 129.5, 127.1 and 122.0 ppm.  
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Synthesis of ethyl 2-(4-(1,3-dioxoisoindolin-2-yl)phenyl)thiazolidine-4-carboxylate (38): 
Compound was synthesized in the same way as Ethyl-2-Phenylthiazolidine-4-carboxylate 18A. 
Compound was obtained as pale powder (Yield=82%). Selected 
1
H-NMR (400 MHz, CDCl3): δ 
7.85 (2H, m), 7.79 (2H, m), 7.29 (2H, d, J = 8.0 Hz), 7.09 (2H, d, J = 8.0 Hz), 4.95 (m, 1H), 4.12 
(m, 2H), 3.73 (m, 1H), 3.04 (m, 1H), 2.87 (m, 1H) and 1.30 (t, J=8.9, 3H) ppm. 
13
C-NMR (400 
MHz, CDCl3): δ 171.1, 170.0, 136.3, 133.2, 132.0, 129.5, 128.67, 127.1, 69.23, 62.26, 61.3, and 
61.5 ppm. 
 
Synthesis of (S)-2-amino-3-(benzylthio)propanoic acid (40): To a rapidly stirring solution of 
L-cysteine (5 gm, 41 mmol) in 25 mL of 2N sodium hydroxide, benzyl bromide (4.91 mL, 7.06 
gm, 41 mmol) in 48 mL ethanol was added. Reaction mixture was allowed to stir at rt for 30 
minutes. After which it was neutralized to pH 6-7 by careful addition of 5% HCl solution and 
cooled to get precipitate. Filtered, washed with water, ethanol and ether to give 8.1 gm of 
compound 47 (yield= 93%). Selected 
1
H-NMR (400 MHz, perdeuteriomethanol-trifluoroacetic 
acid): δ 7.3 (m, 5H), 6.8 (s, 2H), 4.06 (dd, J=7.2, 3.6 Hz, 1H), 3.75 (s, 2H), 3.05 (dd, J=14.4, 7.2 
Hz, 1H ) and 2.91 (dd, 1H, J=14.4, 3.6 Hz, 1H ) ppm; 
13
C-NMR (400 MHz, 
perdeuteriomethanol-trifluoroacetic acid): δ 174.79, 138.35, 128.69, 127.23, 57.75, 38.29 and 
35.53 ppm. 
 
S-Benzyl-L-cysteine ethyl ester hydrochloride (41): Dry HCl gas (prepared by carefully 
pouring dropwise fuming sulfuric acid over sodium chloride) was purged through a solution of S-
benzyl-L-cysteine HCl 47 (5.2 gm, 25 mmol) in ethanol 100 mL for 1 h, followed by refluxing 
25h. Solvent evaporated to dryness and the residue was purified by recrystallization from 
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absolute ethanol-ether (1 : 10) to afford 6.2 gm (Yield= 91%) of white powder as pure product, 
mp 152–154 °C, Lit. 155 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.88 (s, 3H, NH3
+
), 7.34 (s, 5H), 
4.20 (m, 3H ), 3.86 (s, 2H), 3.0 (d, J=9.8 Hz, 2H) and 1.23 (t, J=10.6 Hz, 3H) ppm. 
13
C-NMR 
(400 MHz, DMSO-d6): δ 172.03, 136.27, 128.98, 127.21, 61.23, 53.99,  39.12 and 15.28 ppm. 
 
Synthesis of monobromoarene, General procedure:  A mixture of methyl benzene derivative 
(5 mmol), N-bromosuccinamide (5 mmol), and benzoylperoxide (0.5 mmol) in benzene (10 ml) 
was refluxed under microwave heating (magnetron power 500W, magnetron power 200W with 
bead).  After reaction was completed solvent was evaporated to get a solid residue. This was 
dissolved in dichloromethane (100 ml) and washed with saturated sodium bicarbonate solution 
(3X15 ml) and water (3X15 ml).  Solvent was evaporated and the resulting solid residue was 
purified by silica gel column chromatography with hexane-dichloromethane as an eluent. 
 
4-(Bromomethyl)phenylphthalimide (44): Product was isolated as pale powder with isolated 
yield of 85%. 
1
H-NMR (CDCl3): δ 7.98 (2H, m), 7.80 (2H, m), 7.55 (2H, d, J = 8 Hz), 7.45 (2H, 
d, J = 8 Hz), and 4.55 (2H, s) ppm. 
13
C-NMR  (CDCl3): δ 167.1, 140.0, 138.2, 135.1, 132.0, 
130.2, 127.5, 124.3 and 33.0 ppm. C15H10BrNO2 (MW 316.15). MS (m/z) 317.99 (10%), 314.99 
(100%), and 316.99 (95%). 
 
 (S)-ethyl 2-amino-3-(4-(1,3-dioxoisoindolin-2-yl)benzylthio)propanoate (46): Same as 
compound 47. Isolated yield (69%). 
1
H-NMR (CDCl3): δ 7.88 (2H, m), 7.75 (2H, m), 7.44 (2H, 
d, J = 8Hz), 7.38 (2H, d, J = 8Hz), 4.25 (m, 2H), 3.76 (s, 2H), 3.45 (m, 1H), 3.17 (m, 1H), 2.97 
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(m, 1H) and 1.23 (t, J=10.6 Hz, 3H) ppm; 
13
C-NMR  (CDCl3): δ 171.02, 167.12, 133.02, 131.29, 
128.09,  121.45, 61.52, 54.22, 38.65, 35.89,  and 14.19 ppm. 
 
L-cysteine HCl tosylate salt (47): To the water (15 mL) solution of cysteine hydrochloride 
hydrate (7.88 g, 50 mmol), slowly added a solution of p-toluenesulfonic acid hydrate (11.41 g, 
60 mmol) in 5 mL of H2O. Allowed the reaction to stir at rt for 1h to recover white ppt as 
product. Filter ppt and dried under reduced pressure to give 12.3 gm, 90% yield of pure product 
51. Selected 
1
H NMR (D2O, 400 MHz): δ 7.57 (d, J = 6.6 Hz, 2 H), 7.25 (d, J = 7.8 Hz, 2 H), 
4.16 (dd, J = 5.4, 4.2 Hz, 1 H), 2.94-3.09 (m, 2 H) and 2.27 (s, 3 H) ppm. 
 
S-benzoyl-L-cysteine-tosylate salt (48): To a solution of 51 (0.1 gm, 0.25 mmol) in DCM, 
added benzoyl chloride (0.15, 0.25 mmol) and allowed to stir at room temperature for 20h. 
Solvent was evaporated under reduced pressure to get a ppt (0.15 mg, yield=89%) which was 
taken to the next step. Selected 
1
H NMR (D2O, 400 MHz): δ 7.88-7.59 (m, 5H), 7.34 (m, 2H), 
4.72 (m, 1H ), 3.86 (m, 1H), 3.75 (m, 1H) and 2.23 (s, 3H) ppm. 
 
(R)-3-(benzoylthio)-1-butoxy-1-oxopropan-2-aminium chloride (49): 
1
H NMR (CDCl3, 400 
MHz): δ 7.89 (m, 2H), 7.76-7.66 (m, 3H), 4.54 (t, J = 4.3, 1H), 4.32-4.26 (m, 1H), 4.23-4.18 (m, 
3H), 1.73 – 1.61 (m, 2H), 1.43-1.34 (m, 2H) and 0.93 (t, J = 7.4, 3H) ppm. 13C NMR (CDCl3, 
400 MHz): δ 191.2, 172.36, 134.89, 134.59, 130.02, 128.90, 64.98, 52.24, 31.34, 31.22, 18.79 
and 13.99 ppm. 
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(R)-1-butoxy-1-oxo-3-(tritylthio)propan-2-aminium chloride (50): L-Cysteine-O-butyl 
hydrochloride (0.5 gm, 2.15 mmol) and trityl chloride (0.601 gm, 2,15 mmol) were dissolved in 
6 mL of  trifluoroacetic acid obtaining a deep brown solution. Reaction mixture was allowed to 
stir at room temperature in an inert atmosphere. After this it was diluted with DCM (50 mL) and 
washed with water (2 X25 mL), dried over anhydrous sodium sulfate, solvent removed under 
reduced pressure. Product was obtained as sticky yellow substance (0.89 gm, yield=85%). 
Selected 
1
H NMR (400 MHz, CDCl3): δ 7.42-7.20 (m, 15H), 4.53 (t, J = 4.3, 1H), 4.08 (t, J = 
4.3, 2H), 3.63 (m, 1H), 3.36 (m, 1H), 1.73-1.61 (m, 2H), 1.43-1.34 (m, 2H), 0.93 (t, J = 7.4, 3H) 
ppm; 
13
C NMR (CDCl3, 400 MHz): δ 172.67, 143.99, 129.32, 128.20, 126.78, 67.34, 64.98, 
55.24, 31.14, 23.22, 18.79 and 13.99 ppm.  
 
4,4',4''-methanetriyltribenzenamine (54): Pararosaniline (100mg, 0.32mmol) was dissolved in 
10 mL ethanol. Sodium borohydride (0.32 mmol) was added to it and allowed to stir at room 
temperature for 2h. The solvent was removed. Crude product was dissolved in ethyl acetate (50 
mL) and washed with water, dried over sodium sulfate. Solvent removed under reduced pressure 
to get a light yellow product (yield= 57%). Selected 
1
H NMR (400 MHz, DMSO-d6): δ 6.85 (d, 
J= 7.89, 6H), 6.54 (d, J= 7.89, 6H) and 5.58 (s, 1H) ppm. 
13
C NMR (400 MHz, DMSO-d6): δ 
151.2, 135.67, 130.12, 115.87 and 54.67 ppm. 
 
2,2',2''-(4,4',4''-methanetriyltris(4,1-phenylene))triisoindoline-1,3-dione (56): The synthesis 
was done in the same way as for compound 27. Product isolated as yellow powder in the yield of 
80%. Selected 
1
H NMR (400 MHz, DMSO-d6): δ 7.88 (s, 12H), 7.24 (d, J= 12.89, 6H), 7.02 (d, 
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J= 12.89, 6H) and 5.45 (s, 1H) ppm. 
13
C NMR (400 MHz, DMSO-d6): δ 169.02, 134.21, 130.23, 
128.06, 127.54, 123.12 and 56.36 ppm. 
 
Synthesis of 1,1',1''-(4,4',4''-(hydroxymethanetriyl)tris(4,1-phenylene))tripyrrolidine-2,5-
dione (52): Procedure same as compound 27. Isolated as yellow powder (yield=76%).  Selected 
1
H NMR (400 MHz, DMSO-d6): δ 7.41 (m, 6H), 7.11 (m, 6H), and 2.90 (s, 6H) ppm. 
13
C NMR 
(400 MHz, DMSO-d6): δ 180.02, 140.51, 132.23, 128.61, 123.54, 81.08 and 27.67 ppm. 
 
Synthesis of butyl 2-amino-3-(tris(4-(2,5-dioxopyrrolidin-1-
yl)phenyl)methylthio)propanoate (53): Product isolated as a powder a yellow precipitate with 
an isolated yield of 35%. Selected 
1
H NMR (400 MHz, DMSO-d6) δ 7.34 – 7.09 (m, 12H), 4.36 
(s, 2H), 4.27 – 4.07 (m, 1H), 2.96 (d, J = 10.1, 2H), 2.79 (d, J = 7.6, 1H), 2.75 – 2.67 (m, 2H), 
1.48 (m, 1H), 1.33 (d, J = 7.1, 1H) and 1.02 – 0.76 (m, 1H) ppm. 13C NMR (400 MHz, DMSO-
d6): δ 177.25, 172.15, 140.04, 132.78, 127.84, 121.23, 67.45, 65.71, 54.67, 32.12, 30.06, 27.65, 
19.3 and 13.78 ppm 
 
General Procedure for Benzylation of Amino Acids : A solution of an amino acid, (S-tyrosine) 
(50.0 mmol) in 2 M NaOH (25 mL, 50.0 mmol) and a solution of CuSO4.5H2O (6.24 g, 25.0 
mmol) in water (25 mL) were mixed  together under stirring at room temperature. The blue 
precipitate of the Cu-complex separated immediately. After 1 h of reflux, the mixture was 
allowed to cool down to room temperature, and was dissolved in methanol (180 mL) and 2 M 
NaOH (25 mL, 50 mmol). Benzylbromide (6.25 mL, 52.5 mmol, 5 % excess) was added, and the 
mixture was stirred at room temperature overnight. The Cu-complex precipitate was collected, 
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washed with water and MeOH, stirred with 1 M HCl (100 mL) for 1 h to transform the Cu-
complex into hydrochloride. The precipitate was filtered, washed with water (125 mL) and 
treated with 1 M NH3 (2X100 mL) to remove HCl, again washed with water (125 mL)and 
acetone (60 mL), and dried. 
 
O-Benzyl-S-tyrosine (61): Benzylation of L-tyrosine was accomplished using the general 
procedure for benzylation of amino acids as described above to give the product as white powder 
( 5.2 gm, yield=73 %); m.p. 222 °C. Selected 
1
H NMR (DMSO-d6) δ 7.2–6.9 (m, 9H, Ph), 5.0 (s, 
2H),   4.4 (m, 1H) and 3.4–3.1 (m, 2H) ppm. 13C NMR (400 MHz, DMSO-d6) δ 175.07, 160.32, 
137.01, 133.05, 131.33, 131.08, 130.65, 128.17, 119.32, 74.81, 58.00 and 36.99 ppm. 
 
3-(4-(benzyloxy)phenyl)-2-(1,3-dioxoisoindolin-2-yl)propanoic acid (62): Procedure followed 
was the same as compound 27. Product was isolated as a white powder with a yield of 93%. 
Selected 
1
H NMR (400 MHz, CDCl3) δ 7.99 – 7.90 (m, 2H), 7.83 – 7.75 (m, 2H), 7.69 (t, J = 
6.3, 1H), 7.51 (d, J = 8.4, 2H), 7.44 (d, J = 8.2, 2H), 7.09 (d, J = 8.4, 2H), 6.81 (d, J = 8.5, 2H), 
5.11 (t, J = 10.4, 1H), 5.01 (s, 2H) and 3.63 – 3.39 (m, 1H) ppm. 13C NMR (400 MHz, CDCl3) δ 
175.12, 168.23, 156.98, 141.20, 133.23, 132.12, 129.18, 128.67, 127.67, 126.89, 126.12, 114.2, 
70.18, 56.25 and 34.21 ppm. 
 
Ethyl-3-(4-(benzyloxy)phenyl)-2-(1,3-dioxoisoindolin-2-yl)propanoate (63): Selected 
1
H 
NMR (400 MHz, CDCl3) δ 7.99 – 7.90 (m, 2H), 7.83 – 7.75 (m, 2H), 7.69 (t, J = 6.3, 1H), 7.51 
(d, J = 8.4, 2H), 7.44 (d, J = 8.2, 2H), 7.09 (d, J = 8.4, 2H), 6.81 (d, J = 8.5, 2H), 5.11 (t, J = 
10.4, 1H), 5.01 (s, 2H) and 4.25 (q, J = 9.3, 2H), 3.63 – 3.39 (m, 1H), and 1.26 (t, J = 7.1, 3H) 
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ppm. 
13
C NMR (400 MHz, CDCl3) δ 175.12, 168.23, 156.98, 141.20, 133.23, 132.12, 129.18, 
128.67, 127.67, 126.89, 126.12, 114.2, 70.18, 61.23, 56.25, 34.21 and 14.54 ppm. 
 
L-tyrosine-ethyl ester (64): L-tyrosine (0.01 mol) was taken in ethanolic hydrochloride (20 mL) 
and refluxed for 5h. The solvent was removed under reduced pressure to obtain pure product as 
white crystalline compound (yield quantitative). Selected 
1
H NMR (400 MHz, DMSO-d6) δ 7.12 
(d, J= 5.85, 2H), 6.89 (d, J= 5.85, 2H), 4.23 (q, J= 12.85, 7.65, 2H), 3.82 (m, 1H), 2.97-3.02 (m, 
2H) and 1.25 (t, J= 6.82, 3H) ppm. 
13
C NMR (400 MHz, DMSO-d6) δ 176.12,  153.87,132.16, 
128.87, 115.67, 61.32, 53.21, 39.82 and 12.31 ppm.   
 
2-(1,3-dioxoisoindolin-2-yl)-3-(4-hydroxyphenyl)propanoic acid (65): Synthesized using 
procedure for compound 24 and obtained in quantitative yield. Recrystallized from 
dichloroethane. 
1
H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 5.5, 2H), 7.70 (d, J = 5.4, 2H), 7.11 
(d, J = 8.3, 2H), 6.74 (d, J = 8.5, 2H), 3.99 – 3.70 (m, 2H) and 3.05 – 2.77 (m, 1H) ppm. 13C 
NMR (400 MHz, CDCl3) δ 176.2, 167.89, 154.23, 131.75, 130.28, 128.32, 127.12, 115.98, 56.12 
and 32.67 ppm.  
 
Ethyl 2-(1,3-dioxoisoindolin-2-yl)-3-(4-hydroxyphenyl)propanoate (66): Isolated as white 
powder in quantitative yield. Selected 
1
H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 5.5, 2H), 7.70 
(d, J = 5.4, 2H), 7.11 (d, J = 8.3, 2H), 6.74 (d, J = 8.5, 2H), 4.23 (q, 2H), 3.99 – 3.70 (m, 2H), 
3.05 – 2.77 (m, 1H) and 1.35 (t, 3H) ppm. 13C NMR (400 MHz, CDCl3) δ 176.2, 167.89, 154.23, 
131.75, 130.28, 128.32, 127.12, 115.98, 62.24, 56.12, 42.67 and 32.67 ppm.  
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2-(1,3-dioxoisoindolin-2-yl)-3-(4-(methoxycarbonyloxy)phenyl)propanoic acid (68): 
Compound was isolated as pale powder (yield=95%). Selected 
1
H NMR (400 MHz, CDCl3) δ 
7.83 (d, J = 5.5, 2H), 7.70 (d, J = 5.4, 2H), 7.11 (d, J = 8.3, 2H), 6.74 (d, J = 8.5, 2H), 3.21(m, 
1H), 2.99 (m, 1H) and 3.38 (s, 3H) ppm. 
13
C NMR (400 MHz, CDCl3) δ 176.2, 167.89, 154.23, 
131.75, 130.28, 128.32, 127.12, 115.98, 58.23, 56.12 and 32.67 ppm. 
 
Ethyl 2-(1,3-dioxoisoindolin-2-yl)-3-(4-(methoxycarbonyloxy)phenyl)propanoate (69): 
Isolated in quantitative yield. Selected 
1
H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 5.5, 2H), 7.70 
(d, J = 5.4, 2H), 7.11 (d, J = 8.3, 2H), 6.74 (d, J = 8.5, 2H), 4.22 (q, 2H), 3.21(m, 1H), 2.99 (m, 
1H), 3.38 (s, 3H) and 1.25(t, 3H) ppm. 
13
C NMR (400 MHz, CDCl3) δ 176.2, 167.89, 154.23, 
131.75, 130.28, 128.32, 127.12, 115.98, 62.23, 58.23, 56.12, 32.67 and 14.23 ppm. 
 
Ethyl 2-(1,3-dioxoisoindolin-2-yl)-3-(4-(4-(1,3-dioxoisoindolin-2-
yl)benzyloxy)phenyl)propanoate (67): Yield (78%). Selected 
1
H NMR (400 MHz, CDCl3) δ 
7.85 (d, J = 8.5, 2H), 7.72 (d, J = 8.5, 2H),  7.35 (d, J = 10.5, 2H), 7.19 (d, J = 10.5, 2H),  7.11 
(d, J = 10.3, 2H), 6.74 (d, J = 10.5, 2H), 5.15 (s, 2H), 4.82(m, 1H), 4.22 (q, 2H), 3.23(m, 1H), 
2.97 (m, 1H), and 1.32 (t, J = 15.5, 3H) ppm. 
13
C NMR (400 MHz, CDCl3) δ 168.2, 167.12, 
156.85, 136.87, 132.00, 131.78, 131.16, 130.28, 128.72, 127.61, 127.06, 121.78, 114.25, 70.08, 
62.23, 53.23, 32.67 and 14.23 ppm. 
  
2-(1,3-dioxoisoindolin-2-yl)-3-(4-(4-(1,3-dioxoisoindolin-2-yl)benzyloxy)phenyl)propanoic 
acid (70): Yield (75%). Selected 
1
H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 8.5, 2H), 7.72 (d, J 
= 8.5, 2H),  7.35 (d, J = 10.5, 2H), 7.19 (d, J = 10.5, 2H),  7.11 (d, J = 10.3, 2H), 6.74 (d, J = 
194 
 
10.5, 2H), 5.15 (s, 2H), 4.82(m, 1H), 3.23(m, 1H) and 2.97 (m, 1H) ppm. 
13
C NMR (400 MHz, 
CDCl3) δ 168.2, 167.12, 156.85, 136.87, 132.00, 131.78, 131.16, 130.28, 128.72, 127.61, 127.06, 
121.78, 114.25, 70.08, 53.23 and 32.67 ppm. 
 
2-(1,3-dioxoisoindolin-2-yl)-2-phenylacetic acid (72): The compound was isolated as white 
powder in quantitative yield. Selected 
1
H NMR (400 MHz, CDCl3) δ 7.75 (m, 2H), 7.62 (m, 2H), 
7.35 (d, J = 9.63, 2H), 7.21 (d, J = 9.65, 2H) and 5.47 (m, 1H) ppm. 
13
C NMR (400 MHz, 
CDCl3) δ 172.21, 170.02, 133.45, 129. 56, 128.67, 127.12 and 57.78 ppm 
 
3-(2-(1,3-dioxoisoindolin-2-yl)-2-phenylacetyl)-2,2-dimethylthiazolidine-4-carboxylic acid 
(74): Yield (54%). Selected 
1
H NMR (400 MHz, DMSO-d6) δ 7.78 (m, 5H), 7.35 (m, 2H), 7.21 
(t, 1H), 7.08 (m, 2H), 5.45 (s, 1H), 4.75 (m, 1H), 3.05 (m, 1H), 2.91 (m, 1H) and 1.61 (s, 6H) 
ppm. 
13
C NMR (400 MHz, DMSO-d6) δ 175.23, 169.12, 168.45, 131.89, 132.56, 127.89, 127.34, 
65.42, 61.89, 53.23, 31.25 and 26.75 ppm. 
 
Ethyl 3-(3-(4-acetoxyphenyl)-2-(1,3-dioxoisoindolin-2-yl)propanoyl)-2,2-
dimethylthiazolidine-4-carboxylate (110): Yield 58%. Selected 
1
H NMR (400 MHz, CDCl3): δ 
7.86 (d, J= 9.23 Hz, 2H), 7.54 (d, J= 9.23 Hz, 2H), 7.09 (m, 2H), 7.01 (m, 2H), 5.02 (m, 1H), 
4.71 (m, 1H), 4.24 (q, 2H), 3.58 (m, 1H), 3.32 (m, 1H), 3.12 (m, 1H), 2.89 (m, 1H), 2.29 (s, 3H), 
1.61 (s, 6H) and 1.30 (t, 3H) ppm.   
13
C NMR (400 MHz, CDCl3): δ 172.51, 169.00, 168.12, 
167.12, 148.56, 137.18, 132.23, 131.90, 128.12, 127.56, 121.45, 62.32, 61.29, 61.35, 52.45, 
35.67, 30.45, 27.91, 20.81 and 14.51 ppm. 
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Butyl 2-(3-(4-acetoxyphenyl)-2-(1,3-dioxoisoindolin-2-yl)propanamido)-3-
(tritylthio)propanoate (111): Yield (62%). Selected 
1
H NMR (400 MHz, CDCl3): δ 7.86 (d, J= 
10.52, 2H), 7.54 (d, J= 10.52 Hz, 2H), 7.01-7.21 (m, 19H), 4.90 (m, 1H), 4.70 (m, 1H), 4.08 (t, 
J=8.25 Hz, 2H), 3.52 (m, 1H), 3.32 (m, 1H), 3.15 (m, 1H), 2.95 (m, 1H), 2.35 (t, J=15.25 Hz, 
2H), 1.57 (m, 2H), 1.33 (m, 2H) and 0.98 (t, J=15.25 Hz, 3H) ppm. 
13
C NMR (400 MHz, 
CDCl3): δ 172.12, 171.25, 169.02, 167.89, 148.25, 142.23, 136.78, 131.45, 128.98, 128.12, 
127.89, 127.15, 126.31, 122.50, 67.84, 64.79, 54.23, 53.12, 34.68, 31.12, 27.89, 20.13, 18.78 and 
13.23 ppm. 
 
Ethyl 2-(3-(4-acetoxyphenyl)-2-(1,3-dioxoisoindolin-2-yl)propanamido)-3-
(benzylthio)propanoate (112): Yield 62%. Selected 
1
H NMR (400 MHz, CDCl3): δ 7.86 (d, J= 
10.52, 2H), 7.54 (d, J= 10.52 Hz, 2H), 7.29-7.24 (m, 3H), 7.18-7.06 (m, 6H),  4.90 (m, 1H), 4.70 
(m, 1H), 3.53 (m, 1H), 3.25 (m, 1H), 3.16 (m, 1H), 2.98 (m, 1H), 1.57 (m, 2H) and 1.33 (m, 3H) 
ppm. 
13
C NMR (400 MHz, CDCl3): δ 172.10, 171.26, 169.02, 167.89, 148.25, 142.23, 136.78, 
131.45, 128.98, 128.12, 127.89, 127.15, 126.31, 122.50, 67.84, 54.23, 53.12, 34.68, 31.12, 27.89, 
and 14.23 ppm. 
 
Butyl 2-(3-(4-acetoxyphenyl)-2-(isoindolin-2-yl)propanamido)-3-(tris(4-(2,5-
dioxopyrrolidin-1-yl)phenyl)methylthio)propanoate (113): Yield (71%): Selected 
1
H NMR 
(400 MHz, DMSO-d6): δ 7.34 – 7.01 (m, 12H), 4.66 (m, 1H), 4.18 (t, J=7.29, 2H), 3.98 (m, 1H),  
3.25 (m, 1H), 3.05 (m, 2H), 2.98 (m, 2H), 2.92 (d, J = 10.1, 2H), 2.32 (s, 3H), 1.57 (m, 2H), 1.35 
(m, 2H) and 0.93 (t, J = 15.23, 3H) ppm.
 13
C NMR (400 MHz, DMSO-d6): δ 177.23, 171.89, 
171.25, 168.98, 168.0, 148.25, 139.51, 135.81, 132.67, 132.02, 131.98, 128.1, 127.12, 122.24, 
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121.54,  68.19, 64.87, 54.35, 53.76, 34.81, 31.12, 27.89, 27.16, 21.02, 20.35, 18.50 and 12.87 
ppm. 
 
General Procedure for Preparation of S-Acylcysteines: L-cysteine hydrochloride 1 (2 mmol) 
solution in H2O (3 mL) was added to a solution of the corresponding acid chloride of substrate (2 
mmol) in CH3CN (15 mL). The heterogeneous mixture was allowed to stir at room temperature 
for 18 h. Now the solid residue was filtered off, washed with water (3 X10 mL), dichloroethane 
(3 X10 mL), diethyl ether (3 X10 mL). The compound was completely dried under reduced 
pressure and vacuum to yield S-acylcysteine. 
 
S-(Benzoyl)-L-cysteine hydrochloride (91): Obtained as white precipitate in a yield of 65%; 
Selected 
1
H NMR (400 MHz, TFA-DMSO-d6): δ 8.64-8.66 (m, 2H), 8.45 (t, J=9.25 Hz, 1H), 
8.20 (t, J=7.62 Hz, 2H), 5.56-5.57 (m, 1H), 4.73 (dd, J = 15.5, 4.2 Hz, 1H) and 4.47 (dd, J = 
15.5, 3.8 Hz, 1H) ppm. 
13
C NMR (400 MHz, TFA-DMSO-d6): δ 201.01, 172.98, 138.7, 137.5, 
132.00, 130.12, 57.65 and 30.78 ppm. 
 
General Procedure for Preparation of N-Acylcysteines:  L-cysteine hydrochloride 1 (2 mmol) 
and triethylamine (2 mmol) solution was prepared in CH3CN (8 mL) and the corresponding acid 
chloride substrate was added to this mixture. After allowing the mixture to stir at room 
temperature from 2-5h solvent was removed under reduced pressure and diluted with ethyl 
acetate (10 mL). Ethyl acetate layer was washed with 2 N HCl and brine. Solvent was removed 
under reduced pressure and recrystallized (AcOEt:hexanes = 3:1) to get N-acylcysteines. 
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N-(Benzoyl)-L-cysteine (92): Obtained as a colorless oily compound (Yield=65%) 
1
H NMR 
(400 MHz, DMSO-d6) δ 8.61 (br s, 1H), 7.78-7.85 (m, 2H), 7.41-7.58 (m, 3H), 7.20 (d, J=6.9 
Hz, 1H), 5.06-5.14 (m, 1H), 3.10-3.28 (m, 2H) and 1.54 (t, J = 9.0 Hz, 1H) ppm. 
13
C NMR (400 
MHz, DMSO-d6) δ 173.12, 168.45, 131.98, 129.02, 128.90, 127.71, 127.62, 127.52, 54.21 and  
26.78 ppm.  
 
General Procedure for Cysteinyl peptide Zinc complex: A solution of Cysteine coupled 
substrate (0.01 mol) and NaOH (0.02 mol) in water (100 mL) was mixed with zinc acetate (0.01 
mol). The mixture sonicated for 8h. At this point product was isolated as white precipitate. It was 
washed with water (3 X100 mL) and acetone (3 X100 mL) and finally dried under vacuum to get 
white precipitate as product.  
 
N-(Benzoyl)-L-cysteine zinc dihydrate (93):  Yield (72%). Selected 
1
H NMR (400 MHz, TFA-
DMSO-d6) δ 8.78 (br s, 1H), 7.85 (m, 2H), 7.70 (m, 2H), 7.50 (d, J= 16.9 Hz, 1H), 4.82 (m, 1H) 
and 3.02-3.21 (m, 2H) ppm. 
13
C NMR (400 MHz, TFA- DMSO-d6) δ 175.02, 169.15, 132.09, 
130.02, 128.95, 127.72, 127.42, 127.12, 54.42 and 26.54 ppm.  
 
1-carboxy-2-(2-(1,3-dioxoisoindolin-2-yl)-2-phenylacetylthio)ethanaminium chloride (94): 
Yield= 72%. Selected 
1
H NMR (400 MHz, TFA-DMSO-d6) δ 7.76 (m, 2H), 7.69 (m, 2H), 7.35 
(m, 1H), 7.25 (m, 2H), 7.02 (m, 2H), 5.65 (s, 1H), 4.82 (m, 1H) and 3.02-3.21 (m, 2H) ppm. 
13
C 
NMR (400 MHz, TFA- DMSO-d6) δ 198.12, 175.02, 168.15, 135.09, 130.02, 129.3, 128.65, 
127.72, 127.42, 65.72, 54.42 and 31.23 ppm.  
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2-(2-(1,3-dioxoisoindolin-2-yl)-2-phenylacetamido)-3-mercaptopropanoic acid (95): Yield= 
72%. Selected 
1
H NMR (400 MHz, TFA-DMSO-d6) δ 7.76 (m, 2H), 7.70 (m, 2H), 7.31 (m, 1H), 
7.25 (m, 2H), 7.04 (m, 2H), 5.82 (s, 1H), 4.82 (m, 1H) and 3.17-2.98 (m, 2H) ppm. 
13
C NMR 
(400 MHz, TFA- DMSO-d6) δ 175.02, 169.21, 168.24, 136.71, 132.35, 131.02, 129.78, 129.06, 
127.72, 127.32, 57.72, 55.42 and 26.23 ppm. 
 
2-(2-(1,3-dioxoisoindolin-2-yl)-2-phenylacetamido)-3-mercaptopropanate zinc dihydrate 
(96):  Yield=75%. Selected 
1
H NMR (400 MHz, TFA-DMSO-d6) δ 7.78 (m, 2H), 7.72 (m, 2H), 
7.51 (m, 1H), 7.28 (m, 2H), 7.04 (m, 2H), 5.81 (s, 1H), 4.81 (m, 1H) and 3.17-2.98 (m, 2H) ppm. 
13
C NMR (400 MHz, TFA- DMSO-d6) δ 175.02, 169.21, 168.24, 136.71, 132.35, 132.02, 
129.76, 129.13, 127.72, 127.35, 60.72, 55.45 and 20.23 ppm. 
 
2-(3-(4-acetoxyphenyl)-2-(1,3-dioxoisoindolin-2-yl)propanoylthio)-1-carboxyethanaminium 
chloride (97):  Yield=71%. Selected 
1
H NMR (400 MHz, TFA-DMSO-d6) δ 7.78 (m, 2H), 7.72 
(m, 2H), 7.12 (d, J=6.82 Hz, 2H), 7.02 (d, J=6.82 Hz, 2H), 4.87 (m, 1H), 4.56 (m, 1H), 3.85 (m, 
1H), 3.67 (m, 1H), 3.32 (m, 1H), 3.08 (m, 1H) and 2.31 (s, 3H) ppm. 
13
C NMR (400 MHz, TFA- 
DMSO-d6) δ 202.12, 173.52, 170.12, 168.23, 149, 136.24, 132.32, 132, 128, 127.6, 121.45, 65, 
54.42, 35.27, 30.09 and 21.37 ppm. 
 
2-(3-(4-acetoxyphenyl)-2-(1,3-dioxoisoindolin-2-yl)propanamido)-3-mercaptopropanoic 
acid (98): Yield=65%. Selected 
1
H NMR (400 MHz, TFA-DMSO-d6) δ 7.78 (m, 2H), 7.75 (m, 
2H), 7.10 (d, J=8.85 Hz, 2H), 7.00 (d, J=8.82 Hz, 2H), 4.89 (m, 1H), 4.75 (m, 1H), 3.58 (m, 1H), 
3.45 (m, 1H), 3.17 (m, 1H), 3.01 (m, 1H) and 2.32 (s, 3H) ppm. 
13
C NMR (400 MHz, TFA- 
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DMSO-d6) δ 175.52, 171.12, 169.38, 168.23, 148.72, 136.24, 132.25, 132.12, 128.21, 127.16, 
121.45, 57.42, 34.92, 27.09 and 20.31 ppm. 
 
2-(3-(4-acetoxyphenyl)-2-(1,3-dioxoisoindolin-2-yl)propanamido)-3-mercaptopropanoate 
Zinc dihydrate (99): Yield=70%. Selected 
1
H NMR (400 MHz, TFA-DMSO-d6) δ 7.82 (m, 
2H), 7.78 (m, 2H), 7.12 (d, J=10.12 Hz, 2H), 7.00 (d, J=12.65 Hz, 2H), 5.02 (m, 1H), 4.86 (m, 
1H), 3.68 (m, 1H), 3.52 (m, 1H), 3.15 (m, 1H), 3.12 (m, 1H) and 2.45 (s, 3H) ppm. 
13
C NMR 
(400 MHz, TFA- DMSO-d6) δ 182.52, 172.12, 170.38, 169.23, 148.86, 136.42, 132.51, 132.27, 
128.25, 127.16, 121.45, 58.42, 34.92, 27.58 and 21.31 ppm. 
 
1-carboxy-2-(2-(1,3-dioxoisoindolin-2-yl)-3-(4-(1,3-dioxoisoindolin-2-
yl)phenyl)propanoylthio)ethanaminium chloride (100): Yield=60%. Selected 
1
H NMR (400 
MHz, TFA-DMSO-d6) δ 7.78 (m, 4H), 7.72 (m, 4H), 7.15 (m, 2H), 7.04 (m, 2H), 4.86 (m, 1H), 
4.54 (m, 1H), 3.86 (m, 1H), 3.67 (m, 1H), 3.32 (m, 1H) and 3.08 (m, 1H) ppm. 
13
C NMR (400 
MHz, TFA- DMSO-d6) δ 200.12, 174.54, 171.21, 169.45, 150.23, 137.44, 133.78, 131.21, 
127.82, 127.54, 121.52, 66.75, 54.42, 36.17 and 31.09 ppm. 
 
2-(2-(1,3-dioxoisoindolin-2-yl)-3-(4-(1,3-dioxoisoindolin-2-yl)phenyl)propanamido)-3-
mercaptopropanoic acid (101): Yield=60%. Selected 
1
H NMR (400 MHz, TFA-DMSO-d6) δ 
7.74 (m, 4H), 7.62 (m, 4H), 7.12 (m, 2H), 7.04 (m, 2H), 4.74 (m, 1H), 4.41 (m, 1H), 3.85 (m, 
1H), 3.62 (m, 1H), 3.21 (m, 1H) and 3.04 (m, 1H) ppm. 
13
C NMR (400 MHz, TFA- DMSO-d6) δ 
192.25, 175.54, 171.12, 169.35, 151.23, 136.54, 133.58, 130.32, 127.92, 127.52, 121.6, 65.75, 
56.42, 34.17 and 29.09 ppm. 
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2-(2-(1,3-dioxoisoindolin-2-yl)-3-(4-(1,3-dioxoisoindolin-2-yl)phenyl)propanamido)-3-
mercaptopropanoate Zinc dihydrate (102): Yield=72%. Selected 
1
H NMR (400 MHz, TFA-
DMSO-d6) δ 7.78 (m, 4H), 7.67 (m, 4H), 7.21 (m, 2H), 7.02 (m, 2H), 4.98 (m, 1H), 4.45 (m, 
1H), 3.9 (m, 1H), 3.67 (m, 1H), 3.3 (m, 1H) and 2.93 (m, 1H) ppm. 
13
C NMR (400 MHz, TFA- 
DMSO-d6) δ 195.5, 178.41, 172.2, 168.35, 152.23, 136.49, 132.58, 130.32, 128.12, 127.62, 
122.6, 66.75, 55.42, 34.72 and 30 ppm. 
 
A007-cysteine adduct ( 107): 
1
H NMR (400 MHz, DMSO-d6) δ 11.14 (s, 1H), 8.81 (s, 1H), 
8.42 (s, 1H), 8.21 (d, J = 9.6, 1H), 7.52 (s, 2H), 7.40 (s, 2H), 7.18 (d, J = 8.0, 2H), 6.95 (d, J = 
11.6, 2H), 5.30 (s, 4H), 4.91 (m, 1H), 4.60 (t, J = 23.4, 4H), 4.13 (d, J = 30.0, 4H), 3.65 (s, 3H), 
3.01 (d, J = 5.5, 1H), 2.83 (d, J = 22.7, 1H), 1.76 (s, 12H) and 1.29 – 1.07 (m, 3H) ppm. 
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CHAPTER-4: SYNTHESIS OF NOVEL PROTECTIVE GROUPS FOR AMINO ACIDS 
 
In the course of synthesis of cysteinyl peptides, several problems emerged while 
protecting the hydroxyl, sulfur and amino groups of the L-amino acids selected for peptide 
synthesis. Although there are several reported protective groups in literature. When applied in 
our peptide synthetic scheme they did not yield the desired results. In our pursuit to synthesize 
novel radical capture cysteinyl compounds (as described in chapter 3) we desired to trap the free 
β-sulfhydryl and α-carboxy functional group of L-cysteine hydrochloride by complexing with 
metals like zinc, calcium and magnesium. These on entering the body would liberate free 
sulfhydryl group that can act as a radical scavenger. Peptide synthesis by coupling the N-terminal 
of L-cysteine to carboxy terminal of the other amino acid like L-tyrosine presented problems in 
terms of racemization, yields and non-reproducibility of synthetic method when using the 
commonly used protective groups for our peptide synthesis. In the last few years, more than 250 
protecting groups have been proposed as suitable for peptide synthesis
1
; however, a relatively 
small number of those are actually used because of the stringent requirements that a protecting 
group should meet, particularly with respect to the requirement of the preservation of other 
functionalities and stereochemistry.  
 
4.1. Cyclic imides  
Imide derivatives constitute an important class of organic compounds with numerous 
uses in biology
2
, synthetic chemistry
3
, nanomaterials
4
 and polymer chemistry
5
. For instance, 
cyclic imides, particularly phthalimides, have been widely used as amino acid protective group
6
 
and have attracted considerable attention in peptide chemistry
7
. The relatively easy cleavage of 
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the phthaloyl group under mild condition makes it suitable as a protective group for the peptide 
synthesis
9
. Phthalimides are a subject of widespread interest
11
 because of their interesting 
photophysical properties, which is still not completely understood
12
, and their applications as 
fluoroprobes
11
 and in synthetic chemistry. Phthalimide derivatives undergo various 
photochemical reactions that have attracted a lot of attention in recent years
10
. On the other hand, 
maleimides and succinimides are important constituents of peptide-conjugate haptens, antibody–
antibody conjugates, immune conjugates, and enzyme inhibitors
8
. 
Phthalimide derivatives are reported to have local anesthetic properties comparable to 
Novesine by Settimo et al
13
.  Among other biological activities are DNA cleaving agents
14
 and 
tumericidal activity
15
. Pyromellitic dianhydride is an analogous compound, which undergoes 
facile polymerization reaction with diamines to give amide or imides containing polymers. Its 
relevance and application in nanomaterials has been studied by Holman et al
16
. Several 
phthalimides derivatives can self-assemble to form nano-tube like structures
17
 and have 
interesting host to guest chemistry which is being investigated
18
.  Another important amino acid 
phthaloyl derivative N-phthaloylglycine, a simple N-protected amino acid, has interesting 
supramolecular structural features on forming metal complexes
20
. Owing to the great importance 
of amino acids in physiological and pharmacological processes and biological interactions
19
 and 
their importance in peptide synthesis, it is desired to find a simple, moderate, clean and 
convenient method for preparation of N-phthaloyl amino acid derivatives. The present work 
represents the synthesis of N-phthaloyl amino acids and their derivatives under mild conditions 
using microwave irradiation as a rapid, convenient method to give excellent yields and high 
purity of the products compared to conventional methods. The synthesized cyclic imide 
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derivatives were successfully used for protection of several amino acids and explored for peptide 
synthesis.  
 
4.2. Cyclic imide Synthesis 
Despite the wide applicability of cyclic imides, available routes for their synthesis are 
limited. Generally, most methods involve Lewis acid mediated condensation of an amine with 
maleic or phthalic anhydrides
21
. These methods are limited by low yields, by-product formation 
and harsh reaction conditions
22
. The development of simple and general synthetic routes for 
widely used organic compounds from readily available reagents is one of the major challenges in 
organic synthesis. Among the widely used method are the dehydrative condensation of an 
anhydride and an amine at high temperature
2
 and the cyclization of the amic acid
23,24
 in the 
presence of acidic reagents are the typical methods of choice
25
. The direct N-alkylation of 
maleimide with alcohols under Mitsunobu reaction conditions is an alternative method for the 
synthesis of imide derivatives in reasonably good yield
26
. However, each of these routes has its 
own synthetic problems when applied to a range of derivatives. For instance, synthesis of 
functionalized maleimide derivatives either by the direct condensation or through the 
intermediate amic acid cyclization method gives poor yields of the desired maleimide 
derivatives. Although the amic acid formation proceeds in quantitative yield, the subsequent 
cyclization results in only low yields of the desired maleimide derivatives together with 
extensive byproducts due to the incompatibility of the olefin functionality with harsh reaction 
conditions
27
. Similarly, in the Mitsunobu reaction only a narrow range of imide derivatives can 
be synthesized because alkanols are used as starting materials
28
. Recently, a solvent-free 
procedure using TaCl5 +silica gel as catalyst has been described for the preparation of imides 
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under microwave irradiation
39
. Finally, Sandhu et al.
 40
 advocated the use of a more ecofriendly 
solvent-free system involving the reaction of equal amounts of anhydride and amines or amino 
acids in the absence of solvent in a domestic oven without any catalyst. In the case of the 
reaction of the anhydride with amino acids, a reaction between two solids was involved, for 
example between phthalic anhydride and glycine. Unfortunately, no temperature measurements 
were reported. Therefore, synthesis of functionalized imide derivatives is still a challenging 
endeavor. We describe herein an efficient and mild approach for the synthesis of imide 
derivatives of amino acids. These can be used as protection groups for peptide synthesis or 
exploration of other properties and activities. The development of environmentally friendly 
processes and economic reactions has attracted much attention of chemists
23
. Phthalimides 
exhibits a number of applications in biology and synthetic chemistry
29
. The easy cleavage of the 
phthaloyl group under mild condition makes it suitable as a protecting group for the amino 
group
9
. However, simple, efficient and environmentally benign processes are not available. 
Furthermore, in previously described procedures, amino acids with functionalized side chains, 
such as tryptophan and tyrosine, failed to give phthaloyl derivatives in good yields and in 
satisfactory purity. The use of phthaloyl moiety as a primary amine-protecting group is 
extensively documented in the literature
6b
. Several investigators have synthesized phthaloyl 
amino acids. The use of this protective group has not been practical in some sensitive substrates 
due to harsh conditions involved for protection and deprotection steps.  
Billman and Harting
30
 and Sheehan and Frank
31
 obtained N-phthaloyl amino acids by 
heating mixtures of phthalic anhydride and appropriate amino acids at high temperatures. This 
resulted in racemization
32
 as the experimental conditions were too drastic for N-phthaloylation of 
amino acids specially the ones containing additional functional groups
33
 like tryptophan and 
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tyrosine. Sheehan and Frank
31  
 prepared N-phthaloyl amino acids
 
by fusion methods in good 
yields for some cases but in others, the reaction conditions were too drastic. In order to control 
the temperature it is possible to perform reaction in the presence of boiling solvents like dioxane, 
pyridine or acetic acid, but then the reaction time is often too long. Balenovic et al.
33
 used O-
carboethoxythiobenzoic acid in their N-phthaloylation of amino acids. However, applications of 
this procedure are limited because the preparation of the reagent and the reaction procedure are 
laborious and the yields are very low. Phthaloyl amino acid esters, which on acid hydrolysis
31
 
can be converted into phthaloyl amino acids, are prepared more easily. However, the synthesis is 
carried out in two steps. First, a phthalimic acid derivative is obtained by reaction of phthalic 
anhydride and amino acid ester. The resulting compound was converted into N-phthaloyl amino 
acid esters with thionyl chloride
34
 or a mixed anhydride
35
. In a modification of this method Bose, 
Greer and Price
36 
obtained phthaloyl amino acid esters by heating an amino acid ester with 
phthalic anhydride in an inert solvent like benzene for several hours. The water formed in the 
dehydration of intermediate was collected in a separator. However, diketopiperazines was 
formed as by-products of this reaction. Nefkens et al.
37 
reported N-phthaloylation by using N-(O-
ethoxycarbonyl)phthalimide in aqueous sodium carbonate. It was claimed to be a simple 
preparation of phthaloyl amino acids and led to retention of chirality and high yields. However, 
their method failed in the case of tryptophan and diferent yields
38
 were reported by other 
investigators in number of cases. Other investigations have been carried out in order to establish 
optimal reaction conditions, but the reported procedures do not seem to be satisfactory.  
In order to obtain high yields without racemization it seems necessary to affect the 
synthesis of the phthaloylamino acids and their intermediate N-substituted phthalamic acids in 
solution and at moderate temperatures. The synthetic challenge is to selectively protect and 
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deprotect the side chain functional groups under mild conditions without racemization in an 
effective and efficient manner that is industrially viable. Therefore, we explored a rapid and one 
pot synthesis of phthaloyl derivatives of α-amino carboxamides under microwave irradiation. In 
this work, we report about an efficient and green process for the production of N-phthaloyl 
amino acids by fusing free amino acids or their esters with phthalic anhydride. We improved the 
fusion process, described earlier by Billman and Harting
30
, by using microwave irradiation using 
a suitable solvent. The microwave reaction offered several advantages over the convention 
phthaloylation methods. Microwave reaction did not required any pressure to remove water 
instead exposing the reaction for 1-2 minutes can actually help get rid of water.  The reaction did 
not have to be heated at high temperatures for long hours that lead to racemization. Microwave 
reaction usually provided the product in pure form and when required product was further 
purified by crystallization or a silica gel column using EtOAc-Hexane. The yield were almost 
quantitative and conversion happened in less than 30 minutes in most cases thus avoiding long 
heating exposures and any formation of undesired impurities. N-Phthaloylation of tryptophan 
was always difficult, because of the instability of the side chain. However, in our new procedure 
tryptophan was phthaloylated in good yields. L-Tyrosine and it ester derivatives were turned into 
the corresponding N-phthaloyl derivative in almost quantitative yield and high purity, which 
could not be obtained by Bose’s procedure36. The fact that phthalic anhydride is contaminated 
with phthalic acid and could have adverse effect on amino acid phthaloylation was studied by 
Zeng et al
41
. We did not observe any adverse effect of presence phthalic acid. It is speculated 
that if any phthalic acid was present as contamination in the reaction mixture it would have been 
easily dehydrated to phthalic anhydride under microwave irradiation. Therefore, there was no 
interference observed by phthalic acid if it was present during the course of reaction.  
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Several parameters have been used to deal with protecting group during peptide-coupling 
reactions. A key issue is the use of appropriate N-protecting groups, such as the carbamate [tert-
butyloxycarbonyl (Boc, 1)
42
, benzyloxycarbonyl (Cbz, Z, 2)
43
, 9-fluorenylmethy-loxcarbonyl 
(Fmoc, 3)
44
, or the recent type of base-sensitive amino protecting groups 1,1- 
dioxobenzo[b]thiophene-2-ylmethyloxycarbonyl (Bsmoc,4)
45
, 2-(tert-butylsulfonyl)-2-
propyloxycarbonyl (Bspoc, 5a)
46
, and 2- methylsulfonyl- 3-phenyl-1-prop-2-enyloxycarbonyl 
(Mspoc, 5b)
47
 (Fig.4.1).  
 
 
Figure 4.1 Structures of Protective Groups. 
 
It is rarely mentioned about the N-Phthaloyl group in peptide synthesis, but it is very useful for 
synthesis
46 
and other application, because it can be easily removed by aqueous HBr
47 
or 
hydrazine in ethanol
48
. But this might not be a suitable deprotection condition for some longer 
peptide synthesis. Although the wide application of microwave-mediated synthesis of organic 
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compounds, only very little work appeared about N-phthaloylamino acids. Inspection in the 
literature cites two works where phthalic anhydride couples with amino acids under microwave-
mediated conditions. In 1995 Bose et al.
49
 reported that N-phthaloylamino acids could be 
synthesized within few minutes in good yields using microwave irradiation in DMF. Vidal et 
al.
50
 reported examination of the latter technique for synthesis of phthalimides, among them 
phthaloylglycine which was obtained in 90 and 81% yields in xylenes and DMF, respectively. 
However, at the end of irradiation of these syntheses, the products are usually extracted with 
acetone. Here we re-examined this non-thermal methodology under solvent conditions for the 
preparation of N-phthaloyl- amino acids and their esters. We applied this procedure for the 
synthesis of target compounds, which proved to give excellent yields in short time reactions, 
while using conventional method takes 10–15h reflux in acetic acid or DMF. The synthetic 
pathway depicted in Scheme 4.1 outlines the chemistry of the present study. Full characterization 
of the synthesized compounds was based on the spectral data, particularly 
1
H and 
13
C NMR. 
 
 
Scheme 4.1 Microwave assisted N-phthaloylation of amino acids. 
 
 
 
O
O
O
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6 7 8
 
217 
 
Table 4.1 N-Phthaloylated amino acids 
 
Product 
No. 
Amino acid N-phthaloylation 
Microwave Conventional 
Time 
(mins) 
Yield 
(%) 
Time 
(hours) 
Yield 
(%) 
9. 
Ph
NH3
+Cl-
COOH
 
Ph
N
HOOC
O
O  
20 95 15 51 
10. 
NH2
O OH
 
N
O OH
O
O  
15 96 12 80 
11. 
H2N
OHOHO  
N
OHOHO
O
O
 
15 100 15 86 
12. 
NH2
O
NaO
O
OH
 
N
O
O
COOH
COONa
 
10 90 10 60 
13. 
SH
NH2
O
OBu
HCl
 
S N
O
OBu
SN
O
BuO
O
O
O
O
 
15 95 10 75 
14. 
BzO
OHH2N
O
 
BzO
OH
N
O
O
O  
30 94 12 60 
15. 
HO
NH3
COO
 
HO
N
COOHO
O  
15 96 14 86 
16. 
HO
NH2
OO
 
HO
N
O
O
OEtO
 
20 85 14 75 
17. NH2
N
H
O
OH
 
N
HN
O
OH O
O
 
20 75 - - 
18. 
HO
NH2
OBuO
 
HO
N
O
O
OBuO
 
15 97 14 70 
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DMF was found to be the most suitable solvent for the microwave N-phthaloylation 
reaction out of solvents like toluene, ethyl acetate and benzene for N-phthaloylation of amino 
acids. DMF was the superior solvent in comparison to others concerning both the reaction time 
and isolated yield.  There are also reports of microwave-assisted synthesis without solvent
39
. 
However, the solvent free method can only be successful if one of the reactants absorbs 
microwave irradiation and has relatively low melting point. On the other hand, our procedure is 
applicable to broad range of amino acids regardless of their physical state or microwave radiation 
absorption ability because our identified solvent (DMF) is an excellent microwave reaction 
media, as it was demonstrated on the several amino acid reactions (Table 4.1). At the same time, 
it was observed that microwave-assisted reaction was far superior to the conventional N-
phthaloylation reaction of amino acids. 
The phthaloyl moiety as protection group is a very attractive approach. However, 
phthaloyl may not be practical in some sensitive substrates due to the harsh conditions required 
for its removal after achieving peptide synthesis. Addition of electron-withdrawing groups to the 
phthalimide aromatic ring greatly enhances deprotection under milder reaction conditions than 
those used for phthalimido group. Fraser-Reid and Schmidt
51
 group have described use of 
tetrachlorophthalimido group while working on amino sugars. The application of 
tetrachlorophthalimido protective group is limited to sugar chemistry
52
.  
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Scheme 4.2 Microwave assisted tetrachloro phthaloylation of amino acids. 
 
Here we explored the use of tetrachlorophthalic anhydride for N-phthaloylation of amino acids 
(Scheme 4.2) and results are presented in Table 4.2. The reactions were carried out by mixing the 
tetrachlorophthalic anhydride with a desired amino acid in DMF and subjected to microwave 
irradiation. The reactions were usually completed in less than 15 minutes at a microwave power 
of 300 watt (Scheme 4.2). The microwave reaction offers simplicity and efficiency. The same 
reaction when performed under conventional heating took 20-22 hours of relux. When DMF was 
used as solvent, impurities were higher and decomposition observed because of long reaction 
time under reflux conditions. Therefore, much satisfactory results were obtained when reactions 
were carried out with dichloromethane
53
. Evidently, the reaction for tetrachlorophthaloylation 
under microwave irradiation proceeded well in terms of yield and reaction time (Table 4.2). The 
product was precipitated on addition of ice to the crude reaction mixture. When required a 
further purification was performed by crystallization using dichloroethane or a silica gel column 
using EtOAc-Hexane as eluent. 
 
 
 
O
O
O
Cl
Cl
Cl
Cl
+ H-aa(P)-OH
Microwave
DMF
TCP-aa(P)-OH
aa= amino acid
P= side chain protecting group
TCP=tetrachlorophthaloyl
19
7 20
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Table 4.2 Tetrachloro phthaloylated derivatives of amino acids. 
 
 
Product
. No. 
Amino acid TCP-aa(P)-OH 
Microwave Conventional 
Time 
(mins) 
Yield 
(%) 
Time 
(hours) 
Yield 
(%) 
21. 
HO
NH3
COO
 
HO
N
COOH
O
O
Cl
Cl
ClCl  
15 96 20 65 
22. 
HO
NH2
OO
 
HO
N
COOEt
O
O
Cl
Cl
ClCl  
10 98 22 70 
23. 
Ph
NH3
+Cl-
COOH
 
Ph
N
HOOC
O
O
Cl
Cl
Cl
Cl  
15 92 20 62 
24. 
NH2
O OH
 
N
O OH
O
O
Cl
Cl
ClCl  
15 95 20 90 
25. 
SH
NH2
O
OBu
HCl
 
S N
O
OBu
SN
O
BuO
O
O
O
O
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
 
10 96 20 60 
26. 
NH2
N
H
O
OH
 
N
HN
O
OH O
O Cl
Cl
Cl
Cl
 
15 94 20 62 
27. 
HO
NH2
OBuO
 
HO
N
O
O
OBuO
Cl Cl
Cl
Cl
 
10 98 20 72 
25. 
S NH2
O
OBu
SH2N
O
BuO
 
S N
O
OBu
SN
O
BuO
O
O
O
O
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
 
5 95 20 60 
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4.3. Cyclic imides derivatives as amino acid protecting groups 
The synthetic challenge is to selectively protect and deprotect the side chain functional 
groups under mild conditions without racemization in an effective and efficient manner that is 
industrially viable. Therefore, several methods for the protection and deprotection of sulfhydryl 
group were attempted to improve the synthetic methodology. In order to accomplish cysteinyl 
peptide synthesis using L-Cysteine it is mandatory to have appropriate sulfhydryl protective 
groups. The nucleophilic thiol could be acylated, alkylated, or oxidized to disulfide by during 
peptide synthesis. In order to develop a protective group that is convenient to synthesize from 
inexpensive starting material with inherent properties of being recyclable, stable to heat, light, 
and moisture and peptide synthesis reaction conditions. At the same time after the completion of 
peptide synthesis, it should be easy to remove and purify to yield the desired peptide. Due to the 
sensitivity of the cysteine molecule toward oxidation and elimination, it is usually necessary to 
protect β-sulfhydryl function in addition to the amino or the carboxyl group during peptide 
synthesis. Even the protected Cysteine is susceptible to several side reactions. Elimination of the 
protected cysteine occurs on exposure to alkaline conditions, strong bases like sodium in liquid 
ammonia can remove the benzyl group, hydrazynolysis and strong acids like HF. The extent of 
elimination also depends strongly on the type of protecting group being used. Oxidation and 
alkylation of thioether protected cysteine
54-56
. This is less critical than in the case of Methionine 
but has been reported to occur. The cysteine residues can be protected against oxidation at 
deprotection stage by using ten percent water as scavenger
57
.  
Cysteine can easily react with the carbocations being generated at the deprotection step 
under acidic conditions. Formaiton of S-tert-butylated cysteine has been observed after the 
removal of the Boc group or after deprotection in Fmoc/tBu protective strategy
58
. During 
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acidolytic cleavage resin-bound carbocations are generated that can react with the protected as 
well as unprotected cysteine which leads to reattachment of the peptide to the resin
59
. Another 
commonly observed phenomenon is the transfer of acetamidomethyl group to Ser, Thr, Gln, and 
Tyr during Acm removal
60
. Formation of thiazolidine of N-terminal cysteine can result from His- 
protecting groups that generate formaldehyde such as Bom (benzyloxymethyl) or Bum (tert-
butyloxymethyl), at the deprotection stage. This has been minimized by using cysteine as 
scavenger
61
. A more common problem is cysteine is highly susceptible to racemize during the 
anchoring to the solid support or during the coupling reactions
62
.
 
The extent of the racemization 
also depends on the S-protecting groups (StBu > Trt > Acm > MeBn > tBu)
63,64 
and coupling 
methods used. Racemization is favored if preactivation is achieved in the presence of base and if 
the coupling methods involve the use of a base. Epimerization of the cysteine linked to a 
hydroxyl resin can even take place during the synthesis as a result of the repetitive base 
treatments to remove the Fmoc group, with 2-chlorotrityl resin being the least prone to this 
process
65
. The most commonly used protecting groups for the Fmoc/tBu strategy are the Acm or 
Trt groups, when the desired product is the disulfide, and the Trt group, when the desired product 
is the free thiol. For the Boc/Bn strategy, the most used are Bn and Meb (p-methylbenzyl) to 
obtain the free thiol and Acm to obtain disulfides. In the search for better protecting groups we 
were able to successfully synthesize protective groups that could be used for selective sulfhydryl 
protection. Large numbers of protective groups have been effectively and efficiently used for 
complex peptide synthesis
6b, 66
. In our case, the target molecules required additional functional 
properties that are not commonly associated with the traditional protection groups. For instance, 
one of the requirements is to alter the physical properties of the protected molecules in order to 
get intermediates that could be easily purified, characterized, and subjected to harsh reaction 
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conditions during our synthetic strategy. Secondly, the desired protecting groups should also be 
resistant to most reagents required for the preparation of our complex targeted molecules, 
allowing their convenient removal at the end of the synthetic procedure. Therefore, cyclic imides 
of p-aminobenzyl and pararoaniline were chosen as ideal candidates to be explored as protective 
groups for the purposes of target molecule synthesis (Fig.4.2).  
N CHyBrz
O
O
28:x=z=1;y=2 for -OH protection
29:x=y=1;z=2 for thiazole formation/diol protection
30:x=3,y=0,z=1 for sulfhydryl and amino group protection
x
 
Figure 4.2 Novel sulhydryl, amino and alcohol protective groups. 
 
The rationale behind choosing cyclic imides is that these compounds crystallize well and are 
relatively stable in acidic, neutral, and basic reaction media thus making them easier to handle 
from milligram to grams scale
67
. Another important advantage offered by these protecting groups 
over other commonly used protective groups is their acid sensitivity can be easily altered by 
removal of the phthalate protection by treatment with hydrazine or a base. The resulting p-amino 
benzyl protection can be easily removed under moderate conditions without affecting the peptide 
bond. Similarly trityl is great protection group which was explored in selective β-sulfhydryl 
protection of L-cysteine hydrochloride, but it suffers from the disadvantage of being highly acid 
sensitive. Thus making it extremely difficult to use it in our target molecule that needs to be 
altered a various steps in synthetic strategy using acidic conditions. A better alternative to the 
trityl would be a cyclic imide of pararosaniline. It works on the same prinicipal as cyclic imides 
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of p-amino benzyl derivatives. For thiazolidine formation dibromo is hydrolysed to give the 
corresponding carbonyl to protect the sulfhydryl and amino groups of L-cysteine. For alcohol 
protection phenylmethyl bromide 28 is an ideal protective group, whereas for 1,2- and 1,3-diols 
the phenylmethylene dibromide 29 is the ideal protective group. Finally, for thiols and amines, 
the triphenylmethyl bromide 30 is the ideal protective group (Fig.4.2)
68-70
. Cyclic imides are 
compounds that crystallize well and are relatively stable in acidic, neutral, and dry basic reaction 
media
84
. When these groups are part of the protected aminoacids and derivatives either in the 
ether, thioether, or amine form, they are relatively stable in the mentioned reaction conditions. 
The major advantage of these benzyl-based protection groups over others that their acid 
sensitivity can be significantly increased by removal of imide protection using hydrazine or a 
base. The resulting p-amino benzyl ethers, thioethers, or amines are easily cleaved under 
moderate conditions.  
 
Scheme 4.3 L-cysteine thiazolidine protection. 
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Pararosaniline 43 has three free amino groups that were protected as phthalate (Scheme 
3.11). Pararosanilne 43 was reduced using sodium borohydride to the corresponding derivative. 
It was treated with phthalic anhydride under microwave conditions to yield in ten minutes at 
microwave power of 300 watt.  The resulting compound was not reactive enough to selectively 
protect the β-sulfhydryl group of L-cysteine hydrochloride. Phthalate on reaction with compound 
43 resulted in compound 44, which selectively protected butyl ester of L-cysteine hydrochloride 
to give compound 45. Reaction of 43 with succinic anhydride under microwave power of 500 
watt yielded compound 46, which on further reaction with butyl ester of L-cysteine, gave the 
desired β-sulfhydryl protected compound 47.  
 
 
Scheme 4.4 Pararosaniline derivatives as novel protective groups. 
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Table 4.3 Novel Protective groups for amino acids 
 
 
Product. 
No 
Protective group Cysteine protection 
38. N
O
O
O  
S
H
NO
O
N
O
O  
39. N
Br
O
O  
N
O
O
S
OH2N
O
 
40. N
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O
O  
O
N
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N
O
O
O
O  
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O
O O
O  
N
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O O
O
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O
O
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N
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O
O
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In our continued pursuit to find new protective groups pararosaniline was selected as a 
substrate to synthesize new protective groups. The rationale to choose pararosaniline is that it has 
three amino groups that can be protected as phthalate and then introduced on L-Cysteine as 
selective β-sulfhydryl protection group. For the deprotection the phthalate group could be 
removed either under basic condition or by use of hydrazine hydrate. The free amine will 
stabilize the carbocation of the trityl derivative thus making it easier at the deprotection step. The 
phthalate group provides stability under acidic conditions and makes it more stable under low pH 
compared to trityl group. Therefore, it was chosen as an alternative to trityl to provide facile 
protective groups for our synthesis of target molecule. Since, pararoaniline cannot be used as 
such because of the presence of three free amino groups, it was protected. Therefore, phthalate 
was used as protective group but the resulting compound was found to have low solubility in the 
common organic solvents for our synthetic purpose. Phthalate was then replaced with succinate 
and tetrachloro phthalate derivatives to get better results. All these synthetic procedures were 
carried out using microwave assisted imide synthesis. This prompted us to explore new 
protection groups and new synthetic methodology to improve the reaction conditions and yields. 
One such improvement was developed for phthaloylation of α amino acids.  
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4.4. Conclusions 
In conclusion, we have developed novel cyclic imides as protective groups for use in 
peptide synthesis. Synthesis for cyclic imides and their brominated derivatives were successfully 
achieved under microwave irradiation. The developed methods for protecting amino acids have 
potential to be used at large-scale industrial process for synthesis of cyclic imides derivatives 
very efficiently and in good yields under microwave conditions. N-phthaloylation of amino acids 
was achieved under microwave irradiation efficiently with improved yields compared to the 
reported procedures in the literature. The reactions were carried out under refluxing DMF for 
few minutes that avoided any racemization or denaturation of final products. 
 Tetrachlorophthaloylation was so far used for sugar chemistry or solid phase peptide 
synthesis. We explored the possibilities of synthesizing TCP derivatives under solvent conditions 
using microwave. Several amino acids including cysteine and tryptophan that have not been 
studied extensively in literature were explored in this dissertation. Introduction of electron 
withdrawing group on phthalate stabilized the molecule for use as protective groups in amino 
acids and facilitated the subsequent removal at the end of peptide synthesis.  
Pararosaniline and p-amino benzyl compounds were explored for synthesis of protective 
groups in peptide synthesis. Efficient methods were developed that are reproducible at large 
scale with high yields. These methods were environment friendly and economic. All procedures 
are simple and materials can be obtained in large quantities. L-cysteine was selectively protected 
as thiazolidine and used for peptide synthesis. Selective hydroxyl, amino and β-sulfhydryl 
protection of amino acids including L-cysteine was successfully accomplished. 
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4.5. Experimental 
 
General procedure for synthesis of N
α
-phthaloyl-protected-L-aminoacids: 
Method A: A suspension of phthalic anhydride (1.5 g; 0.01 mol) in N,N-dimethylformamide (20 
ml) was taken in a round bottom flask (100 ml) and heated in microwave for 2 min to get a clear 
solution. The corresponding amine L-amino acid (0.01 mol) was then added to this clear 
solution. The reaction mixture was put inside the microwave equipped with a reflux condenser 
and a magnetic stirrer.  It was allowed to stir under microwave irradiation with mild solvent 
refluxing (magnetron power between 200 and 300 W).  Once the reaction is completed it was 
poured over ice to get the precipitate to give white powder as pure product in more than 95% 
yield. Further 
1
H-NMR and 
13
C-NMR spectra were recorded to establish the structure of 
compounds. 
Method B: A suspension of phthalic anhydride (1.5 g; 0.01 mol) in N,N-dimethylformamide (20 
ml) was taken in a round bottom flask (100 ml) and heated in microwave for 2 min to get a clear 
solution. The corresponding L-amino acid (0.01mol) was added to this clear solution. The 
reaction mixture was put inside the microwave equipped with a reflux condenser and a magnetic 
stirrer.  It was allowed to stir under microwave irradiation with mild solvent refluxing 
(magnetron power between 200 and 300 W).  Once the reaction was completed, it was cooled to 
room temperature diluted with ethyl acetate (100 mL) and washed with water (2 X50 mL), brine 
and dried over magnesium sulafte. Solvent was removed under reduced pressure. When required 
product was recrystallized from 1,2-dichloroethane. Product was obtained in more than 90% 
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yield. Further product formation was confirmed by 
1
H-NMR and 
13
C-NMR spectra to establish 
the structure of compounds. 
2-(1,3-dioxoisoindolin-2-yl)-2-phenylacetic acid (9): 
1
H NMR (400 MHz, DMSO-d6) δ 7.99-
7.85 (m, 4H), 7.55-7.28 (m, 5H) and 5.99 (s, 1H) ppm. 
13
C NMR (400 MHz, DMSO-d6) δ 
168.37, 167.70, 135.27, 134.5, 131.88, 129.4, 127.9, 127.6, 123.1 and 56.9 ppm. 
 
2-(1,3-dioxoisoindolin-2-yl)-3-(4-hydroxyphenyl)propanoic acid (15): 
1
H NMR (400 MHz, 
DMSO-d6) δ 9.14 (s, 1H), 7.81 (s, 4H), 6.91 (d, J = 8.3, 2H), 6.53 (d, J = 8.3, 2H), 5.01 (dd, 
J=12 Hz, J=4.8 Hz, 1H), 3.33(dd, J=13.8 Hz, J=5.4 Hz, 1H) and 3.21 (t, J=12 Hz, 1H) ppm. 
13
C 
NMR (400 MHz, DMSO-d6) δ 170.2, 167.1, 155.8, 134.9, 130.8, 129.6, 127.3, 123.4, 115.2, 
53.2 and 33.1 ppm. 
 
Butyl 2-amino-3-(tris(4-(1,3-dioxoisoindolin-2-yl)phenyl)methylthio)propanoate (45): 
1
H 
NMR (400 MHz, DMSO-d6) δ 7.91 (m, 12H), 7.25 (m, 12H), 4.97 (m, 1H), 4.06 (m, 1H), 3.29 – 
3.10 (m, 2H), 1.46 (m, 2H), 1.18 (m, 2H), 0.76 (t, J = 7.4, 3H) ppm.
 13
C NMR (400 MHz, 
DMSO-d6) δ 172.52, 167.09, 139.58, 132.34, 132.05, 128.45, 127.87, 123.01, 67.87, 65.05, 
54.66, 31.21, 30.06, 18.87, 13.89 ppm. 
 
Butyl 2-amino-3-(tris(4-(2,5-dioxopyrrolidin-1-yl)phenyl)methylthio)propanoate (47): 
1
H 
NMR (400 MHz, DMSO-d6) δ 7.24 (dd, J = 17.7, 8.5, 12H), 4.37 (t, J = 4.3, 2H), 4.28-4.06 (m, 
1H), 2.97 (s, 1H), 2.80 (s, 1H), 2.76 (s, 12H), 1.71-1.51 (m, 2H), 1.35 (m, 2H) and 0.88 (t, J = 
7.4, 3H) ppm.
 13
C NMR (400 MHz, DMSO-d6) δ 176.54, 171.45, 139.56, 132.78, 128.42, 
122.09, 68.9, 65.2, 54.76, 31.12, 30.86, 27.67, 18.89 and 13.88 ppm. 
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2-(1,3-Dioxoisoindolin-2-yl)-3-phenylpropanoic acid (10): White powder, m.p. 156–157, 1H 
NMR (400 MHz, DMSO-d6) δ: 9.94 (s, 1H) , 7.66 (m, 2H), 7.76 (m, 2H), 5.22 (t, J=8.8 Hz, 1H) 
and 3.58 (d, J=8.8 Hz, 2H), ppm 
13
C NMR (400 MHz, DMSO-d6) δ: 174.75, 167.53, 134.29, 
131.51, 128.9, 128.7, 127.04, 123.66, 53.17 and 34.35 ppm.  
 
Sodium 4-carboxy-4-(1,3-dioxoisoindolin-2-yl)butanoate (12) ): 
1
H NMR (400 MHz, DMSO-
d6) δ: 9.94 (s, 1H) , 7.68-7.87 (m, 4H), 4.82 (m, 1H) and 2.22-2.48 (m, 4H), ppm. 
13
C NMR (400 
MHz, DMSO-d6) δ: 175.15, 170.23, 167.53, 134.29, 131.51, 124.28, 57.82, 32.25 and 22.58 
ppm.  
 
dibutyl 3,3'-disulfanediylbis(2-(1,3-dioxoisoindolin-2-yl)propanoate) (13): 
1
H NMR (400 
MHz, CDCl3) δ: 7.90 (m, 8H), 4.97 (s, 2H), 4.07 (d, J = 27.0 Hz, 1H), 3.39 – 2.92 (m, 2H), 2.48 
(s, 4H), 1.44 (s, 4H), 1.18 (s, 4H) and 0.76 (s, 6H) ppm. 
13
C NMR (400 MHz, DMSO-d6) δ: 
167.53, 134.63, 132.05, 123.64, 115.62, 77.18, 66.25, 54.90, 30.45, 24.02, 19.15 and 13.63 ppm. 
 
2-(1,3-dioxoisoindolin-2-yl)-3-(1H-indol-3-yl)propanoic acid (17): 
1
H NMR (400 MHz, 
DMSO-d6): δ 10.74 (s, 1H), 7.80 (s, 4H), 7.26 (d, 1H, J = 8.2 Hz), 7.49 (d, 1H, J = 8.1 Hz), 7.00 
(t, 1H, J = 8 Hz), 6.89 (t, 1H, J = 7.3 Hz), 5.13 (dd, 1H, J1 = 10 Hz, J2 = 6.7 Hz) and 3.55–3.62 
(m, 2H) ppm. 
13
C NMR (400 MHz, DMSO-d6): δ 170.4, 167.2, 136.1, 134.9, 130.9, 126.9, 
123.4, 121.0, 118.5, 117.9, 111.5, 109.8, 52.7, and 24.1 ppm. 
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2-phenyl-2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)acetic acid (23): 
1
H NMR (400 MHz, 
DMSO-d6) δ 7.55-7.28 (m, 5H) and 5.99 (s, 1H) ppm. 
13
C NMR (400 MHz, DMSO-d6) δ 169.37, 
168.70, 138.27, 135.5, 133.88, 129.4, 129.45, 127.9, 127.6, 125.1 and 56.9 ppm. 
 
3-(4-hydroxyphenyl)-2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)propanoic acid (21): 
1
H 
NMR (400 MHz, DMSO-d6) δ 7.06 (d, J=8.5 Hz, 2H), 6.85 (d, J=8.5 Hz, 2H), 5.19 (dd, J1=6.1, 
J2=10.7 Hz, 1H), 3.60 (dd, J1=10.7, J2=14.4 Hz, 1H) and 3.50 (dd, J1=10.7, J2=6.1 Hz, 1H) 
ppm. 
13
C NMR (400 MHz, DMSO-d6) δ 172.05, 162.65, 154.24, 140.28, 131.23, 129.76, 129.19, 
127.22, 124.48, 78.57, 53.83 and 33.56 ppm. 
 
3-phenyl-2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)propanoic acid (23):
 1
H NMR (400 
MHz, DMSO-d6) δ 7.40-7.29 (m, 5H), 5.42 (dd, J1=6.1, J2=11.7 Hz, 1H), 3.78 (dd, J1=5.2, 
J2=14.2 Hz, 1H) and 3.65 (dd, J1=11.7, J2=14.2 Hz, 1H) ppm. 
13
C NMR (400 MHz, DMSO-d6) 
δ 169.75, 163.65, 140.38, 138.03, 130.23, 129.76, 129.29, 128.45, 127.49, 54.89 and 34.56 ppm. 
 
dibutyl 3,3'-disulfanediylbis(2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)propanoate) 
(25): 
1
H NMR (400 MHz, CDCl3) δ: 4.97 (s, 2H), 4.07 (d, J = 27.0 Hz, 1H), 3.39 – 2.92 (m, 2H), 
2.48 (s, 4H), 1.44 (s, 4H), 1.18 (s, 4H) and 0.76 (s, 6H) ppm. 
13
C NMR (400 MHz, DMSO-d6) δ: 
167.53, 134.63, 132.05, 123.64, 115.62, 77.18, 66.25, 54.90, 30.45, 24.02, 19.15 and 13.63 ppm. 
 
Synthesis of phthalimides, general procedure: Phthalic anhydride (1.5 g; 0.01 mol), 
corresponding amine (0.01) and N,N-dimethylformamide (20 ml) were mixed together in a round 
bottom flask (100 ml).  The reaction mixture stirred in the microwave reactor equipped with a 
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condenser and magnetic stirrer.  The reaction mixture was stirred under microwave irradiation 
with mild solvent refluxing (magnetron power between 300 to 400W).  After completion of the 
reaction, the resulting mixture was poured on crushed ice.  This precipitated the compound as a 
white precipitate, which was separated by filtration, washed thoroughly with water and dried 
under reduced pressure.  The compounds were obtained in more than 95 percent purity. Further 
1
H-NMR and 
13
C-NMR spectra were recorded to establish structure of molecules. 
 
4-methylphenylphthalimide (32): Isolated in quantitative yield. Selected
 1
H NMR (400 MHz, 
CDCl3):  7.98 (d, 2H), 7.80 (d, 2H), 7.35(s, 4H) and 2.41(s, 3H) ppm. 
13
C NMR (400 MHz, 
CDCl3):   168.0, 138.2, 134.5, 132.0, 130.0, 129.5, 127.1 124.0, and 21.5 ppm.  
 
Preparation of dibromoarene, general procedure:  A mixture of methylbenzene derivative 
(3.3 mmol), N-bromsucinimide (10 mmol), and benzoylperoxide (0.31 mmol) in benzene (10 ml) 
was refluxed for three hours under microwave radiation (magnetron power 500W, magnetron 
power 200W with bead).  After completion of the reaction, the solvent was evaporated under 
reduced pressure and the solid residue was dissolved in dichloromethane (100 ml).  
Dichloromethane solution was washed with saturated sodium bicarbonate (3X15 ml), water 
(3X20 ml) and subsequently dried over anhydrous sodium sulfate.  The solvent was evaporated 
under reduced pressure and the residue was further purified by filtration through short silica gel 
column with hexane-dichloromethane as solvent. 
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4,4’-(dibromomethyl)phenylphthalimide (34):  The product was isolated as white powder 
(Yield=90%).  Selected 
1
H-NMR (CDCl3): δ 7.98 (2H, m), 7.82 (2H, m), 7.72 (2H, d, J = 8.0 
Hz), 7.51 (2H, d, J = 8.0 Hz), and 6.68 (1H, s) ppm. 
13
C-NMR (CDCl3): δ 167.1, 141.0, 135.3, 
133.2, 131.0, 128.5, 127.1, 124.0 and 40.2 ppm. C15H9Br2NO2 (MW 395.05). MS (m/z) 396.90 
(50%), 395.90 (10%), 394.90 (100%), 392.90 (50%). 
 
Synthesis of 4-(1,3-dioxoisoindolin-2-yl)benzaldehyde (35): Refluxed 4,4’-
(dibromomethyl)phenylphthalimide (28) in pyridine and water for 30 mins to ge the 
corresponding ketone in quantitative yield. Selected 
1
H-NMR (CDCl3): δ 9.87 (1H, s), 7.85 (2H, 
m), 7.79 (2H, m), 7.72 (2H, d, J = 8.0 Hz), and 7.51 (2H, d, J = 8.0 Hz) ppm. 
13
C-NMR (CDCl3): 
δ 191.1, 170.0, 138.3, 133.2, 132.0, 129.5, 127.1 and 122.0 ppm.  
 
butyl 3-(4-hydroxyphenyl)-2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)propanoate (27): 
1
H NMR (400 MHz, DMSO-d6) δ 7.06 (d, J=8.5 Hz, 2H), 6.85 (d, J=8.5 Hz, 2H), 5.19 (dd, 
J1=6.1, J2=10.7 Hz, 1H), 3.60 (dd, J1=10.7, J2=14.4 Hz, 1H),  4.10 (m, 2H), 3.50 (dd, J1=10.7, 
J2=6.1 Hz, 1H),  1.33 (m, 2H), 1.58 (m, 2H) and 0.95 (t, J=16.8, 3H) ppm. 
13
C NMR (400 MHz, 
DMSO-d6) δ 172.05, 162.65, 154.24, 140.28, 131.23, 129.76, 129.19, 127.22, 124.48, 78.57, 
64.89, 53.83, 33.56, 31.26, 18.78 and 13.56 ppm. 
 
Synthesis of monobromoarene, General procedure:  A mixture of methyl benzene derivative 
(5 mmol), N-bromosuccinamide (5 mmol), and benzoylperoxide (0.5 mmol) in benzene (10 ml) 
was refluxed under microwave heating (magnetron power 500W, magnetron power 200W with 
bead).  After reaction was completed, solvent evaporated to get a solid residue. The residue was 
235 
 
dissolved in dichloromethane (100 ml) and washed with saturated sodium bicarbonate solution 
(3X15 ml) and water (3X15 ml).  Solvent was evaporated to dryness and the resulting solid 
residue was purified by silica gel column chromatography with hexane-dichloromethane as an 
eluent. 
 
4-(Bromomethyl)phenylphthalimide (33): Product was isolated as pale powder with isolated 
yield of 85%. 
1
H-NMR (CDCl3): δ 7.98 (2H, m), 7.80 (2H, m), 7.55 (2H, d, J = 8 Hz), 7.45 (2H, 
d, J = 8 Hz), and 4.55 (2H, s) ppm. 
13
C-NMR (CDCl3): δ 167.1, 140.0, 138.2, 135.1, 132.0, 
130.2, 127.5, 124.3 and 33.0 ppm. C15H10BrNO2 (MW 316.15). MS (m/z) 317.99 (10%), 314.99 
(100%), and 316.99 (95%). 
 
Synthesis of butyl 2-amino-3-(tris(4-(2,5-dioxopyrrolidin-1-yl)phenyl)methylthio) 
propanoate (47): Product isolated as a powder a yellow precipitate with an isolated yield of 
35%. Selected 
1
H NMR (400 MHz, DMSO-d6) δ 7.34 – 7.09 (m, 12H), 4.36 (s, 2H), 4.27 – 4.07 
(m, 1H), 2.96 (d, J = 10.1, 2H), 2.79 (d, J = 7.6, 1H), 2.75 – 2.67 (m, 2H), 1.48 (m, 1H), 1.33 (d, 
J = 7.1, 1H) and 1.02 – 0.76 (m, 1H) ppm. 13C NMR (400 MHz, DMSO-d6): δ 177.25, 172.15, 
140.04, 132.78, 127.84, 121.23, 67.45, 65.71, 54.67, 32.12, 30.06, 27.65, 19.3 and 13.78 ppm. 
 
Synthesis of ethyl 2-(4-(1,3-dioxoisoindolin-2-yl)phenyl)thiazolidine-4-carboxylate (37): 
Compound was synthesized in the same way as Ethyl-2-Phenylthiazolidine-4-carboxylate  
(Compound 18A, Chapter 3). Compound was obtained as pale powder (Yield=82%). Selected 
1
H-NMR (400 MHz, CDCl3): δ 7.85 (2H, m), 7.79 (2H, m), 7.29 (2H, d, J = 8.0 Hz), 7.09 (2H, d, 
J = 8.0 Hz), 4.95 (m, 1H), 4.12 (m, 2H), 3.73 (m, 1H), 3.04 (m, 1H), 2.87 (m, 1H) and 1.30 (t, 
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J=8.9, 3H) ppm. 
13
C-NMR (400 MHz, CDCl3): δ 171.1, 170.0, 136.3, 133.2, 132.0, 129.5, 
128.67, 127.1, 69.23, 62.26, 61.3, and 61.5 ppm. 
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